>LZ948192.1 JP 2016521994-A/261: OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
CCNNNNNNNNNGG
>LZ950362.1 JP 2016526895-A/3: BIOMARKERS FOR PREMATURE BIRTH
AGGCCCAGCATTT
>LZ950249.1 JP 2016521995-A/435: DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETING AND MODELING DISEASES AND DISORDERS OF POST MITOTIC CELLS
CCNNNNNNNNNGG
>LZ949707.1 JP 2016523082-A/435: DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETING AND MODELING DISEASES AND DISORDERS OF POST MITOTIC CELLS
CCNNNNNNNNNGG
>LZ951004.1 JP 2016521993-A/346: DELIVERY, ENGINEERING AND OPTIMIZATION OF TANDEM GUIDE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
CCNNNNNNNNNGG
>LZ949201.1 JP 2016524472-A/822: DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
GTGGGCCTTTTTT
>LZ949132.1 JP 2016524472-A/753: DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
CCNNNNNNNNNGG
>LZ943143.1 JP 2016526889-A/10: COMPOSITIONS AND METHODS FOR SAMPLE PROCESSING
TCTACACNNNNNN
>LZ985937.1 JP 2017529872-A/9: Aptamers for use against autoantibody-associated diseases
TGGTGGTGGTGGT
>LZ985466.1 JP 2017529090-A/53: USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH AN FGFR INHIBITOR
AGCGCTGCCCGCA
>LZ255214.1 JP 2016136957-A/38: Lowering Saturated Fatty Acid Content of Plant Seeds
ACAACCAAAAATG
>LZ255213.1 JP 2016136957-A/37: Lowering Saturated Fatty Acid Content of Plant Seeds
GGATCCAACAATG
>LZ255148.1 JP 2016171789-A/38: Lowering Saturated Fatty Acid Content of Plant Seeds
ACAACCAAAAATG
>LZ255147.1 JP 2016171789-A/37: Lowering Saturated Fatty Acid Content of Plant Seeds
GGATCCAACAATG
>LZ254280.1 JP 2016178944-A/1: COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS
WATCAANNNNTTR
>LZ253540.1 JP 2016178948-A/30: Non-Human Animals Expressing Antibodies Having A Common Light Chain
CCACTGGCATCCC
>LZ253409.1 JP 2016182143-A/281: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
TGATACTGACTGT
>LZ253364.1 JP 2016182143-A/236: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
GCTCTTCAGCCTT
>LZ253244.1 JP 2016182143-A/116: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
GACCCTGCCTGCT
>LZ253184.1 JP 2016182143-A/56: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
TGATACTGACTGT
>LZ253177.1 JP 2016182143-A/49: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
CTTCATTACACCT
>LZ253062.1 JP 2016182139-A/24: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAAA
>LZ253047.1 JP 2016182139-A/9: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAGA
>LZ253046.1 JP 2016182139-A/8: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAAA
>LZ253045.1 JP 2016182139-A/7: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACATGGTCCAGA
>LZ252424.1 JP 2016171815-A/86: Compositions of asymmetric interfering RNA and uses thereof
CTGATATTGATGG
>LZ252136.1 JP 2016168050-A/86: Compositions of asymmetric interfering RNA and uses thereof
CTGATATTGATGG
>LZ247054.1 JP 2016152818-A/190: COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS
ACCTAAAGTCATG
>LZ246566.1 JP 2016144474-A/336: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
TTATTTCCCAGGT
>LZ246496.1 JP 2016144474-A/266: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
AATAGCGAGAGNG
>LZ246495.1 JP 2016144474-A/265: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
AATAGCGAGAANG
>LZ246494.1 JP 2016144474-A/264: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
GATAAGAAGAANC
>LZ246493.1 JP 2016144474-A/263: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
AATAAGAAGAANC
>LZ246492.1 JP 2016144474-A/262: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CAAAAGAAAAANT
>LZ246491.1 JP 2016144474-A/261: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CAAAAGAACAANT
>LZ246490.1 JP 2016144474-A/260: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CAACAGAACAANT
>LZ246489.1 JP 2016144474-A/259: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CAACAGCACAANT
>LZ246488.1 JP 2016144474-A/258: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CCACAGCATACNC
>LZ246487.1 JP 2016144474-A/257: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CCACAGCCTACNC
>LZ246486.1 JP 2016144474-A/256: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CCACCGCCTACNC
>LZ246485.1 JP 2016144474-A/255: PRODUCTS AND PROCESSES FOR MULTIPLEX NUCLEIC ACID IDENTIFICATION
CCACCGCCTCCNC
>LZ985978.1 JP 2017529872-A/50: Aptamers for use against autoantibody-associated diseases
CCTGCCCCCTAAA
>LZ985733.1 JP 2017531433-A/3: MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR KINASE DOMAIN
AACATCTGCCCTC
>LZ951965.1 JP 2017211886-A/70: Customized information delivery system for women's health-promoting benefits
GGGCCCAGGACGC
>MI371227.1 Sequence 24 from patent US 9850535
ACCTACTACCTCA
>MI352219.1 Sequence 21 from patent US 9850481
NNNNNNGCCTCGC
>MI352217.1 Sequence 19 from patent US 9850481
NNNNNNCCTCGCC
>MI352215.1 Sequence 17 from patent US 9850481
NNNNNNCCTCGCC
>MI352213.1 Sequence 15 from patent US 9850481
NNNNNNATGCATG
>MI344816.1 Sequence 147 from patent US 9844196
CAGTGCGCTGGAC
>MI344813.1 Sequence 144 from patent US 9844196
TTGTGCAGACCCC
>MI344812.1 Sequence 143 from patent US 9844196
TTGTGCATACCCC
>MI344807.1 Sequence 138 from patent US 9844196
CCGCTAGCTTTCA
>MI344806.1 Sequence 137 from patent US 9844196
CCGCTAGCCTTCA
>MI344805.1 Sequence 136 from patent US 9844196
CTGGCGGTGCAGC
>MI344802.1 Sequence 133 from patent US 9844196
CTCAACCAAAAGC
>MI344487.1 Sequence 2 from patent US 9840740
CTTTTGGGACCGC
>MI344486.1 Sequence 1 from patent US 9840740
GCGGTCCCAAAAG
>MI340734.1 Sequence 18 from patent US 9840707
AGTATTTGGTCTC
>MI340732.1 Sequence 16 from patent US 9840707
AAGTATTTGGTCT
>MI340731.1 Sequence 15 from patent US 9840707
AAAGTATTTGGTC
>MI340709.1 Sequence 120 from patent US 9840706
CCGCCATTTCTCA
>MI340708.1 Sequence 119 from patent US 9840706
GTGTCTTTCTGAG
>MI331724.1 Sequence 543 from patent US 9834824
CGAAAAAAACGCG
>MI331028.1 Sequence 18 from patent US 9834817
AGCTGGTGGCGTA
>MI331022.1 Sequence 12 from patent US 9834817
ATCACGCAGCTCA
>MI331020.1 Sequence 10 from patent US 9834817
CACCGTGCARCTC
>MI330900.1 Sequence 28 from patent US 9834800
TATATATATATAT
>MI319750.1 Sequence 2 from patent US 9833479
TTTCTCTCCACAG
>MI319621.1 Sequence 6 from patent US 9833439
TTCAAATATGGTA
>MI252281.1 Sequence 66 from patent US 9828639
GAGAGGAAGGAAA
>MI252222.1 Sequence 6 from patent US 9828639
GAGAGGAAGGAAA
>MI251387.1 Sequence 1315 from patent US 9828610
ACAGCAGCAAACC
>MI251386.1 Sequence 1314 from patent US 9828610
CACAGCAACAAAC
>MI251379.1 Sequence 1307 from patent US 9828610
CAGCGCAGGGCTA
>MI251378.1 Sequence 1306 from patent US 9828610
CAGCGCAGAGCTA
>MI250071.1 Sequence 12 from patent US 9828609
TCACACAGGAAAG
>MI224070.1 Sequence 2 from patent US 9822401
CCATCTCATCCCT
>MI224054.1 Sequence 16 from patent US 9822395
GATCCGACNGTCG
>MI224053.1 Sequence 15 from patent US 9822395
GATCCGACNGTCG
>MI222468.1 Sequence 240 from patent US 9822369
GATCACACCACGC
>MI184145.1 Sequence 30 from patent US 9816149
GACGTGGTGCAAA
>MI184130.1 Sequence 9 from patent US 9816149
GACGTGGTGCAGA
>MI184129.1 Sequence 8 from patent US 9816149
GACGTGGTGCAAA
>MI184128.1 Sequence 7 from patent US 9816149
GACATGGTCCAGA
>MI178259.1 Sequence 28 from patent US 9816089
GCATTGGTATTCA
>MI178255.1 Sequence 23 from patent US 9816089
TAGTCCAGTTCAC
>MI178252.1 Sequence 20 from patent US 9816089
CCAGGCAGAGACA
>MI178251.1 Sequence 19 from patent US 9816089
TGTCTCTGCCTGG
>MI178249.1 Sequence 17 from patent US 9816089
TGAATACCAATGC
>MI178248.1 Sequence 16 from patent US 9816089
TGAATACCAATGC
>MI178247.1 Sequence 15 from patent US 9816089
TGAATACCAATGC
>MI178241.1 Sequence 7 from patent US 9816089
TGAATACCAATGC
>MI178239.1 Sequence 5 from patent US 9816089
GCATTGGTATTCA
>MI177954.1 Sequence 100 from patent US 9816078
GCCGCCRCCATGG
>MI176611.1 Sequence 57 from patent US 9809863
GCTCTTCCGATCT
>MI166978.1 Sequence 1231 from patent US 9809817
ACAAATACGATTA
>MI166883.1 Sequence 1136 from patent US 9809817
ACAAATACGATTA
>MI163967.1 Sequence 118 from patent US 9809628
TACACCCTTTTTT
>MI163966.1 Sequence 117 from patent US 9809628
TACACCCGGGGGG
>MI163965.1 Sequence 116 from patent US 9809628
TACACCCCCCCCC
>MI163964.1 Sequence 115 from patent US 9809628
TACACCCAAAAAA
>MI163963.1 Sequence 114 from patent US 9809628
TTGTATATAACTT
>MI163916.1 Sequence 63 from patent US 9809628
TACACCCNNNCAT
>MI163906.1 Sequence 53 from patent US 9809628
GACACCCAAACAT
>MI163905.1 Sequence 52 from patent US 9809628
CACACCCAAACAT
>MI163904.1 Sequence 51 from patent US 9809628
AACACCCAAACAT
>MI163857.1 Sequence 4 from patent US 9809628
TACACCCAAACAT
>MI163648.1 Sequence 17 from patent US 9808508
AGGTGAAATTTAA
>MI163647.1 Sequence 16 from patent US 9808508
AGATAAAAGGACA
>MI163646.1 Sequence 15 from patent US 9808508
AGGTGAAAGGGCA
>MI163645.1 Sequence 14 from patent US 9808508
AGGCGAAAGGACC
>MI163644.1 Sequence 13 from patent US 9808508
AGGTGAAAGGCTA
>MI163643.1 Sequence 12 from patent US 9808508
AGGTGAAAGGACA
>MI163642.1 Sequence 11 from patent US 9808508
AGGTGAAAGGACA
>MI163641.1 Sequence 10 from patent US 9808508
AGGTCAAAGGTCA
>MI162783.1 Sequence 220 from patent US 9803249
AGACCCCAGTTGC
>MI162779.1 Sequence 216 from patent US 9803249
CCCCTCCTCAGAG
>MI160773.1 Sequence 1 from patent US 9803234
CCCGCGCGCGCCC
>MI160770.1 Sequence 16 from patent US 9803233
ATCATGAGCGTCG
>MI160769.1 Sequence 15 from patent US 9803233
ATCATGAGCTTCG
>MI160768.1 Sequence 14 from patent US 9803233
ATCCTGAGCTTCG
>MI160767.1 Sequence 13 from patent US 9803233
ATCCTCAGCTTCG
>MI157044.1 Sequence 31 from patent US 9803203
GTGTGAATGAATG
>MI157040.1 Sequence 27 from patent US 9803203
TACTCTGAATGTT
>MI157020.1 Sequence 7 from patent US 9803203
GTTAATGTGTTCT
>MI157016.1 Sequence 3 from patent US 9803203
TTGCCCTTGCTCA
>MI156031.1 Sequence 69 from patent US 9803193
TTTTTTTTTTTTT
>MI155652.1 Sequence 1481 from patent US 9803177
GCCGCCRCCATGG
>MI152763.1 Sequence 16 from patent US 9802936
AGGTCANAGGTCA
>MI152713.1 Sequence 48 from patent US 9801948
GTTATGGTAATTT
>MI152705.1 Sequence 35 from patent US 9801948
TTCACTAGCTTGC
>MI152685.1 Sequence 13 from patent US 9801948
TGGCCAAGGTAAC
>MI152684.1 Sequence 12 from patent US 9801948
TGGTCAGGGTAAC
>MI152682.1 Sequence 8 from patent US 9801948
CGGCCACGGAAAC
>MI152681.1 Sequence 7 from patent US 9801948
TGGCCAGGGTAAC
>MI152680.1 Sequence 6 from patent US 9801948
CGGTCACGGAAAC
>MI152679.1 Sequence 5 from patent US 9801948
CGGTCAGGGCAAC
>MI152678.1 Sequence 4 from patent US 9801948
CGGTCAGGGTAAC
>MI125936.1 Sequence 4 from patent US 9796957
CGAGAAGCTTCCC
>MI125924.1 Sequence 30 from patent US 9796788
CCACTGGCATCCC
>MI124676.1 Sequence 16 from patent US 9796747
GTTAGGGTTAGAC
>MI124672.1 Sequence 12 from patent US 9796747
ACGGTGGAAGGCG
>MI124671.1 Sequence 11 from patent US 9796747
CGGTGGAAGGCGG
>MI124669.1 Sequence 9 from patent US 9796747
GTGGAAGGCGGCA
>MI124668.1 Sequence 8 from patent US 9796747
GGAAGGCGGCAGG
>MI124665.1 Sequence 5 from patent US 9796747
CAGTTAGGGTTAG
>MI124663.1 Sequence 3 from patent US 9796747
TAGGGTTAGACAA
>MI119800.1 Sequence 76 from patent US 9790532
DTAAACATGTAGG
>MI118850.1 Sequence 137 from patent US 9790521
GGCCCTGCAGGCC
>MI116485.1 Sequence 90 from patent US 9790494
NGTCTATGTATAG
>MI116482.1 Sequence 87 from patent US 9790494
NAATCCATGGNAG
>MI116481.1 Sequence 86 from patent US 9790494
GGCAAGCATCNTG
>MI116467.1 Sequence 72 from patent US 9790494
GNATTGGTATTNA
>MI116464.1 Sequence 69 from patent US 9790494
TNNTCGGCCTNTG
>MI116426.1 Sequence 31 from patent US 9790494
NNTCTATGTANNN
>MI116423.1 Sequence 28 from patent US 9790494
NNATCCATGGNNN
>MI116422.1 Sequence 27 from patent US 9790494
NNCAAGCATCNNN
>MI116408.1 Sequence 13 from patent US 9790494
NNATTGGTATNNN
>MI116405.1 Sequence 10 from patent US 9790494
NNNTCGGCCTNNN
>MI115316.1 Sequence 1518 from patent US 9790490
NCCACTGTTAAAA
>MI115313.1 Sequence 1515 from patent US 9790490
NCCACTGTTAAAA
>MI115199.1 Sequence 1398 from patent US 9790490
AGACTTTTAACAG
>MI115182.1 Sequence 1381 from patent US 9790490
AGACTTTTAACAG
>MI115164.1 Sequence 1363 from patent US 9790490
ATCTACAACAGTA
>MI115163.1 Sequence 1362 from patent US 9790490
ATCTACAACAGTA
>MI115162.1 Sequence 1361 from patent US 9790490
ATCTACAACAGTA
>MI115161.1 Sequence 1360 from patent US 9790490
ATCTACAACAGTA
>MI115160.1 Sequence 1359 from patent US 9790490
ATCTACAACAGTA
>MI115159.1 Sequence 1358 from patent US 9790490
ATCTACAACAGTA
>MI115146.1 Sequence 1345 from patent US 9790490
GCCACTGTTAAAA
>MI114422.1 Sequence 60 from patent US 9790477
CGAGTTGGTTGGA
>MI114413.1 Sequence 51 from patent US 9790477
TGGACTTGAATTG
>MI114406.1 Sequence 44 from patent US 9790477
GCTTCAACTATCA
>MI114405.1 Sequence 43 from patent US 9790477
GGACGCTTGAACT
>MI113676.1 Sequence 8 from patent US 9789197
CTGTGGAAGTCTA
>MI113672.1 Sequence 3 from patent US 9789197
CTGTGGAAGTCTA
>MI113240.1 Sequence 60 from patent US 9788505
TGGGAGGCAATTC
>MI111717.1 Sequence 449 from patent US 9783827
TGATACTGACTGT
>MI111672.1 Sequence 377 from patent US 9783827
GCTCTTCAGCCTT
>MI111552.1 Sequence 186 from patent US 9783827
GACCCTGCCTGCT
>MI111492.1 Sequence 121 from patent US 9783827
TGATACTGACTGT
>MI111485.1 Sequence 114 from patent US 9783827
CTTCATTACACCT
>MI109381.1 Sequence 13 from patent US 9783817
GCCGCCNCCATGG
>MI107230.1 Sequence 56 from patent US 9783801
GATCTCCNNNNNN
>MI107014.1 Sequence 40 from patent US 9783787
CCACGGGCGCCGT
>MI104335.1 Sequence 182 from patent US 9782437
ACGTAGACTGAGG
>MI104333.1 Sequence 180 from patent US 9782437
GAAGTCTGCCGTT
>MI104332.1 Sequence 179 from patent US 9782437
GAAGTCTGCCGTT
>MI104302.1 Sequence 119 from patent US 9782437
AACACGAAACGTG
>MI104272.1 Sequence 48 from patent US 9782437
TAGAGGAGAAAGG
>MI104149.1 Sequence 4 from patent US 9779205
GCCGCCRCCATGG
>MI103977.1 Sequence 5 from patent US 9778249
CGCGAAAAACGCG
>MI103966.1 Sequence 11 from patent US 9777406
AAAAAACCCCCCC
>MI103273.1 Sequence 62 from patent US 9777330
GGCCNNNNNGGCC
>MI103176.1 Sequence 29 from patent US 9777327
CTGGTCTCAGAGT
>MI095721.1 Sequence 11 from patent US 9771667
AAAAAACCCCCCC
>MI095501.1 Sequence 22 from patent US 9771622
CAGATAACATTTT
>MI095500.1 Sequence 21 from patent US 9771622
NAGNNNNCWTWNN
>MI089062.1 Sequence 337 from patent US 9771588
TTCCGCGTACGTT
>MI089058.1 Sequence 331 from patent US 9771588
TTCCGCGTACGTT
>MI089025.1 Sequence 296 from patent US 9771588
TTCCGCGTACGTT
>MI089024.1 Sequence 294 from patent US 9771588
TTCCGCGTACGTT
>MI088816.1 Sequence 84 from patent US 9771588
TTCCGCGTACGTT
>MI088181.1 Sequence 76 from patent US 9771585
ACGATTAGCATTA
>MI088180.1 Sequence 75 from patent US 9771585
ACGATTAGCATTA
>MI088179.1 Sequence 74 from patent US 9771585
ACGATTAGCATTA
>MI088178.1 Sequence 73 from patent US 9771585
ACGATTAGCATTA
>MI088177.1 Sequence 72 from patent US 9771585
ACGATTAGCATTA
>MI088176.1 Sequence 71 from patent US 9771585
ACGATTAGCATTA
>MI088175.1 Sequence 70 from patent US 9771585
ACGATTAGCATTA
>MI088174.1 Sequence 69 from patent US 9771585
ACGATTAGCATTA
>MI088173.1 Sequence 68 from patent US 9771585
ACGATTAGCATTA
>MI088172.1 Sequence 67 from patent US 9771585
ACGATTAGCATTA
>MI088171.1 Sequence 66 from patent US 9771585
ACGATTAGCATTA
>MI088170.1 Sequence 65 from patent US 9771585
ACGATTAGCATTA
>MI088169.1 Sequence 64 from patent US 9771585
ACGATTAGCATTA
>MI088168.1 Sequence 63 from patent US 9771585
ACGATTAGCATTA
>MI088167.1 Sequence 62 from patent US 9771585
ACGATTAGCATTA
>MI088166.1 Sequence 61 from patent US 9771585
ACGATTAGCATTA
>MI088165.1 Sequence 60 from patent US 9771585
ACGATTAGCATTA
>MI088164.1 Sequence 59 from patent US 9771585
ACGATTAGCATTA
>MI088163.1 Sequence 58 from patent US 9771585
ACGATTAGCATTA
>MI088162.1 Sequence 57 from patent US 9771585
ACGATTAGCATTA
>MI088159.1 Sequence 54 from patent US 9771585
ACGATTAGCATTA
>MI087690.1 Sequence 93 from patent US 9771579
GCCAGTCACAAAT
>MI087689.1 Sequence 92 from patent US 9771579
GCCAGTCACAAAT
>MI085059.1 Sequence 56 from patent US 9765407
GTAGAAACCTCGC
>MI084882.1 Sequence 116 from patent US 9765404
TGCATGCGCAGTA
>MI084327.1 Sequence 11 from patent US 9765387
AAAAAACCCCCCC
>MI078945.1 Sequence 23 from patent US 9765109
TAGGTGTAAGCAA
>MI078944.1 Sequence 22 from patent US 9765109
TAGGGTTAGACAA
>MI078941.1 Sequence 19 from patent US 9765109
TAGGTGTAAGCAA
>MI078940.1 Sequence 18 from patent US 9765109
TAGGGTTAGACAA
>MI068171.1 Sequence 34 from patent US 9758786
CTAGTACCGCCTT
>MI068170.1 Sequence 33 from patent US 9758786
GGATCGCCTCGAT
>MI068169.1 Sequence 32 from patent US 9758786
AGCGCGACCGTGA
>MI068160.1 Sequence 23 from patent US 9758786
TCTGTAGGAGGGC
>MI068157.1 Sequence 20 from patent US 9758786
GGCGGGATGGCAT
>MI068152.1 Sequence 15 from patent US 9758786
TCTGCCCGCGGAT
>MI068150.1 Sequence 13 from patent US 9758786
CAGAAGTTGGCAT
>MI068149.1 Sequence 12 from patent US 9758786
CAGAAGTTGGCAT
>MI067457.1 Sequence 23 from patent US 9758780
CCTCAGCCCTTTG
>MI067455.1 Sequence 21 from patent US 9758780
GGAAACCCCGGCC
>MI065312.1 Sequence 11 from patent US 9757420
TTTCTCTCCACAG
>MI064889.1 Sequence 190 from patent US 9752201
ACCTAAAGTCATG
>MI064775.1 Sequence 75 from patent US 9752201
CCAGTANCAGTNA
>MI064697.1 Sequence 22 from patent US 9752200
CAGATAACATTTT
>MI064696.1 Sequence 21 from patent US 9752200
NAGNNNNCWTWNN
>MI061657.1 Sequence 788 from patent US 9752146
TGCTGCATCTCTG
>MI047711.1 Sequence 58 from patent US 9745636
ACGATGGGACCGT
>MI047703.1 Sequence 50 from patent US 9745636
CTTCCGGGGTGAA
>MI047702.1 Sequence 49 from patent US 9745636
ACAGTACCGCAGC
>MI047689.1 Sequence 36 from patent US 9745636
CAACACAGGCGGC
>MI047661.1 Sequence 8 from patent US 9745636
ATTCCAGGCACCG
>MI046086.1 Sequence 11 from patent US 9745619
AAAAAACCCCCCC
>MI045974.1 Sequence 1 from patent US 9745614
AAATCAAAAAAAC
>MI043403.1 Sequence 31 from patent US 9745574
CTGTGGAAGTCTA
>MI043399.1 Sequence 27 from patent US 9745574
CTGTGGAAGTCTA
>MI043397.1 Sequence 25 from patent US 9745574
CTGTGGAAGTCTA
>MI043395.1 Sequence 23 from patent US 9745574
CTGTGGAAGTCTA
>MI043393.1 Sequence 21 from patent US 9745574
CTGTGGAAGTCTA
>MI043391.1 Sequence 19 from patent US 9745574
CTGTGGAAGTCTA
>MI042230.1 Sequence 282 from patent US 9745364
GTGGACGTTCGGC
>MI042223.1 Sequence 268 from patent US 9745364
TTGGGTGTTCGGC
>MI042211.1 Sequence 243 from patent US 9745364
GTGGACGTTCGGC
>MI040576.1 Sequence 10 from patent US 9738907
GCCGCCACCATGG
>MI040507.1 Sequence 37 from patent US 9738900
CGTTCGCCGTGTT
>MI040491.1 Sequence 21 from patent US 9738900
CGTTCGCCGTGTT
>MI040168.1 Sequence 337 from patent US 9738899
TTCCGCGTACGTT
>MI040164.1 Sequence 331 from patent US 9738899
TTCCGCGTACGTT
>MI040131.1 Sequence 296 from patent US 9738899
TTCCGCGTACGTT
>MI040130.1 Sequence 294 from patent US 9738899
TTCCGCGTACGTT
>MI039922.1 Sequence 84 from patent US 9738899
TTCCGCGTACGTT
>MI039598.1 Sequence 8 from patent US 9738891
TTAATTTAAGGAA
>MI039324.1 Sequence 85 from patent US 9738879
AGACTGTGGTTAC
>MI037918.1 Sequence 48 from patent US 9738701
GGCCNNNNNGGCC
>MI030967.1 Sequence 35 from patent US 9738680
GTGTGTGTGTGTC
>MI030955.1 Sequence 23 from patent US 9738680
GTGTGTGTGTGTT
>MI030309.1 Sequence 74 from patent US 9737484
CAGATGACATTAG
>MI030296.1 Sequence 61 from patent US 9737484
GGTTCAGACCAGG
>MI029715.1 Sequence 35 from patent US 9732385
TGCTCCGGCGCCA
>MI029714.1 Sequence 34 from patent US 9732385
CATGGCTGGATCC
>MI029713.1 Sequence 33 from patent US 9732385
CATGGCTGGACCC
>MI029260.1 Sequence 14 from patent US 9732348
GCCTCCTGTCGAA
>MI023601.1 Sequence 337 from patent US 9732344
TTCCGCGTACGTT
>MI023597.1 Sequence 331 from patent US 9732344
TTCCGCGTACGTT
>MI023564.1 Sequence 296 from patent US 9732344
TTCCGCGTACGTT
>MI023563.1 Sequence 294 from patent US 9732344
TTCCGCGTACGTT
>MI023355.1 Sequence 84 from patent US 9732344
TTCCGCGTACGTT
>MI023093.1 Sequence 1147 from patent US 9732342
TTAAGGCACGCGG
>MI023091.1 Sequence 1145 from patent US 9732342
GCGGTGAATGCCA
>MI023088.1 Sequence 1142 from patent US 9732342
TTAAGGCACGCGG
>MI023081.1 Sequence 1135 from patent US 9732342
GCGGTGAATGCCA
>MI023060.1 Sequence 1114 from patent US 9732342
TTAAGGCACGCGG
>MI021909.1 Sequence 90 from patent US 9732341
NGTCTATGTATAG
>MI021906.1 Sequence 87 from patent US 9732341
NAATCCATGGNAG
>MI021905.1 Sequence 86 from patent US 9732341
GGCAAGCATCNTG
>MI021891.1 Sequence 72 from patent US 9732341
GNATTGGTATTNA
>MI021888.1 Sequence 69 from patent US 9732341
TNNTCGGCCTNTG
>MI021850.1 Sequence 31 from patent US 9732341
NNTCTATGTANNN
>MI021847.1 Sequence 28 from patent US 9732341
NNATCCATGGNNN
>MI021846.1 Sequence 27 from patent US 9732341
NNCAAGCATCNNN
>MI021832.1 Sequence 13 from patent US 9732341
NNATTGGTATNNN
>MI021829.1 Sequence 10 from patent US 9732341
NNNTCGGCCTNNN
>MI021782.1 Sequence 90 from patent US 9732340
NGTCTATGTATAG
>MI021779.1 Sequence 87 from patent US 9732340
NAATCCATGGNAG
>MI021778.1 Sequence 86 from patent US 9732340
GGCAAGCATCNTG
>MI021764.1 Sequence 72 from patent US 9732340
GNATTGGTATTNA
>MI021761.1 Sequence 69 from patent US 9732340
TNNTCGGCCTNTG
>MI021723.1 Sequence 31 from patent US 9732340
NNTCTATGTANNN
>MI021720.1 Sequence 28 from patent US 9732340
NNATCCATGGNNN
>MI021719.1 Sequence 27 from patent US 9732340
NNCAAGCATCNNN
>MI021705.1 Sequence 13 from patent US 9732340
NNATTGGTATNNN
>MI021702.1 Sequence 10 from patent US 9732340
NNNTCGGCCTNNN
>MI021072.1 Sequence 3 from patent US 9732319
CCCCGACGCGTCT
>MI020259.1 Sequence 3 from patent US 9732114
TAGGTGTAAGCAA
>MI020258.1 Sequence 2 from patent US 9732114
TAGGGTTAGACAA
>MI019732.1 Sequence 46 from patent US 9730954
GTGCACCCGTGGG
>MI019720.1 Sequence 33 from patent US 9730954
TGTGCCTAATTCA
>MI019718.1 Sequence 31 from patent US 9730954
AGGACCCTTCCAG
>MI019699.1 Sequence 8 from patent US 9730954
TGGTCCCCTCCCC
>MI018741.1 Sequence 5 from patent US 9725771
CGTGGTACCCCTT
>MI018739.1 Sequence 3 from patent US 9725771
CGTGGTGACCCTT
>MI018222.1 Sequence 3 from patent US 9725761
GGCTGCGCAGTAT
>MI017983.1 Sequence 9391 from patent US 9725759
CGCGGGTGCCGGG
>MI017936.1 Sequence 9344 from patent US 9725759
CGGGTGCCGGGCA
>MI008583.1 Sequence 96 from patent US 9725757
CGANNNNNNTACC
>MI008444.1 Sequence 56 from patent US 9725755
AGTTTGGCCAGCC
>MI008443.1 Sequence 55 from patent US 9725755
AGTTTGGCCAGCC
>MI008441.1 Sequence 53 from patent US 9725755
TTTTGGGCTGGCC
>MI008440.1 Sequence 52 from patent US 9725755
TTTTGGGCTGGCC
>MI008418.1 Sequence 30 from patent US 9725755
TCATCACGCAGCT
>MI008417.1 Sequence 29 from patent US 9725755
CATCACGCAGCTC
>MI008416.1 Sequence 28 from patent US 9725755
CATCACGCAGCTC
>MI008411.1 Sequence 23 from patent US 9725755
AGGTTAAAGGTCT
>MI003305.1 Sequence 118 from patent US 9725715
GGTAACTAGAGAT
>MI001110.1 Sequence 2 from patent US 9724430
AGGTCANAGGTCA
>LZ242374.1 JP 2017526627-A/22: ACINETOBACTER LYSINS
AATTCGGCTCGAG
>LZ230368.1 JP 2017184651-A/51: Method of Discriminating a Cultivar of Hevea brasiliensis and Kit for Discriminating a Cultivar of Hevea brasiliensis
AAGCAAATAATAG
>LZ231174.1 JP 2017186298-A/8: ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS
GGCCTCTGCGGCC
>LZ231173.1 JP 2017186298-A/7: ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS
GGCCCAGCCGGCC
>LZ229418.1 JP 2017522015-A/18: DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN KRAS
TACGCCAGCAGCT
>LZ229417.1 JP 2017522015-A/17: DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN KRAS
CGCCAGCAGCTCC
>LZ229416.1 JP 2017522015-A/16: DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN KRAS
CCAGCAGCTCCAA
>LZ228046.1 JP 2017522004-A/24: ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS
ATAGTTTCTCTCC
>LZ220524.1 JP 2017169573-A/14: FUNCTIONAL NUCLEIC ACID MOLECULE AND USE THEREOF
CATAGGGTTCATT
>LZ218638.1 JP 2017163971-A/31: Detection of Staphylococcus schweitzeri
GAAGTTGAATTTG
>LZ218628.1 JP 2017163971-A/21: Detection of Staphylococcus schweitzeri
GTACAAAGGAAAA
>LZ218620.1 JP 2017163971-A/13: Detection of Staphylococcus schweitzeri
ATCAAAGCAATTG
>LZ218570.1 JP 2017163969-A/108: Detection of Staphylococcus argenteus
TTGAAAGATATTG
>LZ218548.1 JP 2017163969-A/86: Detection of Staphylococcus argenteus
ATTTAAATATTTG
>LZ218515.1 JP 2017163969-A/53: Detection of Staphylococcus argenteus
ATGGTAGAGAATG
>LZ218512.1 JP 2017163969-A/50: Detection of Staphylococcus argenteus
CATTTACGAAGAA
>KH986692.1 Sequence 40721 from patent US 9719131
GAAGAGCGGACAG
>KH945718.1 Sequence 3 from patent US 9719137
CGNTGACTNNNAC
>KH945663.1 Sequence 92 from patent US 9719122
AAGGAAAAAAAAT
>KH945662.1 Sequence 91 from patent US 9719122
AAGGAAAAAAAAG
>KH945661.1 Sequence 90 from patent US 9719122
AAGGAAAAAAAAA
>KH943316.1 Sequence 3 from patent US 9719084
GGGAAAGGAAGAG
>KH940906.1 Sequence 139 from patent US 9717749
AAAAAAAGCAAAA
>KH940867.1 Sequence 100 from patent US 9717749
AAAAAGCTTTTTT
>KH936698.1 Sequence 346 from patent US 9708674
CGTCACGGCGGAG
>KH936679.1 Sequence 327 from patent US 9708674
TGCGCCAATGCAT
>KH936627.1 Sequence 275 from patent US 9708674
CACCGCCGGTATG
>KH936619.1 Sequence 267 from patent US 9708674
CGGCGGCGGAGAG
>KH936515.1 Sequence 163 from patent US 9708674
CCGTCCGCGGTGT
>KH933777.1 Sequence 6 from patent US 9708657
TTCAGGGGGGGCT
>KH933693.1 Sequence 210 from patent US 9708652
GGGGCGGATCGCG
>KH933692.1 Sequence 209 from patent US 9708652
GGGGCGGACCGCG
>KH933691.1 Sequence 208 from patent US 9708652
GGGGTGGATTGTG
>KH933690.1 Sequence 207 from patent US 9708652
GGGGCGGACCGCG
>KH933652.1 Sequence 169 from patent US 9708652
CGAAGAGAGAGGG
>KH933518.1 Sequence 35 from patent US 9708652
NCCTATAGTGAGT
>KH933324.1 Sequence 19 from patent US 9708636
GTGGAGATCAAAC
>KH933322.1 Sequence 16 from patent US 9708636
ACCGTCTCTTCAG
>KH933320.1 Sequence 13 from patent US 9708636
CTGCTACTTCTAG
>KH933318.1 Sequence 10 from patent US 9708636
TCAGGAACTGCAG
>KH921979.1 Sequence 75 from patent US 9708589
ATAAATACCTTCT
>KH921534.1 Sequence 136 from patent US 9708414
GGATCCGGCTGCT
>KH920602.1 Sequence 4 from patent US 9708360
CAGTTAGGGTTAG
>KH920601.1 Sequence 3 from patent US 9708360
TAGGGTTAGACAA
>KH919821.1 Sequence 41 from patent US 9702879
ATGGAGGCTTGAC
>KH918089.1 Sequence 7 from patent US 9701998
GAACNNNNNNTAC
>KH918087.1 Sequence 5 from patent US 9701998
GAAGNNNNNNTAC
>KH918086.1 Sequence 4 from patent US 9701998
GAACNNNNNNTCC
>KH918083.1 Sequence 1 from patent US 9701998
GGCCNNNNNGGCC
>KH917589.1 Sequence 2 from patent US 9701971
CGTCTAAATCATG
>KH901847.1 Sequence 41 from patent US 9701964
GTTTTTGTACTCT
>KH901842.1 Sequence 29 from patent US 9701964
AAAATCATTTGAG
>KH901841.1 Sequence 28 from patent US 9701964
AAATTCATTTGAG
>KH853145.1 Sequence 981 from patent US 9697460
AGGAAACAGAACC
>KH853108.1 Sequence 941 from patent US 9697460
TCACACAGGAAAG
>KH853106.1 Sequence 939 from patent US 9697460
AGGAGGATTACAA
>KH852203.1 Sequence 27 from patent US 9697460
AGGAATTTAAATG
>KH850504.1 Sequence 41 from patent US 9695442
GCTTCGGCAGGCT
>KH850503.1 Sequence 38 from patent US 9695442
ACCCGGACCTCAG
>KH850497.1 Sequence 19 from patent US 9695442
CATCTGCTACTCG
>KH844271.1 Sequence 414 from patent US 9688988
AGTATTTGGTCTC
>KH844269.1 Sequence 412 from patent US 9688988
AAGTATTTGGTCT
>KH844268.1 Sequence 411 from patent US 9688988
AAAGTATTTGGTC
>KH844258.1 Sequence 401 from patent US 9688988
ATCATGTCGAATT
>KH844257.1 Sequence 400 from patent US 9688988
TCATGTCGAATTT
>KH844256.1 Sequence 399 from patent US 9688988
TCCCCTAATGGCT
>KH844255.1 Sequence 398 from patent US 9688988
CCCCTAATGGCTT
>KH844254.1 Sequence 397 from patent US 9688988
AGCGCTGGCAACC
>KH844253.1 Sequence 396 from patent US 9688988
GGGGGCTTTCTAA
>KH844245.1 Sequence 388 from patent US 9688988
ATCTGCCCCTAAT
>KH844190.1 Sequence 333 from patent US 9688988
GCCCACGTAGTAC
>KH844189.1 Sequence 332 from patent US 9688988
ACTCCGGTGACAT
>KH844188.1 Sequence 331 from patent US 9688988
GAGGTATCGCCAG
>KH844187.1 Sequence 330 from patent US 9688988
TTTAACTTGAGCC
>KH844186.1 Sequence 329 from patent US 9688988
CATAGATTTCGTT
>KH844185.1 Sequence 328 from patent US 9688988
TAGTAGTCGGCCT
>KH844184.1 Sequence 327 from patent US 9688988
TAGTCCCGCGGCC
>KH844183.1 Sequence 326 from patent US 9688988
TGCCGAGAGCGCG
>KH844182.1 Sequence 325 from patent US 9688988
TCCCACGGAAATA
>KH844181.1 Sequence 324 from patent US 9688988
GTCGGAGAGAGAT
>KH844180.1 Sequence 323 from patent US 9688988
TGCGCCCGAGGTC
>KH844179.1 Sequence 322 from patent US 9688988
GTCGGCGACTCCC
>KH844178.1 Sequence 321 from patent US 9688988
GACGCCGTGTAGG
>KH844177.1 Sequence 320 from patent US 9688988
AAGCGTCCCCGGC
>KH844176.1 Sequence 319 from patent US 9688988
TCGCGCCAAGAGG
>KH844070.1 Sequence 213 from patent US 9688988
CGGCACGCAGCAC
>KH844069.1 Sequence 212 from patent US 9688988
ACCATTAGCACGC
>KH844068.1 Sequence 211 from patent US 9688988
TTAGCACGCGGGT
>KH844043.1 Sequence 186 from patent US 9688988
TTGCAGGAGCGCA
>KH844042.1 Sequence 185 from patent US 9688988
AGTTGGCATGGTA
>KH844041.1 Sequence 184 from patent US 9688988
GCATGGTAGCCCT
>KH844040.1 Sequence 183 from patent US 9688988
TGGGCTCGTGGAT
>KH844039.1 Sequence 182 from patent US 9688988
GGCTCGTGGATCC
>KH844038.1 Sequence 181 from patent US 9688988
CGCCAGGAATTGT
>KH844037.1 Sequence 180 from patent US 9688988
CCACCCGGTCGCG
>KH844036.1 Sequence 179 from patent US 9688988
CACCCGGTCGCGG
>KH844035.1 Sequence 178 from patent US 9688988
TCGCGGGTGCTGT
>KH843998.1 Sequence 141 from patent US 9688988
TCTGTAGGAGGGC
>KH843964.1 Sequence 107 from patent US 9688988
GGTCGGCAGTCAA
>KH843963.1 Sequence 106 from patent US 9688988
CTAGTACCGCCTT
>KH843962.1 Sequence 105 from patent US 9688988
TCCACCCTAGATC
>KH843961.1 Sequence 104 from patent US 9688988
CGGTTGGTCTGTT
>KH843960.1 Sequence 103 from patent US 9688988
ATCTGAACTCGGC
>KH843959.1 Sequence 102 from patent US 9688988
GGCGCTCGGTACT
>KH843958.1 Sequence 101 from patent US 9688988
GTCGCGGTTGCGT
>KH843957.1 Sequence 100 from patent US 9688988
TTGCTCGCTTAGG
>KH843904.1 Sequence 47 from patent US 9688988
TCTGTAGGAGGGC
>KH843896.1 Sequence 39 from patent US 9688988
GGCGGGATGGCAT
>KH843884.1 Sequence 27 from patent US 9688988
CGAAGGAGAGCCA
>KH843883.1 Sequence 26 from patent US 9688988
TGTAGCGCTGGGT
>KH843882.1 Sequence 25 from patent US 9688988
AAGTGGGCGGGAT
>KH843881.1 Sequence 24 from patent US 9688988
GAAATCACCTCCG
>KH843879.1 Sequence 22 from patent US 9688988
AAGTGGGCGGGAT
>KH843878.1 Sequence 21 from patent US 9688988
CAGAAGTTGGCAT
>KH843872.1 Sequence 15 from patent US 9688988
GGATCGCCTCGAT
>KH843868.1 Sequence 11 from patent US 9688988
TCTGCCCGCGGAT
>KH843865.1 Sequence 8 from patent US 9688988
AGCGCGACCGTGA
>KH843680.1 Sequence 49 from patent US 9688985
AATCTAATAAGCT
>KH843679.1 Sequence 48 from patent US 9688985
CAATCTAATAAGC
>KH843674.1 Sequence 43 from patent US 9688985
ATCTAATAAGCTA
>KH843666.1 Sequence 35 from patent US 9688985
AGTCTGATAAGCT
>KH843665.1 Sequence 34 from patent US 9688985
CAGTCTGATAAGC
>KH843652.1 Sequence 21 from patent US 9688985
GTCTGATAAGCTA
>KH839566.1 Sequence 36 from patent US 9683266
TCACACAGGAAAG
>KH835652.1 Sequence 968 from patent US 9683233
ATTTCCTTTTATG
>KH835394.1 Sequence 710 from patent US 9683233
CCTCCCCTCGATG
>KH833761.1 Sequence 576 from patent US 9683028
GGCCNNNNNGGCC
>KH833704.1 Sequence 514 from patent US 9683028
GGCCNNNNNGGCC
>KH833675.1 Sequence 483 from patent US 9683028
AGCCACCCTGTCT
>KH833634.1 Sequence 436 from patent US 9683028
GGCCNNNNNGGCC
>KH833618.1 Sequence 420 from patent US 9683028
GGCCNNNNNGGCC
>KH833583.1 Sequence 385 from patent US 9683028
GGTGANNNNNNNN
>KH833576.1 Sequence 378 from patent US 9683028
GAAGANNNNNNNN
>KH833575.1 Sequence 377 from patent US 9683028
GGTGANNNNNNNN
>KH832767.1 Sequence 20 from patent US 9682144
TCGCCATGCTGCT
>KH831471.1 Sequence 26 from patent US 9681616
TGCTGGCTTTTTG
>KH786812.1 Sequence 20 from patent US 9678074
ATCGCAGCGGCCC
>KH786811.1 Sequence 19 from patent US 9678074
ATCGCAGAAGGCC
>KH786808.1 Sequence 16 from patent US 9678074
ATCGCAGCGGCCC
>KH786807.1 Sequence 15 from patent US 9678074
ATCGCAGAAGGCC
>KH786183.1 Sequence 57 from patent US 9677127
AGAATCCCCAGGA
>KH786180.1 Sequence 54 from patent US 9677127
GTATATCCTATGG
>KH786160.1 Sequence 34 from patent US 9677127
GACGAACTGTTCA
>KH786159.1 Sequence 33 from patent US 9677127
GACGAAATTGTCA
>KH786158.1 Sequence 32 from patent US 9677127
GACGAAATGTTCA
>KH786157.1 Sequence 31 from patent US 9677127
GACGAACTGTTCA
>KH786152.1 Sequence 26 from patent US 9677127
GCAATGGAAGTTG
>KH786151.1 Sequence 25 from patent US 9677127
GCAATGAAAGTTG
>KH786143.1 Sequence 17 from patent US 9677127
GCTGAACAGGAAG
>KH786139.1 Sequence 13 from patent US 9677127
GCTGAAAAGGAAG
>KH786135.1 Sequence 9 from patent US 9677127
GCTGAAAAGGAAG
>KH786131.1 Sequence 5 from patent US 9677127
GCTGAACAGGAAG
>KH782992.1 Sequence 2 from patent US 9677071
GAAAANNGAAASY
>KH782692.1 Sequence 286 from patent US 9677055
GCCGCCRCCATGG
>KH780033.1 Sequence 10 from patent US 9675642
AGGTCANAGGTCA
>KH779957.1 Sequence 13 from patent US 9675071
CGCGAGTCTCCTC
>KH779956.1 Sequence 12 from patent US 9675071
CGCGACTCTCCTC
>KH779953.1 Sequence 9 from patent US 9675071
TCATCTCTGATAA
>KH779952.1 Sequence 8 from patent US 9675071
TCATGTGTGATAA
>KH779951.1 Sequence 7 from patent US 9675071
TCATCTGTGATAA
>KH778321.1 Sequence 27 from patent US 9670531
GCAACGCGGCGTC
>KH778316.1 Sequence 22 from patent US 9670531
CGACGCCGCGTTG
>KH775311.1 Sequence 300 from patent US 9670499
CTATGGCATTCCC
>KH775307.1 Sequence 296 from patent US 9670499
TCCCCCGTCCGCC
>KH775292.1 Sequence 281 from patent US 9670499
CACGACAATCCCT
>KH775291.1 Sequence 280 from patent US 9670499
CACGACGATCCCT
>KH775272.1 Sequence 261 from patent US 9670499
ATGGCCAAACAAC
>KH775271.1 Sequence 260 from patent US 9670499
ATGGCCGAACAAC
>KH775212.1 Sequence 201 from patent US 9670499
CCGTCAATGATCC
>KH775211.1 Sequence 200 from patent US 9670499
CCGTCCATGATCC
>KH775152.1 Sequence 141 from patent US 9670499
CAGGCGAACCTTT
>KH775117.1 Sequence 106 from patent US 9670499
CCCGGGCCGAACG
>KH775116.1 Sequence 105 from patent US 9670499
CCCGGCCCGAACG
>KH775077.1 Sequence 66 from patent US 9670499
CGAGGAGGCCTCC
>KH774939.1 Sequence 63 from patent US 9670495
TTCNNGAANNTTC
>KH772532.1 Sequence 294 from patent US 9670491
GGGGGGCGCGACC
>KH772530.1 Sequence 292 from patent US 9670491
GGGGGRCGCGAYC
>KH757831.1 Sequence 91 from patent US 9669109
GCGCCATTGTACT
>KH757827.1 Sequence 87 from patent US 9669109
AGTACAATGGCGC
>KH757820.1 Sequence 80 from patent US 9669109
TCTGTATCTGAAT
>KH757798.1 Sequence 58 from patent US 9669109
ATTCAGATACAGA
>KH757793.1 Sequence 53 from patent US 9669109
CNGGTCATAATCT
>KH756810.1 Sequence 38 from patent US 9663831
GGMTTAGATACCC
>KH756345.1 Sequence 6 from patent US 9663827
AGACGTGCATAGT
>KH752517.1 Sequence 788 from patent US 9663787
TGCTGCATCTCTG
>KH749681.1 Sequence 104 from patent US 9657357
GTCATCATAGACG
>KH749676.1 Sequence 99 from patent US 9657357
CGGGCGGGATTGG
>KH749631.1 Sequence 54 from patent US 9657357
YRGTTTCRYTTYY
>KH749622.1 Sequence 45 from patent US 9657357
TGGGGATTCCCCA
>KH749590.1 Sequence 13 from patent US 9657357
ACTCAGAGGAAAA
>KH749583.1 Sequence 6 from patent US 9657357
TGAATATGGGCCA
>KH749093.1 Sequence 783 from patent US 9657346
GTGCAGGGTCCGA
>KH748102.1 Sequence 265 from patent US 9657342
AGCACTGCAGGTA
>KH746487.1 Sequence 21 from patent US 9657296
CAGTTAGGGTTAG
>KH746482.1 Sequence 14 from patent US 9657296
GTTAGGGTTAGAC
>KH746480.1 Sequence 12 from patent US 9657296
TAGGGTTAGACAA
>KH746476.1 Sequence 8 from patent US 9657296
ACGGTGGAAGGCG
>KH746475.1 Sequence 7 from patent US 9657296
CGGTGGAAGGCGG
>KH746473.1 Sequence 5 from patent US 9657296
GTGGAAGGCGGCA
>KH746472.1 Sequence 4 from patent US 9657296
GGAAGGCGGCAGG
>KH746151.1 Sequence 337 from patent US 9657294
TTCCGCGTACGTT
>KH746147.1 Sequence 331 from patent US 9657294
TTCCGCGTACGTT
>KH746114.1 Sequence 296 from patent US 9657294
TTCCGCGTACGTT
>KH746113.1 Sequence 294 from patent US 9657294
TTCCGCGTACGTT
>KH745905.1 Sequence 84 from patent US 9657294
TTCCGCGTACGTT
>KH745732.1 Sequence 49 from patent US 9657287
TTCCGCGGATCCG
>KH743385.1 Sequence 152 from patent US 9657050
AGTCGGTAAGTTC
>KH743378.1 Sequence 145 from patent US 9657050
ATCAAGCAGAGAA
>KH743367.1 Sequence 134 from patent US 9657050
TGTGTCACCAGAG
>KH743363.1 Sequence 130 from patent US 9657050
TTTTACTCCCTTG
>KH743359.1 Sequence 126 from patent US 9657050
CCATTGTTTCATC
>KH743337.1 Sequence 104 from patent US 9657050
TTAGTTGCTGCTC
>KH743168.1 Sequence 152 from patent US 9657049
AGTCGGTAAGTTC
>KH743161.1 Sequence 145 from patent US 9657049
ATCAAGCAGAGAA
>KH743150.1 Sequence 134 from patent US 9657049
TGTGTCACCAGAG
>KH743146.1 Sequence 130 from patent US 9657049
TTTTACTCCCTTG
>KH743142.1 Sequence 126 from patent US 9657049
CCATTGTTTCATC
>KH743120.1 Sequence 104 from patent US 9657049
TTAGTTGCTGCTC
>KH742796.1 Sequence 2 from patent US 9655955
GCCGCCACCATGG
>KH742234.1 Sequence 6 from patent US 9650674
AGAATGTACGAGT
>KH742233.1 Sequence 5 from patent US 9650674
GAGTGTAGAATGT
>KH742198.1 Sequence 11 from patent US 9650666
AAAAAACCCCCCC
>KH741984.1 Sequence 134 from patent US 9650648
ATCCTCTTRRRRG
>KH741932.1 Sequence 81 from patent US 9650647
TATATACACACGT
>KH741887.1 Sequence 31 from patent US 9650647
TATATACACACGT
>KH738756.1 Sequence 22 from patent US 9650436
GGCCCAGCCGGCC
>KH738104.1 Sequence 15 from patent US 9649371
GAGGAGGGCCGGG
>KH736402.1 Sequence 83 from patent US 9637796
AGGGGTAATGACA
>KH736387.1 Sequence 68 from patent US 9637796
AGTCTGAAAGATG
>KH736376.1 Sequence 56 from patent US 9637796
ACTCTGAAAGAGT
>KH736361.1 Sequence 41 from patent US 9637796
TAGGTCACCTTTT
>KH735844.1 Sequence 11 from patent US 9637778
AAAAAACCCCCCC
>KH735833.1 Sequence 48 from patent US 9637777
AGTCGACACGTTC
>KH733389.1 Sequence 107 from patent US 9637736
AACAACTGACCAG
>KH733009.1 Sequence 62 from patent US 9637554
CAAACGGAAGTAT
>KH733004.1 Sequence 54 from patent US 9637554
TAGCCCGGTCCCT
>KH733002.1 Sequence 51 from patent US 9637554
TCCTCATTACTTG
>KH732270.1 Sequence 57 from patent US 9636354
CCGGGGGGACGGG
>KH731930.1 Sequence 220 from patent US 9632093
AGACCCCAGTTGC
>KH731926.1 Sequence 216 from patent US 9632093
CCCCTCCTCAGAG
>KH725353.1 Sequence 5 from patent US 9631192
ATCTGCACCACCG
>KH722041.1 Sequence 248 from patent US 9617600
CGTGCGCCGCCAA
>KH721996.1 Sequence 203 from patent US 9617600
TGCTCACTTCCCC
>KH721410.1 Sequence 11 from patent US 9617584
AAAAAACCCCCCC
>KH721398.1 Sequence 2 from patent US 9617583
TAGGGTTAGACAA
>KH719369.1 Sequence 1559 from patent US 9617540
TAGCCACCAACTG
>KH719246.1 Sequence 1432 from patent US 9617540
TAGCCTCTGGATT
>KH718978.1 Sequence 1163 from patent US 9617540
GCTAGCCTCTGGA
>KH718186.1 Sequence 292 from patent US 9617540
GCACACAGCTGCC
>KH718176.1 Sequence 280 from patent US 9617540
GGCATGAGCTTCA
>KH718147.1 Sequence 245 from patent US 9617540
TGTTCCAGCCCAG
>KH717565.1 Sequence 18 from patent US 9617535
GCTCGTCGCTGTC
>KH716695.1 Sequence 10 from patent US 9617318
TAGGGTTAGGGTT
>KH716692.1 Sequence 7 from patent US 9617318
GGGTTAGGGTTAG
>KH716301.1 Sequence 2 from patent US 9616090
TTTCTCTCCACAG
>KH716248.1 Sequence 3 from patent US 9616084
GCCGCCACCATGG
>KH716120.1 Sequence 7 from patent US 9612222
CTGCTTCTAAACT
>KH716119.1 Sequence 6 from patent US 9612222
AGTTTAGAAGCAG
>KH716116.1 Sequence 3 from patent US 9612222
AGTTTAGTAGCAG
>KH716115.1 Sequence 2 from patent US 9612222
CTGCTACTAAACT
>KH716114.1 Sequence 1 from patent US 9612222
AGTTTAGTAGCAG
>KH715409.1 Sequence 88 from patent US 9611485
TTCCGTGAAGATC
>KH715330.1 Sequence 9 from patent US 9611485
CGCGAGTCTCCTC
>KH715329.1 Sequence 8 from patent US 9611485
CGCGACTCTCCTC
>KH715326.1 Sequence 5 from patent US 9611485
TCATCTCTGATAA
>KH715325.1 Sequence 4 from patent US 9611485
TCATGTGTGATAA
>KH715324.1 Sequence 3 from patent US 9611485
TCATCTGTGATAA
>KH714682.1 Sequence 17 from patent US 9611480
TCAGGCCTGCTGC
>KH713428.1 Sequence 13 from patent US 9611245
AGAATGTAGGTCA
>LZ186505.1 JP 2017149744-A/67: Vaccination in newborns and infants
GGGTTTTTTTGGG
>LZ186495.1 JP 2017149744-A/57: Vaccination in newborns and infants
GGTTTTTTTTTGG
>LZ186408.1 JP 2017149743-A/67: Vaccination in elderly patients
GGGTTTTTTTGGG
>LZ186398.1 JP 2017149743-A/57: Vaccination in elderly patients
GGTTTTTTTTTGG
>LZ185877.1 JP 2017141245-A/1: Vectors Conditionally Expressing Protein
AGGTCANAGGTCA
>LZ209009.1 WO 2017135397-A/127: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGGTCCCCGCCC
>LZ209008.1 WO 2017135397-A/126: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCATGTTGTGCA
>LZ209007.1 WO 2017135397-A/125: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCATGTTGTGCAA
>LZ209006.1 WO 2017135397-A/124: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTTCGTGACCCAG
>LZ209005.1 WO 2017135397-A/123: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGTGACCCAGTCT
>LZ209004.1 WO 2017135397-A/122: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGACCCAGTCTG
>LZ209003.1 WO 2017135397-A/121: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGACCCAGTCTGC
>LZ209002.1 WO 2017135397-A/120: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GACCCAGTCTGCA
>LZ209001.1 WO 2017135397-A/119: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCCAGTCTGCAT
>LZ209000.1 WO 2017135397-A/118: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTGTGAAGTTGC
>LZ208999.1 WO 2017135397-A/117: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCCCAATGCTGT
>LZ208998.1 WO 2017135397-A/116: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGCTGCCCACCTT
>LZ208997.1 WO 2017135397-A/115: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCACCTTCCTTGT
>LZ208996.1 WO 2017135397-A/114: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTTGGCAGGTGCG
>LZ208995.1 WO 2017135397-A/113: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGCAGAGCCCCG
>LZ208994.1 WO 2017135397-A/112: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCGTCATAGCAG
>LZ208993.1 WO 2017135397-A/111: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGCACTCTGCCT
>LZ208992.1 WO 2017135397-A/110: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTCCAGGACCCC
>LZ208991.1 WO 2017135397-A/109: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTCCAGGACCCCG
>LZ208990.1 WO 2017135397-A/108: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGCCGCCTTTGA
>LZ208989.1 WO 2017135397-A/107: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCGCCTTTGATC
>LZ208988.1 WO 2017135397-A/106: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCGCCTTTGATCT
>LZ208987.1 WO 2017135397-A/105: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCTTTGATCTCT
>LZ208986.1 WO 2017135397-A/104: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTTTGATCTCTA
>LZ208985.1 WO 2017135397-A/103: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCTGGCTGAAGG
>LZ208984.1 WO 2017135397-A/102: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGTGCTGCCCTG
>LZ208983.1 WO 2017135397-A/101: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCGAGACTTTCAC
>LZ208982.1 WO 2017135397-A/100: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACGCCCGAGACTT
>LZ208981.1 WO 2017135397-A/99: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGCTGGGGAGTAG
>LZ208980.1 WO 2017135397-A/98: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGCCCCTTGATAG
>LZ208979.1 WO 2017135397-A/97: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGCGGCCCCTTG
>LZ208978.1 WO 2017135397-A/96: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGGCGGCCCCTT
>LZ208977.1 WO 2017135397-A/95: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ATCAAGAATGGGG
>LZ208976.1 WO 2017135397-A/94: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTCCCTGCACAG
>LZ208975.1 WO 2017135397-A/93: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTGATCAAGCTC
>LZ208974.1 WO 2017135397-A/92: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCCTGATCAAGC
>LZ208973.1 WO 2017135397-A/91: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTTGCCCTGATCA
>LZ208972.1 WO 2017135397-A/90: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGTTGCCCTGATC
>LZ208971.1 WO 2017135397-A/89: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GACGTTGCCCTGA
>LZ208970.1 WO 2017135397-A/88: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGACGTTGCCCTG
>LZ208969.1 WO 2017135397-A/87: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACAAGGAACACTC
>LZ208968.1 WO 2017135397-A/86: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GACAAGGAACACT
>LZ208967.1 WO 2017135397-A/85: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGCTGTGGTGTCT
>LZ208966.1 WO 2017135397-A/84: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGGGGCTGTGGT
>LZ208965.1 WO 2017135397-A/83: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTGTATGGGGGC
>LZ208964.1 WO 2017135397-A/82: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGCTGTATGGGG
>LZ208963.1 WO 2017135397-A/81: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGTTTGGGAACAC
>LZ208962.1 WO 2017135397-A/80: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCTGTGGCATGGT
>LZ208961.1 WO 2017135397-A/79: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTCTCTGTGGCAT
>LZ208960.1 WO 2017135397-A/78: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGTCTCTGTGGCA
>LZ208959.1 WO 2017135397-A/77: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ATGAGATCCGGGA
>LZ209083.1 WO 2017135452-A/43: Transgenic silk worm having mammalian-type glycosylations
TCGAGGCTAGCGG
>LZ209082.1 WO 2017135452-A/42: Transgenic silk worm having mammalian-type glycosylations
CGCGCCGCTAGCC
>LZ209037.1 WO 2017135397-A/155: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCATGTTGTGCAA
>LZ209036.1 WO 2017135397-A/154: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTTCAGCCAGGG
>LZ209035.1 WO 2017135397-A/153: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAGGGCAGCACTT
>LZ209034.1 WO 2017135397-A/152: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGAAAGTCTCGG
>LZ209033.1 WO 2017135397-A/151: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGTCTCGGGCGT
>LZ209032.1 WO 2017135397-A/150: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTACTCCCCAGCT
>LZ209031.1 WO 2017135397-A/149: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTATCAAGGGGCC
>LZ209030.1 WO 2017135397-A/148: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAAGGGGCCGCCA
>LZ209029.1 WO 2017135397-A/147: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGGGGCCGCCAG
>LZ209028.1 WO 2017135397-A/146: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCCATTCTTGAT
>LZ209027.1 WO 2017135397-A/145: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGTGCAGGGAGC
>LZ209026.1 WO 2017135397-A/144: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGCTTGATCAGG
>LZ209025.1 WO 2017135397-A/143: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTTGATCAGGGC
>LZ209024.1 WO 2017135397-A/142: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGATCAGGGCAAC
>LZ209023.1 WO 2017135397-A/141: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GATCAGGGCAACG
>LZ209022.1 WO 2017135397-A/140: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCAGGGCAACGTC
>LZ209021.1 WO 2017135397-A/139: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAGGGCAACGTCA
>LZ209020.1 WO 2017135397-A/138: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGTGTTCCTTGT
>LZ209019.1 WO 2017135397-A/137: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGTGTTCCTTGTC
>LZ209018.1 WO 2017135397-A/136: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGACACCACAGCC
>LZ209017.1 WO 2017135397-A/135: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCACAGCCCCCA
>LZ209016.1 WO 2017135397-A/134: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCCCCATACAGC
>LZ209015.1 WO 2017135397-A/133: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCCATACAGCTC
>LZ209014.1 WO 2017135397-A/132: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGTTCCCAAACC
>LZ209013.1 WO 2017135397-A/131: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCATGCCACAGA
>LZ209012.1 WO 2017135397-A/130: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ATGCCACAGAGAC
>LZ209011.1 WO 2017135397-A/129: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGCCACAGAGACT
>LZ209010.1 WO 2017135397-A/128: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCCCGGATCTCAT
>LZ208958.1 WO 2017135397-A/76: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGGCGGGGACCCA
>LZ208957.1 WO 2017135397-A/75: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGCACAACATGGG
>LZ208956.1 WO 2017135397-A/74: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TTGCACAACATGG
>LZ208955.1 WO 2017135397-A/73: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGGGTCACGAAG
>LZ208954.1 WO 2017135397-A/72: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGACTGGGTCACG
>LZ208953.1 WO 2017135397-A/71: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAGACTGGGTCAC
>LZ208952.1 WO 2017135397-A/70: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCAGACTGGGTCA
>LZ208951.1 WO 2017135397-A/69: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGCAGACTGGGTC
>LZ208950.1 WO 2017135397-A/68: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ATGCAGACTGGGT
>LZ208949.1 WO 2017135397-A/67: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCAACTTCACAGG
>LZ208948.1 WO 2017135397-A/66: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACAGCATTGGGGC
>LZ208947.1 WO 2017135397-A/65: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGGTGGGCAGCC
>LZ208946.1 WO 2017135397-A/64: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACAAGGAAGGTGG
>LZ208945.1 WO 2017135397-A/63: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGCACCTGCCAAG
>LZ208944.1 WO 2017135397-A/62: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGGGGCTCTGCCA
>LZ208943.1 WO 2017135397-A/61: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGCTATGACGGT
>LZ208942.1 WO 2017135397-A/60: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGGCAGAGTGCAG
>LZ208941.1 WO 2017135397-A/59: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGGGTCCTGGAGC
>LZ208940.1 WO 2017135397-A/58: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGGGGTCCTGGAG
>LZ208939.1 WO 2017135397-A/57: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCAAAGGCGGCTC
>LZ208938.1 WO 2017135397-A/56: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GATCAAAGGCGGC
>LZ208937.1 WO 2017135397-A/55: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGATCAAAGGCGG
>LZ208936.1 WO 2017135397-A/54: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGAGATCAAAGGC
>LZ208935.1 WO 2017135397-A/53: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TAGAGATCAAAGG
>LZ208934.1 WO 2017135397-A/52: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTTCAGCCAGGG
>LZ208933.1 WO 2017135397-A/51: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAGGGCAGCACTT
>LZ208932.1 WO 2017135397-A/50: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGAAAGTCTCGG
>LZ208931.1 WO 2017135397-A/49: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGTCTCGGGCGT
>LZ208930.1 WO 2017135397-A/48: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTACTCCCCAGCT
>LZ208929.1 WO 2017135397-A/47: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTATCAAGGGGCC
>LZ208928.1 WO 2017135397-A/46: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAAGGGGCCGCCA
>LZ208927.1 WO 2017135397-A/45: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AAGGGGCCGCCAG
>LZ208926.1 WO 2017135397-A/44: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCCATTCTTGAT
>LZ208925.1 WO 2017135397-A/43: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGTGCAGGGAGC
>LZ208924.1 WO 2017135397-A/42: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGCTTGATCAGG
>LZ208923.1 WO 2017135397-A/41: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTTGATCAGGGC
>LZ208922.1 WO 2017135397-A/40: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGATCAGGGCAAC
>LZ208921.1 WO 2017135397-A/39: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GATCAGGGCAACG
>LZ208920.1 WO 2017135397-A/38: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCAGGGCAACGTC
>LZ208919.1 WO 2017135397-A/37: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CAGGGCAACGTCA
>LZ208918.1 WO 2017135397-A/36: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGTGTTCCTTGT
>LZ208917.1 WO 2017135397-A/35: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGTGTTCCTTGTC
>LZ208916.1 WO 2017135397-A/34: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
AGACACCACAGCC
>LZ208915.1 WO 2017135397-A/33: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCACAGCCCCCA
>LZ208914.1 WO 2017135397-A/32: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCCCCATACAGC
>LZ208913.1 WO 2017135397-A/31: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCCATACAGCTC
>LZ208912.1 WO 2017135397-A/30: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGTTCCCAAACC
>LZ208911.1 WO 2017135397-A/29: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCATGCCACAGA
>LZ208910.1 WO 2017135397-A/28: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ATGCCACAGAGAC
>LZ208909.1 WO 2017135397-A/27: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGCCACAGAGACT
>LZ208908.1 WO 2017135397-A/26: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TCCCGGATCTCAT
>LZ208907.1 WO 2017135397-A/25: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGGTCCCCGCCC
>LZ208906.1 WO 2017135397-A/24: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCCATGTTGTGCA
>LZ208905.1 WO 2017135397-A/23: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCATGTTGTGCAA
>LZ208904.1 WO 2017135397-A/22: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTTCGTGACCCAG
>LZ208903.1 WO 2017135397-A/21: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CGTGACCCAGTCT
>LZ208902.1 WO 2017135397-A/20: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GTGACCCAGTCTG
>LZ208901.1 WO 2017135397-A/19: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGACCCAGTCTGC
>LZ208900.1 WO 2017135397-A/18: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GACCCAGTCTGCA
>LZ208899.1 WO 2017135397-A/17: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCCAGTCTGCAT
>LZ208898.1 WO 2017135397-A/16: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTGTGAAGTTGC
>LZ208897.1 WO 2017135397-A/15: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCCCAATGCTGT
>LZ208896.1 WO 2017135397-A/14: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GGCTGCCCACCTT
>LZ208895.1 WO 2017135397-A/13: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCACCTTCCTTGT
>LZ208894.1 WO 2017135397-A/12: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTTGGCAGGTGCG
>LZ208893.1 WO 2017135397-A/11: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
TGGCAGAGCCCCG
>LZ208892.1 WO 2017135397-A/10: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
ACCGTCATAGCAG
>LZ208891.1 WO 2017135397-A/9: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTGCACTCTGCCT
>LZ208890.1 WO 2017135397-A/8: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCTCCAGGACCCC
>LZ208889.1 WO 2017135397-A/7: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CTCCAGGACCCCG
>LZ208888.1 WO 2017135397-A/6: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GAGCCGCCTTTGA
>LZ208887.1 WO 2017135397-A/5: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCGCCTTTGATC
>LZ208886.1 WO 2017135397-A/4: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCGCCTTTGATCT
>LZ208885.1 WO 2017135397-A/3: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
GCCTTTGATCTCT
>LZ208884.1 WO 2017135397-A/2: Antisense Oligonucleotide for Inhibiting Expression of complement factor B
CCTTTGATCTCTA
>LZ208011.1 WO 2017131124-A/36: Single Strand Oligonucleotide
CGATTGGTATCGC
>LZ208006.1 WO 2017131124-A/31: Single Strand Oligonucleotide
TGAATACCAATGC
>LZ208005.1 WO 2017131124-A/30: Single Strand Oligonucleotide
GCATTGGTATTCA
>LZ207989.1 WO 2017131124-A/14: Single Strand Oligonucleotide
GCATTGGTATTCA
>LZ207988.1 WO 2017131124-A/13: Single Strand Oligonucleotide
GCATTGGTATTCA
>LZ207984.1 WO 2017131124-A/9: Single Strand Oligonucleotide
TTAGCACTGGCCT
>LZ207982.1 WO 2017131124-A/7: Single Strand Oligonucleotide
AGGCCAGTGCTAA
>LZ207981.1 WO 2017131124-A/6: Single Strand Oligonucleotide
TTAGCACTGGCCT
>LZ208135.1 WO 2017131236-A/1: OLIGONUCLEOTIDE CONJUGATE
GNATTGGTATTNA
>LZ208054.1 WO 2017131208-A/8: Pharmaceutical composition for treatment and/or prevention of cancer
TCTGCATCCCCAG
>LZ178467.1 JP 2017140031-A/27: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GCATTGGTATTCA
>LZ178463.1 JP 2017140031-A/23: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TAGTCCAGTTCAC
>LZ178460.1 JP 2017140031-A/20: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
CCAGGCAGAGACA
>LZ178459.1 JP 2017140031-A/19: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGTCTCTGCCTGG
>LZ178457.1 JP 2017140031-A/17: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGAATACCAATGC
>LZ178456.1 JP 2017140031-A/16: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGAATACCAATGC
>LZ178455.1 JP 2017140031-A/15: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGAATACCAATGC
>LZ178447.1 JP 2017140031-A/7: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
TGAATACCAATGC
>LZ178445.1 JP 2017140031-A/5: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GCATTGGTATTCA
>LZ178041.1 JP 2017136063-A/6: METHODS AND APPARATUS FOR MEASURING ANALYTES USING LARGE SCALE FET ARRAYS
GTCGTACGGCTAA
>LZ177232.1 JP 2017136052-A/43: Transgenic silk worm having mammalian-type glycosylations
TCGAGGCTAGCGG
>LZ177231.1 JP 2017136052-A/42: Transgenic silk worm having mammalian-type glycosylations
CGCGCCGCTAGCC
>LZ177368.1 JP 2017141181-A/5: Compounds, probe, condensate and method for detecting cytosine
GCGTTATATTGCG
>LZ177367.1 JP 2017141181-A/4: Compounds, probe, condensate and method for detecting cytosine
GCGTTAGATTGCG
>LZ177366.1 JP 2017141181-A/3: Compounds, probe, condensate and method for detecting cytosine
GCGTTAAATTGCG
>LZ177365.1 JP 2017141181-A/2: Compounds, probe, condensate and method for detecting cytosine
GCGTTACATTGCG
>LZ177364.1 JP 2017141181-A/1: Compounds, probe, condensate and method for detecting cytosine
CGCAATNTAACGC
>LX281127.1 JP 2016509837-A/18: Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
TGAATACCAATGC
>LX281124.1 JP 2016509837-A/15: Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
GCATTGGTATTCA
>LX281119.1 JP 2016509837-A/10: Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
TGAATACCAATGC
>LX281117.1 JP 2016509837-A/8: Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
GCATTGGTATTCA
>LX281110.1 JP 2016509837-A/1: Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
GCATTGGTATTCA
>LX280982.1 JP 2016508367-A/20: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX280975.1 JP 2016508367-A/13: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX280974.1 JP 2016508367-A/12: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX280973.1 JP 2016508367-A/11: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX280971.1 JP 2016508367-A/9: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX280970.1 JP 2016508367-A/8: LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
GCATTGGTATTCA
>LX279310.1 JP 2016105724-A/71: Complexation of nucleic acids with disulfide-linked cationic polymers for transfection and immunostimulation
GGGTTTTTTTGGG
>LX279299.1 JP 2016105724-A/60: Complexation of nucleic acids with disulfide-linked cationic polymers for transfection and immunostimulation
GGTTTTTTTTTGG
>LZ104001.1 JP 2017514479-A/16: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
GTTAGGGTTAGAC
>LZ103997.1 JP 2017514479-A/12: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
ACGGTGGAAGGCG
>LZ103996.1 JP 2017514479-A/11: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
CGGTGGAAGGCGG
>LZ103994.1 JP 2017514479-A/9: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
GTGGAAGGCGGCA
>LZ103993.1 JP 2017514479-A/8: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
GGAAGGCGGCAGG
>LZ103990.1 JP 2017514479-A/5: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
CAGTTAGGGTTAG
>LZ103988.1 JP 2017514479-A/3: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
TAGGGTTAGACAA
>LZ176573.1 JP 2017514908-A/1429: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176571.1 JP 2017514908-A/1427: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176569.1 JP 2017514908-A/1425: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176567.1 JP 2017514908-A/1423: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
NNGNGGAAGNNNA
>LZ176565.1 JP 2017514908-A/1421: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176563.1 JP 2017514908-A/1419: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176561.1 JP 2017514908-A/1417: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176559.1 JP 2017514908-A/1415: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176557.1 JP 2017514908-A/1413: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176555.1 JP 2017514908-A/1411: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
NNGNGGAAGNNNA
>LZ176553.1 JP 2017514908-A/1409: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
NNGNGGAAGNNNA
>LZ176551.1 JP 2017514908-A/1407: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
NNGNGGAAGNNNA
>LZ176549.1 JP 2017514908-A/1405: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
NNGNGGAAGNNNA
>LZ176547.1 JP 2017514908-A/1403: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176545.1 JP 2017514908-A/1401: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176543.1 JP 2017514908-A/1399: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAAGTCTA
>LZ176539.1 JP 2017514908-A/1395: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCGGATCAAACA
>LZ176525.1 JP 2017514908-A/1381: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAACAGTCCTTA
>LZ176524.1 JP 2017514908-A/1380: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAACAGTCCTTA
>LZ176523.1 JP 2017514908-A/1379: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAACAGTCCTTA
>LZ176521.1 JP 2017514908-A/1377: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAACAGTCCTTA
>LZ176517.1 JP 2017514908-A/1373: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACTAGCTTATCA
>LZ176515.1 JP 2017514908-A/1371: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCACTAGCTTATA
>LZ176513.1 JP 2017514908-A/1369: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATCTTTTGCTCTA
>LZ176511.1 JP 2017514908-A/1367: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATCTTTTGCTCA
>LZ176509.1 JP 2017514908-A/1365: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACCACTAGTTCA
>LZ176507.1 JP 2017514908-A/1363: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAACCACTAGTA
>LZ176505.1 JP 2017514908-A/1361: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGAAAGACAGAA
>LZ176503.1 JP 2017514908-A/1359: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGACTGCTGTGA
>LZ176501.1 JP 2017514908-A/1357: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGATTCGCCATTA
>LZ176499.1 JP 2017514908-A/1355: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCGGATCAAACA
>LZ176497.1 JP 2017514908-A/1353: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATTATGCGGATA
>LZ176495.1 JP 2017514908-A/1351: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCAGATTATGCA
>LZ176493.1 JP 2017514908-A/1349: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGAACAGTCCTA
>LZ176491.1 JP 2017514908-A/1347: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCTACTGTTTAA
>LZ176489.1 JP 2017514908-A/1345: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTGGTGCTACTA
>LZ176487.1 JP 2017514908-A/1343: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCTCTCCTTTTA
>LZ176485.1 JP 2017514908-A/1341: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCTCTCTCCTTTA
>LZ176483.1 JP 2017514908-A/1339: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATCTCTCTCCTA
>LZ176481.1 JP 2017514908-A/1337: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAATAAGGTTTCA
>LZ176479.1 JP 2017514908-A/1335: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACACTCAGCTCTA
>LZ176477.1 JP 2017514908-A/1333: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAAAGAGAAAGA
>LZ176475.1 JP 2017514908-A/1331: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAAAAGAGAAAA
>LZ176473.1 JP 2017514908-A/1329: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGAAAAGAGAAA
>LZ176471.1 JP 2017514908-A/1327: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGAAACCACTAA
>LZ176469.1 JP 2017514908-A/1325: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTTATTGGTGTA
>LZ176467.1 JP 2017514908-A/1323: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTAATCCAGAAAA
>LZ176465.1 JP 2017514908-A/1321: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCCTTAATCCAA
>LZ176463.1 JP 2017514908-A/1319: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGTCCTTAATCA
>LZ176461.1 JP 2017514908-A/1317: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAACAGTCCTTAA
>LZ176459.1 JP 2017514908-A/1315: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAACAGTCCTTA
>LZ176457.1 JP 2017514908-A/1313: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATGAGCTTCCTA
>LZ176455.1 JP 2017514908-A/1311: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176453.1 JP 2017514908-A/1309: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176451.1 JP 2017514908-A/1307: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176449.1 JP 2017514908-A/1305: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176447.1 JP 2017514908-A/1303: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176445.1 JP 2017514908-A/1301: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGATTCAAGTCAA
>LZ176443.1 JP 2017514908-A/1299: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176441.1 JP 2017514908-A/1297: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176439.1 JP 2017514908-A/1295: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176437.1 JP 2017514908-A/1293: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176435.1 JP 2017514908-A/1291: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176433.1 JP 2017514908-A/1289: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176431.1 JP 2017514908-A/1287: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176429.1 JP 2017514908-A/1285: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176427.1 JP 2017514908-A/1283: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGATTCAAGTCA
>LZ176425.1 JP 2017514908-A/1281: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGACAAAACCAA
>LZ176423.1 JP 2017514908-A/1279: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGACAGCAAAGAA
>LZ176421.1 JP 2017514908-A/1277: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAGCAACA
>LZ176419.1 JP 2017514908-A/1275: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGATTCAAGTCAA
>LZ176417.1 JP 2017514908-A/1273: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAATCTATGACAA
>LZ176415.1 JP 2017514908-A/1271: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACAGCAAAGATAA
>LZ176413.1 JP 2017514908-A/1269: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTCTACCAGAAA
>LZ176411.1 JP 2017514908-A/1267: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACTCTACCAGAA
>LZ176409.1 JP 2017514908-A/1265: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCAAAGATAATGA
>LZ176407.1 JP 2017514908-A/1263: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAACTCTACCAGA
>LZ176405.1 JP 2017514908-A/1261: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAATATAGCAAA
>LZ176403.1 JP 2017514908-A/1259: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACACAGCATATA
>LZ176401.1 JP 2017514908-A/1257: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATCTATGACAAA
>LZ176399.1 JP 2017514908-A/1255: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAAGCAGAGTACA
>LZ176397.1 JP 2017514908-A/1253: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGTTCAAGCAGA
>LZ176395.1 JP 2017514908-A/1251: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATGACAAGTTCA
>LZ176393.1 JP 2017514908-A/1249: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAACGAAATCTAA
>LZ176391.1 JP 2017514908-A/1247: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTATGACAAGTTA
>LZ176389.1 JP 2017514908-A/1245: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTAAAGATGGAGA
>LZ176387.1 JP 2017514908-A/1243: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACAAGTTCAAGA
>LZ176385.1 JP 2017514908-A/1241: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATATATGTTCTTA
>LZ176383.1 JP 2017514908-A/1239: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCAGAGTACACA
>LZ176381.1 JP 2017514908-A/1237: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCAACACATCAA
>LZ176379.1 JP 2017514908-A/1235: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGCAGAGTACAA
>LZ176377.1 JP 2017514908-A/1233: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAGTACACACAA
>LZ176375.1 JP 2017514908-A/1231: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCATATATATGA
>LZ176373.1 JP 2017514908-A/1229: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCAAGCAGAGTAA
>LZ176371.1 JP 2017514908-A/1227: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCATATATATA
>LZ176369.1 JP 2017514908-A/1225: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACACACAGCATAA
>LZ176367.1 JP 2017514908-A/1223: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGAGTACACACA
>LZ176365.1 JP 2017514908-A/1221: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAAGTTCAAGCAA
>LZ176361.1 JP 2017514908-A/1217: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTGCTTCAGCTA
>LZ176359.1 JP 2017514908-A/1215: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACAGCATATATAA
>LZ176355.1 JP 2017514908-A/1211: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGCTTCAGCTCA
>LZ176353.1 JP 2017514908-A/1209: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CATATATATGTTA
>LZ176351.1 JP 2017514908-A/1207: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCAACAATTCA
>LZ176349.1 JP 2017514908-A/1205: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCATATATATGA
>LZ176345.1 JP 2017514908-A/1201: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTACATTGACTA
>LZ176343.1 JP 2017514908-A/1199: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCATATATATGTA
>LZ176339.1 JP 2017514908-A/1195: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACTATTGCTTCA
>LZ176335.1 JP 2017514908-A/1191: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTACATTGACTTA
>LZ176333.1 JP 2017514908-A/1189: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCATATATATA
>LZ176331.1 JP 2017514908-A/1187: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACAGCATATATA
>LZ176329.1 JP 2017514908-A/1185: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCTCCACGGAGAA
>LZ176327.1 JP 2017514908-A/1183: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCTGCAAGACTA
>LZ176325.1 JP 2017514908-A/1181: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACTATCGACATG
>LZ176323.1 JP 2017514908-A/1179: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCATCGAGGCCAT
>LZ176321.1 JP 2017514908-A/1177: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCGGAAGCGCAT
>LZ176319.1 JP 2017514908-A/1175: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAACATGATCGT
>LZ176317.1 JP 2017514908-A/1173: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCAAGGTCCTG
>LZ176315.1 JP 2017514908-A/1171: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATGATCGTGCG
>LZ176313.1 JP 2017514908-A/1169: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACATGATCGTGC
>LZ176311.1 JP 2017514908-A/1167: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TACAGCAAGGTCC
>LZ176309.1 JP 2017514908-A/1165: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTGGATCCACGA
>LZ176307.1 JP 2017514908-A/1163: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAATTCCTGGCGA
>LZ176305.1 JP 2017514908-A/1161: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGATCGTGCGCTC
>LZ176301.1 JP 2017514908-A/1157: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176299.1 JP 2017514908-A/1155: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176297.1 JP 2017514908-A/1153: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176295.1 JP 2017514908-A/1151: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176293.1 JP 2017514908-A/1149: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176291.1 JP 2017514908-A/1147: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176289.1 JP 2017514908-A/1145: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176287.1 JP 2017514908-A/1143: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176285.1 JP 2017514908-A/1141: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176283.1 JP 2017514908-A/1139: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176281.1 JP 2017514908-A/1137: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176279.1 JP 2017514908-A/1135: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176277.1 JP 2017514908-A/1133: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176275.1 JP 2017514908-A/1131: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ176265.1 JP 2017514908-A/1121: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTCTACATTTCA
>LZ176263.1 JP 2017514908-A/1119: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCTGCCTAAGGAA
>LZ176261.1 JP 2017514908-A/1117: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACGACAACGATGA
>LZ176259.1 JP 2017514908-A/1115: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGACAACAACAAA
>LZ176257.1 JP 2017514908-A/1113: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACTCAAACGAGA
>LZ176255.1 JP 2017514908-A/1111: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATCAGTGTTAA
>LZ103232.1 JP 2017513489-A/28: Therapeutic
CGCGCCACATAGC
>LZ103215.1 JP 2017513489-A/11: Therapeutic
CTCATCATTGGAA
>LZ176253.1 JP 2017514908-A/1109: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGTCAGTTTAGA
>LZ176251.1 JP 2017514908-A/1107: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTAAACCAGTGAA
>LZ176249.1 JP 2017514908-A/1105: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGACGACAACGAA
>LZ176247.1 JP 2017514908-A/1103: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATATGACCGAGAA
>LZ176245.1 JP 2017514908-A/1101: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTCAAACGAGCA
>LZ176243.1 JP 2017514908-A/1099: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAGAAACTCATA
>LZ176241.1 JP 2017514908-A/1097: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTATTGCTATGCA
>LZ176239.1 JP 2017514908-A/1095: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGAAACTCATGA
>LZ176237.1 JP 2017514908-A/1093: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGCTTGTAACAA
>LZ176235.1 JP 2017514908-A/1091: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACAACAACAACA
>LZ176231.1 JP 2017514908-A/1087: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATAAAACAGGTGA
>LZ176227.1 JP 2017514908-A/1083: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGCACTACAAAA
>LZ176223.1 JP 2017514908-A/1079: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAATTTATTAGTA
>LZ176219.1 JP 2017514908-A/1075: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTTGCACTACAAA
>LZ176215.1 JP 2017514908-A/1071: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAATACTTTGCCA
>LZ176211.1 JP 2017514908-A/1067: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGTGTTCTGTTA
>LZ176207.1 JP 2017514908-A/1063: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGGCTTAAGGAA
>LZ176203.1 JP 2017514908-A/1059: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATCAGTGTTAAAA
>LZ176199.1 JP 2017514908-A/1055: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATTTATTGTGTA
>LZ176197.1 JP 2017514908-A/1053: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACGCCAAGGAGGT
>LZ176195.1 JP 2017514908-A/1051: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCCACTAGGAA
>LZ176193.1 JP 2017514908-A/1049: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGTGATCAGAAA
>LZ176191.1 JP 2017514908-A/1047: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGTCCACTAGGA
>LZ176189.1 JP 2017514908-A/1045: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCTCCACATATA
>LZ176187.1 JP 2017514908-A/1043: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCCTGCTAATGT
>LZ176185.1 JP 2017514908-A/1041: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGGTGATCAGAA
>LZ176183.1 JP 2017514908-A/1039: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGCCAAGGAGGTT
>LZ176181.1 JP 2017514908-A/1037: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTTCCATCTACAA
>LZ176179.1 JP 2017514908-A/1035: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCCATCTACAACA
>LZ176177.1 JP 2017514908-A/1033: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTCCATCTACA
>LZ176175.1 JP 2017514908-A/1031: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAAGGAGGTTTA
>LZ176173.1 JP 2017514908-A/1029: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACAGGAACCTGG
>LZ176171.1 JP 2017514908-A/1027: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGCTCTCCTTCGA
>LZ176169.1 JP 2017514908-A/1025: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176167.1 JP 2017514908-A/1023: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176165.1 JP 2017514908-A/1021: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176163.1 JP 2017514908-A/1019: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176161.1 JP 2017514908-A/1017: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176159.1 JP 2017514908-A/1015: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176157.1 JP 2017514908-A/1013: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176155.1 JP 2017514908-A/1011: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176153.1 JP 2017514908-A/1009: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176151.1 JP 2017514908-A/1007: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176149.1 JP 2017514908-A/1005: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176147.1 JP 2017514908-A/1003: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176145.1 JP 2017514908-A/1001: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176143.1 JP 2017514908-A/999: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176141.1 JP 2017514908-A/997: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176139.1 JP 2017514908-A/995: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176137.1 JP 2017514908-A/993: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176135.1 JP 2017514908-A/991: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176133.1 JP 2017514908-A/989: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176131.1 JP 2017514908-A/987: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176105.1 JP 2017514908-A/961: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176103.1 JP 2017514908-A/959: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176101.1 JP 2017514908-A/957: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176099.1 JP 2017514908-A/955: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176097.1 JP 2017514908-A/953: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176095.1 JP 2017514908-A/951: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176093.1 JP 2017514908-A/949: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176091.1 JP 2017514908-A/947: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176089.1 JP 2017514908-A/945: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176087.1 JP 2017514908-A/943: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176085.1 JP 2017514908-A/941: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176083.1 JP 2017514908-A/939: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176081.1 JP 2017514908-A/937: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176079.1 JP 2017514908-A/935: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176077.1 JP 2017514908-A/933: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176075.1 JP 2017514908-A/931: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176073.1 JP 2017514908-A/929: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176071.1 JP 2017514908-A/927: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176069.1 JP 2017514908-A/925: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176067.1 JP 2017514908-A/923: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176065.1 JP 2017514908-A/921: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176063.1 JP 2017514908-A/919: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176031.1 JP 2017514908-A/887: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176029.1 JP 2017514908-A/885: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176027.1 JP 2017514908-A/883: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ176025.1 JP 2017514908-A/881: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176023.1 JP 2017514908-A/879: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176021.1 JP 2017514908-A/877: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176019.1 JP 2017514908-A/875: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176017.1 JP 2017514908-A/873: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176015.1 JP 2017514908-A/871: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176013.1 JP 2017514908-A/869: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176011.1 JP 2017514908-A/867: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176009.1 JP 2017514908-A/865: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176007.1 JP 2017514908-A/863: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176005.1 JP 2017514908-A/861: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ176003.1 JP 2017514908-A/859: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTTCTAGTTGA
>LZ176001.1 JP 2017514908-A/857: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCACCTTTCTAGA
>LZ175999.1 JP 2017514908-A/855: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACCAAAAGTTAA
>LZ175997.1 JP 2017514908-A/853: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACCAAAAGTA
>LZ175993.1 JP 2017514908-A/849: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTGACCAAAAGA
>LZ175991.1 JP 2017514908-A/847: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGTGACCAAAAA
>LZ175987.1 JP 2017514908-A/843: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTGTGACCAAAA
>LZ175985.1 JP 2017514908-A/841: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAGAGTGTGACA
>LZ175983.1 JP 2017514908-A/839: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGAGCTTTCTGA
>LZ175979.1 JP 2017514908-A/835: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCACCTTTCTAA
>LZ175975.1 JP 2017514908-A/831: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTTGAGAGTGTA
>LZ175973.1 JP 2017514908-A/829: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGTTTATTTGTA
>LZ175969.1 JP 2017514908-A/825: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACAAGCCAGATTA
>LZ175965.1 JP 2017514908-A/821: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTTGCCTGTAACA
>LZ175963.1 JP 2017514908-A/819: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTCGATTAGAA
>LZ175961.1 JP 2017514908-A/817: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTGATTCGAAA
>LZ175959.1 JP 2017514908-A/815: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CATTCTGATTCGA
>LZ175957.1 JP 2017514908-A/813: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGAGAAGGAAAA
>LZ175955.1 JP 2017514908-A/811: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATTGAGAAGGAA
>LZ175953.1 JP 2017514908-A/809: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAAGTGTAATTA
>LZ175949.1 JP 2017514908-A/805: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATAGCATCTTAA
>LZ175945.1 JP 2017514908-A/801: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAAGAATGTTAA
>LZ175941.1 JP 2017514908-A/797: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATTAACTCATA
>LZ175939.1 JP 2017514908-A/795: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAGCTGACCTGG
>LZ175937.1 JP 2017514908-A/793: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATCAAGTTTGAG
>LZ175935.1 JP 2017514908-A/791: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCGCAAGATCGGC
>LZ175933.1 JP 2017514908-A/789: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGACACGTTTGGC
>LZ175931.1 JP 2017514908-A/787: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTAAATTCTGTGG
>LZ175929.1 JP 2017514908-A/785: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCTAAATTCTGTG
>LZ175927.1 JP 2017514908-A/783: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGACTTCGGC
>LZ175925.1 JP 2017514908-A/781: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTGCGAAGCTG
>LZ175923.1 JP 2017514908-A/779: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCGAAGCTGACC
>LZ175921.1 JP 2017514908-A/777: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TACGGAGACATGG
>LZ175919.1 JP 2017514908-A/775: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTGTTCCAAGAC
>LZ175917.1 JP 2017514908-A/773: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTACCAGTGCACG
>LZ175915.1 JP 2017514908-A/771: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAATGACAACGCC
>LZ175913.1 JP 2017514908-A/769: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGCGAAGCTGAC
>LZ175911.1 JP 2017514908-A/767: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGAAGCTGACCTG
>LZ175909.1 JP 2017514908-A/765: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTTCCAAGACCT
>LZ175907.1 JP 2017514908-A/763: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTATCAAGTTTG
>LZ175905.1 JP 2017514908-A/761: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCGACTGGAAGAC
>LZ175903.1 JP 2017514908-A/759: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTTGCGAAGCTGA
>LZ175901.1 JP 2017514908-A/757: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGCCTTGCGAAGC
>LZ175899.1 JP 2017514908-A/755: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGAGGTCATGAAG
>LZ175897.1 JP 2017514908-A/753: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGACACGTTTGG
>LZ175895.1 JP 2017514908-A/751: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGCTAAATTCTG
>LZ175893.1 JP 2017514908-A/749: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGTCAGGCCTTGC
>LZ175891.1 JP 2017514908-A/747: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCTAGAGAAGCAG
>LZ175889.1 JP 2017514908-A/745: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGAGTATGTACC
>LZ175887.1 JP 2017514908-A/743: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCAGAACTGCAG
>LZ175885.1 JP 2017514908-A/741: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCAAGTTTGAGCT
>LZ175883.1 JP 2017514908-A/739: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGTCAGGCCTTG
>LZ175881.1 JP 2017514908-A/737: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGACTTCGGCTCC
>LZ175879.1 JP 2017514908-A/735: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGACTTCGGCTC
>LZ175877.1 JP 2017514908-A/733: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGAAGATGTACGG
>LZ175875.1 JP 2017514908-A/731: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCGAAGCTGACCT
>LZ175873.1 JP 2017514908-A/729: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCAGGCCTTGCGA
>LZ175871.1 JP 2017514908-A/727: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACGGAGACATGGC
>LZ175869.1 JP 2017514908-A/725: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACACGTTTGGCC
>LZ175867.1 JP 2017514908-A/723: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGCGAGGTCATGA
>LZ175865.1 JP 2017514908-A/721: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATGACAACGCCT
>LZ175863.1 JP 2017514908-A/719: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGATGTACGGAG
>LZ175861.1 JP 2017514908-A/717: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGAAGACACGTT
>LZ175859.1 JP 2017514908-A/715: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TAAATTCTGTGGA
>LZ175857.1 JP 2017514908-A/713: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGGTCATGAAGA
>LZ175855.1 JP 2017514908-A/711: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGACAACGCCTC
>LZ175853.1 JP 2017514908-A/709: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGGAGACATGGCA
>LZ175851.1 JP 2017514908-A/707: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCTGTGGAGTATG
>LZ175849.1 JP 2017514908-A/705: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGAGCTAAATTCT
>LZ175847.1 JP 2017514908-A/703: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGGCCTTGCGAA
>LZ175845.1 JP 2017514908-A/701: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCGCAAGATCGG
>LZ175843.1 JP 2017514908-A/699: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TACCGACTGGAAG
>LZ175841.1 JP 2017514908-A/697: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGGCCTTGCGAAG
>LZ175839.1 JP 2017514908-A/695: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAGACACGTTTG
>LZ175837.1 JP 2017514908-A/693: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGGTCAGGCCTT
>LZ175835.1 JP 2017514908-A/691: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGTCATGAAGAAG
>LZ175833.1 JP 2017514908-A/689: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGCTGACCTGGA
>LZ175831.1 JP 2017514908-A/687: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTGAAGTGTAA
>LZ175829.1 JP 2017514908-A/685: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTTGTTCCTTAA
>LZ175827.1 JP 2017514908-A/683: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCAGAAAGGTTA
>LZ175825.1 JP 2017514908-A/681: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATACCGAGCTA
>LZ175823.1 JP 2017514908-A/679: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGTTGAGAGTGT
>LZ175821.1 JP 2017514908-A/677: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATACCGAGCTAAA
>LZ175819.1 JP 2017514908-A/675: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGGCCTTTATTA
>LZ175817.1 JP 2017514908-A/673: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACTGGACAGCTT
>LZ175815.1 JP 2017514908-A/671: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATACGAGTAATA
>LZ175813.1 JP 2017514908-A/669: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTATCTAAGTTAA
>LZ175811.1 JP 2017514908-A/667: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTGCTCAGATA
>LZ175809.1 JP 2017514908-A/665: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCTGATCAGTTT
>LZ175807.1 JP 2017514908-A/663: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGGTAGAATGTAA
>LZ175805.1 JP 2017514908-A/661: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCTAAATTCTGT
>LZ175803.1 JP 2017514908-A/659: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTATCAAGTTTGA
>LZ175801.1 JP 2017514908-A/657: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGAAGACACGTTT
>LZ175799.1 JP 2017514908-A/655: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTACCAGTGCAC
>LZ175797.1 JP 2017514908-A/653: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAATGACATCTTT
>LZ175795.1 JP 2017514908-A/651: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTTCAGTAGCACA
>LZ175793.1 JP 2017514908-A/649: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAATTCTGTGGAG
>LZ175791.1 JP 2017514908-A/647: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGTGGAGTATGT
>LZ175789.1 JP 2017514908-A/645: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAAGTTTGAGCTT
>LZ175787.1 JP 2017514908-A/643: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCCTATCAAGTT
>LZ175785.1 JP 2017514908-A/641: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTACGGAGACAT
>LZ175783.1 JP 2017514908-A/639: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATTCTGTGGAGT
>LZ175781.1 JP 2017514908-A/637: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCTATCAAGTTT
>LZ175779.1 JP 2017514908-A/635: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCTGCGAGGAGTG
>LZ175777.1 JP 2017514908-A/633: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCTTGCGAAGCT
>LZ175775.1 JP 2017514908-A/631: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGTACGGAGACA
>LZ175773.1 JP 2017514908-A/629: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCGACTGGAAGA
>LZ175771.1 JP 2017514908-A/627: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGAGTGGAGCGCC
>LZ175769.1 JP 2017514908-A/625: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CATTACAACTGTC
>LZ175767.1 JP 2017514908-A/623: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTACAACTGTCC
>LZ175765.1 JP 2017514908-A/621: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGCCATTACAAC
>LZ175763.1 JP 2017514908-A/619: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCATTACAACTGT
>LZ175761.1 JP 2017514908-A/617: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTGGTCCAGACC
>LZ175759.1 JP 2017514908-A/615: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGAGTGGAGCGC
>LZ175757.1 JP 2017514908-A/613: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGACCTGTGCCTG
>LZ175755.1 JP 2017514908-A/611: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACTGCCTGGTCC
>LZ175753.1 JP 2017514908-A/609: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTGGAAGACACG
>LZ175751.1 JP 2017514908-A/607: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCCATTACAACT
>LZ175749.1 JP 2017514908-A/605: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTTTGAGCTTTCT
>LZ175747.1 JP 2017514908-A/603: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGAGCGCCTGTT
>LZ175745.1 JP 2017514908-A/601: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTGGAGCGCCTG
>LZ175743.1 JP 2017514908-A/599: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGCTTTCTGGCT
>LZ175741.1 JP 2017514908-A/597: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCATTACAACTG
>LZ175739.1 JP 2017514908-A/595: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGAGCGCCTGTTC
>LZ175737.1 JP 2017514908-A/593: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CGACTGGAAGACA
>LZ175735.1 JP 2017514908-A/591: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGTGGAGCGCCT
>LZ175733.1 JP 2017514908-A/589: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACAGGAAGATGTA
>LZ175731.1 JP 2017514908-A/587: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175729.1 JP 2017514908-A/585: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175727.1 JP 2017514908-A/583: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175725.1 JP 2017514908-A/581: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175693.1 JP 2017514908-A/549: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175691.1 JP 2017514908-A/547: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175689.1 JP 2017514908-A/545: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175687.1 JP 2017514908-A/543: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175685.1 JP 2017514908-A/541: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175681.1 JP 2017514908-A/537: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CATCTGCAATAAA
>LZ175677.1 JP 2017514908-A/533: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTGATTGACAA
>LZ175673.1 JP 2017514908-A/529: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATTTGATTGAA
>LZ175669.1 JP 2017514908-A/525: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCACATTTGATTA
>LZ175667.1 JP 2017514908-A/523: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGAAGAAAGTTA
>LZ175665.1 JP 2017514908-A/521: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAGTCTAATGAA
>LZ175663.1 JP 2017514908-A/519: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCAGTATAAGTA
>LZ175661.1 JP 2017514908-A/517: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGCAACACTTGA
>LZ175659.1 JP 2017514908-A/515: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TACTGATAGGAGA
>LZ103127.1 JP 2017513477-A/16: METHODS AND COMPOSITIONS FOR MODIFYING GENOMIC DNA
GGCCNNNNNGGCC
>LZ103113.1 JP 2017513477-A/2: METHODS AND COMPOSITIONS FOR MODIFYING GENOMIC DNA
NACNNNNGTAYCN
>LZ175657.1 JP 2017514908-A/513: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCCAGATCACATA
>LZ175653.1 JP 2017514908-A/509: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATCACATTTGATA
>LZ175651.1 JP 2017514908-A/507: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATTTCATGTCTA
>LZ175649.1 JP 2017514908-A/505: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCTTTTAATGAA
>LZ175647.1 JP 2017514908-A/503: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACCAGTATAAGA
>LZ175645.1 JP 2017514908-A/501: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATACCAGTCTTA
>LZ175641.1 JP 2017514908-A/497: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCACCAACTTACA
>LZ175639.1 JP 2017514908-A/495: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACTCCAAACACA
>LZ175635.1 JP 2017514908-A/491: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTCCAAACACAA
>LZ175633.1 JP 2017514908-A/489: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCTTCCTTCGAAA
>LZ175631.1 JP 2017514908-A/487: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTTGACATCCAGA
>LZ175629.1 JP 2017514908-A/485: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACCTCTCCTATA
>LZ175625.1 JP 2017514908-A/481: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATCACATTTGAA
>LZ175623.1 JP 2017514908-A/479: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCCTATTATACA
>LZ175619.1 JP 2017514908-A/475: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCCACCAACTTAA
>LZ175617.1 JP 2017514908-A/473: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCTCTCCTATTA
>LZ175615.1 JP 2017514908-A/471: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAAACTGCTCAA
>LZ175613.1 JP 2017514908-A/469: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CATTTGATTGACA
>LZ175611.1 JP 2017514908-A/467: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAATACCAGTCTT
>LZ175609.1 JP 2017514908-A/465: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACTGCCTCAATT
>LZ175607.1 JP 2017514908-A/463: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACATTTGATTGA
>LZ175597.1 JP 2017514908-A/453: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGCTGATTCTGGA
>LZ175595.1 JP 2017514908-A/451: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAATTGCAGTGAA
>LZ175593.1 JP 2017514908-A/449: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCTGAAATTTCA
>LZ175591.1 JP 2017514908-A/447: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAAAGAGAACAA
>LZ175589.1 JP 2017514908-A/445: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCAGTGATTTGA
>LZ175587.1 JP 2017514908-A/443: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATGAAAGAGAAA
>LZ175585.1 JP 2017514908-A/441: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACTCCAGTTGTA
>LZ175583.1 JP 2017514908-A/439: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTCACTTTGCA
>LZ175581.1 JP 2017514908-A/437: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCACTTTGCATA
>LZ175579.1 JP 2017514908-A/435: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTTGCATTTAGTA
>LZ175577.1 JP 2017514908-A/433: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTTTGCATTTAGA
>LZ175575.1 JP 2017514908-A/431: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAAGAGAACATA
>LZ175573.1 JP 2017514908-A/429: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCTTTCTCAGTTA
>LZ175571.1 JP 2017514908-A/427: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTTTCTCAGTA
>LZ175569.1 JP 2017514908-A/425: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTAGTCAAAAA
>LZ175567.1 JP 2017514908-A/423: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTTTGCATTTAA
>LZ175565.1 JP 2017514908-A/421: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGCATTTAGTCA
>LZ175563.1 JP 2017514908-A/419: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTTCTCAGTTTAA
>LZ175559.1 JP 2017514908-A/415: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGCTTTTGCCTA
>LZ175555.1 JP 2017514908-A/411: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATTTGCTTTTGA
>LZ175551.1 JP 2017514908-A/407: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACAGCCATGAAA
>LZ175547.1 JP 2017514908-A/403: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATTTCGTATTTA
>LZ175543.1 JP 2017514908-A/399: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTGATTTGCTTTA
>LZ175539.1 JP 2017514908-A/395: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTGCTTTTGCA
>LZ175535.1 JP 2017514908-A/391: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATGAATCTGATA
>LZ175533.1 JP 2017514908-A/389: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCTGCCAGCAAC
>LZ175531.1 JP 2017514908-A/387: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACTCGAACGACT
>LZ175529.1 JP 2017514908-A/385: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAGCAATTAATA
>LZ175527.1 JP 2017514908-A/383: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCCAGCAATTAA
>LZ175525.1 JP 2017514908-A/381: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGAGTCTGGAAA
>LZ175523.1 JP 2017514908-A/379: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATGTGTATCTAT
>LZ175521.1 JP 2017514908-A/377: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCAGCCGTGAAT
>LZ175519.1 JP 2017514908-A/375: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GATGTGATTGATA
>LZ175517.1 JP 2017514908-A/373: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACCAGAGTGCTG
>LZ175515.1 JP 2017514908-A/371: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGTTTATGGACT
>LZ175513.1 JP 2017514908-A/369: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGGTCACTGATT
>LZ175511.1 JP 2017514908-A/367: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAACGAAAGCCA
>LZ175509.1 JP 2017514908-A/365: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCATGAGAATTG
>LZ175507.1 JP 2017514908-A/363: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTCAATTGCTTA
>LZ175505.1 JP 2017514908-A/361: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AATTCCACAGCCA
>LZ175503.1 JP 2017514908-A/359: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAGCATTCCGAT
>LZ175501.1 JP 2017514908-A/357: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGTGCTGAAACC
>LZ175499.1 JP 2017514908-A/355: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAACAGGCTGATT
>LZ175497.1 JP 2017514908-A/353: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACTACCATGAGAA
>LZ175495.1 JP 2017514908-A/351: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCAGCCGTGAA
>LZ175493.1 JP 2017514908-A/349: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATAGTCAGGAACT
>LZ175491.1 JP 2017514908-A/347: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGCCAATGATGA
>LZ175489.1 JP 2017514908-A/345: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TAGTGTGGTTTAT
>LZ175487.1 JP 2017514908-A/343: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACGACTCTGATGA
>LZ175485.1 JP 2017514908-A/341: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCAATTAATAAA
>LZ175483.1 JP 2017514908-A/339: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCAATTGCTTAT
>LZ175481.1 JP 2017514908-A/337: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AACTATCACTGTA
>LZ175479.1 JP 2017514908-A/335: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATTCTATAGAA
>LZ175477.1 JP 2017514908-A/333: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATAACTAATGTGT
>LZ175475.1 JP 2017514908-A/331: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCCGATGTGATT
>LZ175473.1 JP 2017514908-A/329: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TATAAGCGGAAAG
>LZ175471.1 JP 2017514908-A/327: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCAGCTGGATG
>LZ175469.1 JP 2017514908-A/325: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTTGAATGGTGC
>LZ175467.1 JP 2017514908-A/323: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CACCTCACACATG
>LZ175465.1 JP 2017514908-A/321: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCAGCAACCGAA
>LZ175463.1 JP 2017514908-A/319: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCATGAATAGAAA
>LZ175461.1 JP 2017514908-A/317: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGAAATAACTAAT
>LZ175459.1 JP 2017514908-A/315: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GGTTGAATGTGTA
>LZ175457.1 JP 2017514908-A/313: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTGGTTGAATGT
>LZ175455.1 JP 2017514908-A/311: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCCATGAATTT
>LZ175453.1 JP 2017514908-A/309: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCAGAGTGCTGAA
>LZ175451.1 JP 2017514908-A/307: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGAAACGAGTCA
>LZ175449.1 JP 2017514908-A/305: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGTGCATACAAG
>LZ175447.1 JP 2017514908-A/303: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTAGATAGTGCAT
>LZ175445.1 JP 2017514908-A/301: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCAATGAGCATT
>LZ175443.1 JP 2017514908-A/299: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGTTTCGCAGAC
>LZ175441.1 JP 2017514908-A/297: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCCAACGAAAG
>LZ175439.1 JP 2017514908-A/295: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTTTGTGGCTTC
>LZ175437.1 JP 2017514908-A/293: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCTGGAAATAA
>LZ175435.1 JP 2017514908-A/291: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGCCGTGAATTC
>LZ175433.1 JP 2017514908-A/289: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGACGAGGACAT
>LZ175431.1 JP 2017514908-A/287: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TAGACACATATGA
>LZ175429.1 JP 2017514908-A/285: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCTGATGAGTCT
>LZ175427.1 JP 2017514908-A/283: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGCATTTAGTCAA
>LZ175425.1 JP 2017514908-A/281: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TAGTCAGGAACTT
>LZ175423.1 JP 2017514908-A/279: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCATTCCGATGT
>LZ175421.1 JP 2017514908-A/277: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCATTTAGTCAAA
>LZ175419.1 JP 2017514908-A/275: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCAGTCCAGATT
>LZ175417.1 JP 2017514908-A/273: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATATGATGGCCGA
>LZ175415.1 JP 2017514908-A/271: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAATGGTGCATAC
>LZ175413.1 JP 2017514908-A/269: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CCGACCAAGGAAA
>LZ175411.1 JP 2017514908-A/267: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGTTCATTCTATA
>LZ175409.1 JP 2017514908-A/265: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TACCAGTTAAACA
>LZ175407.1 JP 2017514908-A/263: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATATAAGCGGAAA
>LZ175405.1 JP 2017514908-A/261: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CAGTCCAGATTAT
>LZ175403.1 JP 2017514908-A/259: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTATGAAACGAGT
>LZ175401.1 JP 2017514908-A/257: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGTTGAATGTGT
>LZ175399.1 JP 2017514908-A/255: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCAGTCCAGATTA
>LZ175397.1 JP 2017514908-A/253: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATGGAAAGCGA
>LZ175395.1 JP 2017514908-A/251: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTGTCCAGCAATT
>LZ175393.1 JP 2017514908-A/249: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTATAGAAGAA
>LZ175391.1 JP 2017514908-A/247: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGTGTATCTATT
>LZ175389.1 JP 2017514908-A/245: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGATAGTGCATCT
>LZ175387.1 JP 2017514908-A/243: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGATTGATAGTCA
>LZ175385.1 JP 2017514908-A/241: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCGAGGAGTTGAA
>LZ175383.1 JP 2017514908-A/239: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATGATGAGAGCAA
>LZ175381.1 JP 2017514908-A/237: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGTCCAACGAAA
>LZ175379.1 JP 2017514908-A/235: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCTCATGAATAG
>LZ175377.1 JP 2017514908-A/233: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTCTCATGAAT
>LZ175375.1 JP 2017514908-A/231: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCGCCTTCTGATT
>LZ175373.1 JP 2017514908-A/229: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAAATTTCGTATT
>LZ175371.1 JP 2017514908-A/227: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACATGGATGATAT
>LZ175369.1 JP 2017514908-A/225: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAAGCCATGACCA
>LZ175367.1 JP 2017514908-A/223: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ATTTCGTATTTCT
>LZ175365.1 JP 2017514908-A/221: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAATTTCGTATTT
>LZ175363.1 JP 2017514908-A/219: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCGGAAAGCCAAT
>LZ175361.1 JP 2017514908-A/217: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGCCATGACCAC
>LZ175359.1 JP 2017514908-A/215: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GCCATGACCACAT
>LZ175357.1 JP 2017514908-A/213: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
ACCACATGGATGA
>LZ175355.1 JP 2017514908-A/211: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGCGGAAAGCCAA
>LZ175353.1 JP 2017514908-A/209: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AAGCGGAAAGCCA
>LZ175351.1 JP 2017514908-A/207: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
AGTCTCACCATTC
>LZ175349.1 JP 2017514908-A/205: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCACAGCCATGAA
>LZ175347.1 JP 2017514908-A/203: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GACTGAGGTCAAA
>LZ175345.1 JP 2017514908-A/201: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGTCTCACCATT
>LZ175343.1 JP 2017514908-A/199: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGGACTGAGGTCA
>LZ175341.1 JP 2017514908-A/197: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTGATGAATCT
>LZ175339.1 JP 2017514908-A/195: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GTCAGCTGGATGA
>LZ175337.1 JP 2017514908-A/193: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TTCTGAGGTCAAT
>LZ175335.1 JP 2017514908-A/191: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TGAGGTCAATTAA
>LZ175333.1 JP 2017514908-A/189: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
TCTGAGGTCAATT
>LZ175331.1 JP 2017514908-A/187: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
GAGGTCAATTAAA
>LZ175329.1 JP 2017514908-A/185: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTGAGGTCAATTA
>LZ175327.1 JP 2017514908-A/183: METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES
CTCATGAATTAGA
>LZ173433.1 JP 2017515862-A/641: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAAGTGCACACG
>LZ173432.1 JP 2017515862-A/640: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAAGTGCACACG
>LZ173431.1 JP 2017515862-A/639: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAAGTGCACACG
>LZ173422.1 JP 2017515862-A/630: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ173421.1 JP 2017515862-A/629: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ173420.1 JP 2017515862-A/628: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ173419.1 JP 2017515862-A/627: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ173412.1 JP 2017515862-A/620: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ173411.1 JP 2017515862-A/619: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ173410.1 JP 2017515862-A/618: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ173409.1 JP 2017515862-A/617: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ173400.1 JP 2017515862-A/608: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ173399.1 JP 2017515862-A/607: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ173398.1 JP 2017515862-A/606: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ173397.1 JP 2017515862-A/605: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ173392.1 JP 2017515862-A/600: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAACCACTGAAC
>LZ173391.1 JP 2017515862-A/599: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAACCACTGAAC
>LZ173374.1 JP 2017515862-A/582: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGTTCCCAAGAAT
>LZ173371.1 JP 2017515862-A/579: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GTTCCCAAGAATA
>LZ173363.1 JP 2017515862-A/571: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAGGCGAGGGA
>LZ173358.1 JP 2017515862-A/566: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAGGCGAGGGAG
>LZ173354.1 JP 2017515862-A/562: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAGGCGAGGGAGT
>LZ173350.1 JP 2017515862-A/558: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AGGCGAGGGAGTT
>LZ173346.1 JP 2017515862-A/554: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGCGAGGGAGTTC
>LZ173342.1 JP 2017515862-A/550: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAGGGAGTTCT
>LZ173324.1 JP 2017515862-A/532: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGCGAATCCACAC
>LZ173304.1 JP 2017515862-A/512: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCTTGGAGGCTTG
>LZ173298.1 JP 2017515862-A/506: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCAATTTATGCCT
>LZ173297.1 JP 2017515862-A/505: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AATTTATGCCTAC
>LZ173295.1 JP 2017515862-A/503: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TTTATGCCTACAG
>LZ173292.1 JP 2017515862-A/500: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCTCAAGGTCGGT
>LZ173291.1 JP 2017515862-A/499: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CTCAAGGTCGGTC
>LZ173290.1 JP 2017515862-A/498: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTTCACGGTGGT
>LZ173288.1 JP 2017515862-A/496: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTGCAGAGGTGA
>LZ173271.1 JP 2017515862-A/479: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGTGAAGCGAAGT
>LZ173267.1 JP 2017515862-A/475: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GTGAAGCGAAGTG
>LZ173265.1 JP 2017515862-A/473: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGAAGCGAAGTGC
>LZ173262.1 JP 2017515862-A/470: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGCGAAGTGCA
>LZ173257.1 JP 2017515862-A/465: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAGCGAAGTGCAC
>LZ173254.1 JP 2017515862-A/462: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AGCGAAGTGCACA
>LZ173250.1 JP 2017515862-A/458: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAAGTGCACAC
>LZ173236.1 JP 2017515862-A/444: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCGCGTAAAGAGA
>LZ173233.1 JP 2017515862-A/441: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCGTAAAGAGAG
>LZ173228.1 JP 2017515862-A/436: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTAAAGAGAGGT
>LZ173226.1 JP 2017515862-A/434: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TCCGCAGTATGGA
>LZ173224.1 JP 2017515862-A/432: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCGCAGTATGGAT
>LZ173218.1 JP 2017515862-A/426: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCAGTATGGATCG
>LZ173212.1 JP 2017515862-A/420: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCAACGGGGTAAA
>LZ173208.1 JP 2017515862-A/416: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGGGGAAAGCCCT
>LZ173178.1 JP 2017515862-A/386: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TAGCAGCAGGATG
>LZ173176.1 JP 2017515862-A/384: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ATGATAAAACGCC
>LZ173173.1 JP 2017515862-A/381: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGATAAAACGCCG
>LZ173169.1 JP 2017515862-A/377: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GATAAAACGCCGC
>LZ173164.1 JP 2017515862-A/372: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ATAAAACGCCGCA
>LZ173157.1 JP 2017515862-A/365: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAAACGCCGCAGA
>LZ173123.1 JP 2017515862-A/331: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CACGAGTCTAGAC
>LZ173118.1 JP 2017515862-A/326: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ACGAGTCTAGACT
>LZ173112.1 JP 2017515862-A/320: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAAACCCCGCCTG
>LZ173101.1 JP 2017515862-A/309: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAAGTGCACACG
>LZ173098.1 JP 2017515862-A/306: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ173095.1 JP 2017515862-A/303: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ173092.1 JP 2017515862-A/300: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ173090.1 JP 2017515862-A/298: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAACCACTGAAC
>LZ173084.1 JP 2017515862-A/292: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGTTCCCAAGAAT
>LZ173081.1 JP 2017515862-A/289: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GTTCCCAAGAATA
>LZ173073.1 JP 2017515862-A/281: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAGGCGAGGGA
>LZ173068.1 JP 2017515862-A/276: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAGGCGAGGGAG
>LZ173064.1 JP 2017515862-A/272: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAGGCGAGGGAGT
>LZ173060.1 JP 2017515862-A/268: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AGGCGAGGGAGTT
>LZ173056.1 JP 2017515862-A/264: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGCGAGGGAGTTC
>LZ173052.1 JP 2017515862-A/260: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAGGGAGTTCT
>LZ173034.1 JP 2017515862-A/242: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGCGAATCCACAC
>LZ173014.1 JP 2017515862-A/222: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCTTGGAGGCTTG
>LZ173008.1 JP 2017515862-A/216: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCAATTTATGCCT
>LZ173007.1 JP 2017515862-A/215: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AATTTATGCCTAC
>LZ173005.1 JP 2017515862-A/213: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TTTATGCCTACAG
>LZ173002.1 JP 2017515862-A/210: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCTCAAGGTCGGT
>LZ173001.1 JP 2017515862-A/209: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CTCAAGGTCGGTC
>LZ173000.1 JP 2017515862-A/208: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTTCACGGTGGT
>LZ172998.1 JP 2017515862-A/206: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTGCAGAGGTGA
>LZ172981.1 JP 2017515862-A/189: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGTGAAGCGAAGT
>LZ172977.1 JP 2017515862-A/185: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GTGAAGCGAAGTG
>LZ172975.1 JP 2017515862-A/183: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGAAGCGAAGTGC
>LZ172972.1 JP 2017515862-A/180: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGCGAAGTGCA
>LZ172967.1 JP 2017515862-A/175: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAGCGAAGTGCAC
>LZ172964.1 JP 2017515862-A/172: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AGCGAAGTGCACA
>LZ172960.1 JP 2017515862-A/168: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGAAGTGCACAC
>LZ172946.1 JP 2017515862-A/154: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCGCGTAAAGAGA
>LZ172943.1 JP 2017515862-A/151: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCGTAAAGAGAG
>LZ172938.1 JP 2017515862-A/146: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGTAAAGAGAGGT
>LZ172936.1 JP 2017515862-A/144: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TCCGCAGTATGGA
>LZ172934.1 JP 2017515862-A/142: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CCGCAGTATGGAT
>LZ172928.1 JP 2017515862-A/136: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCAGTATGGATCG
>LZ172922.1 JP 2017515862-A/130: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCAACGGGGTAAA
>LZ172918.1 JP 2017515862-A/126: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GGGGGAAAGCCCT
>LZ172888.1 JP 2017515862-A/96: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TAGCAGCAGGATG
>LZ172886.1 JP 2017515862-A/94: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ATGATAAAACGCC
>LZ172883.1 JP 2017515862-A/91: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
TGATAAAACGCCG
>LZ172879.1 JP 2017515862-A/87: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GATAAAACGCCGC
>LZ172874.1 JP 2017515862-A/82: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ATAAAACGCCGCA
>LZ173864.1 JP 2017516487-A/8: METHOD FOR IDENTIFICATION AND ENUMERATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY, OR DNA METHYLATION CHANGES, USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS
AGATCGGAAGAGC
>LZ172867.1 JP 2017515862-A/75: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAAACGCCGCAGA
>LZ172833.1 JP 2017515862-A/41: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CACGAGTCTAGAC
>LZ172828.1 JP 2017515862-A/36: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
ACGAGTCTAGACT
>LZ172822.1 JP 2017515862-A/30: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
AAAACCCCGCCTG
>LZ172811.1 JP 2017515862-A/19: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAAGTGCACACG
>LZ172808.1 JP 2017515862-A/16: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GAAGTGCACACGG
>LZ172805.1 JP 2017515862-A/13: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
GCGTAAAGAGAGG
>LZ172802.1 JP 2017515862-A/10: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGCAGTATGGATC
>LZ172800.1 JP 2017515862-A/8: OLIGOMERS AND OLIGOMER CONJUGATES TARGETING HBV
CGAACCACTGAAC
>LX296474.1 JP 2016516773-A/1: Telomerase Mediated Telomere Altering Compounds
TAGGGTTAGACAA
>LZ172542.1 JP 2017514872-A/5: ANTISENSE TREATMENT OF RADIATION INDUCED DISEASES IN THE GASTROINTESTINAL TRACT
GCCCAAGCTGGCA
>LX295958.1 JP 2016518842-A/8: MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122
TTGTCACACTCCA
>LX295948.1 JP 2016518841-A/6: COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE
TTGTCACACTCCA
>LX295453.1 JP 2015529449-A/27: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
GAAGGCGTTATAG
>LX295452.1 JP 2015529449-A/26: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
NAAAAACTCAGGT
>LX295008.1 JP 2016515385-A/402: Modified TGF-beta oligonucleotides
ATCATGTCGAATT
>LX295007.1 JP 2016515385-A/401: Modified TGF-beta oligonucleotides
TCATGTCGAATTT
>LX295006.1 JP 2016515385-A/400: Modified TGF-beta oligonucleotides
TCCCCTAATGGCT
>LX295005.1 JP 2016515385-A/399: Modified TGF-beta oligonucleotides
CCCCTAATGGCTT
>LX295004.1 JP 2016515385-A/398: Modified TGF-beta oligonucleotides
AGCGCTGGCAACC
>LX295003.1 JP 2016515385-A/397: Modified TGF-beta oligonucleotides
GGGGGCTTTCTAA
>LX294995.1 JP 2016515385-A/389: Modified TGF-beta oligonucleotides
ATCTGCCCCTAAT
>LX294938.1 JP 2016515385-A/332: Modified TGF-beta oligonucleotides
GCCCACGTAGTAC
>LX294937.1 JP 2016515385-A/331: Modified TGF-beta oligonucleotides
ACTCCGGTGACAT
>LX294936.1 JP 2016515385-A/330: Modified TGF-beta oligonucleotides
GAGGTATCGCCAG
>LX294935.1 JP 2016515385-A/329: Modified TGF-beta oligonucleotides
TTTAACTTGAGCC
>LX294934.1 JP 2016515385-A/328: Modified TGF-beta oligonucleotides
CATAGATTTCGTT
>LX294933.1 JP 2016515385-A/327: Modified TGF-beta oligonucleotides
TAGTAGTCGGCCT
>LX294932.1 JP 2016515385-A/326: Modified TGF-beta oligonucleotides
TAGTCCCGCGGCC
>LX294931.1 JP 2016515385-A/325: Modified TGF-beta oligonucleotides
TGCCGAGAGCGCG
>LX294930.1 JP 2016515385-A/324: Modified TGF-beta oligonucleotides
TCCCACGGAAATA
>LX294929.1 JP 2016515385-A/323: Modified TGF-beta oligonucleotides
GTCGGAGAGAGAT
>LX294928.1 JP 2016515385-A/322: Modified TGF-beta oligonucleotides
TGCGCCCGAGGTC
>LX294927.1 JP 2016515385-A/321: Modified TGF-beta oligonucleotides
GTCGGCGACTCCC
>LX294926.1 JP 2016515385-A/320: Modified TGF-beta oligonucleotides
GACGCCGTGTAGG
>LX294925.1 JP 2016515385-A/319: Modified TGF-beta oligonucleotides
AAGCGTCCCCGGC
>LX294924.1 JP 2016515385-A/318: Modified TGF-beta oligonucleotides
TCGCGCCAAGAGG
>LX294818.1 JP 2016515385-A/212: Modified TGF-beta oligonucleotides
CGGCACGCAGCAC
>LX294817.1 JP 2016515385-A/211: Modified TGF-beta oligonucleotides
ACCATTAGCACGC
>LX294816.1 JP 2016515385-A/210: Modified TGF-beta oligonucleotides
TTAGCACGCGGGT
>LX294791.1 JP 2016515385-A/185: Modified TGF-beta oligonucleotides
TTGCAGGAGCGCA
>LX294790.1 JP 2016515385-A/184: Modified TGF-beta oligonucleotides
AGTTGGCATGGTA
>LX294789.1 JP 2016515385-A/183: Modified TGF-beta oligonucleotides
GCATGGTAGCCCT
>LX294788.1 JP 2016515385-A/182: Modified TGF-beta oligonucleotides
TGGGCTCGTGGAT
>LX294787.1 JP 2016515385-A/181: Modified TGF-beta oligonucleotides
GGCTCGTGGATCC
>LX294786.1 JP 2016515385-A/180: Modified TGF-beta oligonucleotides
CGCCAGGAATTGT
>LX294785.1 JP 2016515385-A/179: Modified TGF-beta oligonucleotides
CCACCCGGTCGCG
>LX294784.1 JP 2016515385-A/178: Modified TGF-beta oligonucleotides
CACCCGGTCGCGG
>LX294783.1 JP 2016515385-A/177: Modified TGF-beta oligonucleotides
TCGCGGGTGCTGT
>LX294744.1 JP 2016515385-A/138: Modified TGF-beta oligonucleotides
TCTGTAGGAGGGC
>LX294710.1 JP 2016515385-A/104: Modified TGF-beta oligonucleotides
GGTCGGCAGTCAA
>LX294709.1 JP 2016515385-A/103: Modified TGF-beta oligonucleotides
CTAGTACCGCCTT
>LX294708.1 JP 2016515385-A/102: Modified TGF-beta oligonucleotides
TCCACCCTAGATC
>LX294707.1 JP 2016515385-A/101: Modified TGF-beta oligonucleotides
CGGTTGGTCTGTT
>LX294706.1 JP 2016515385-A/100: Modified TGF-beta oligonucleotides
ATCTGAACTCGGC
>LX294705.1 JP 2016515385-A/99: Modified TGF-beta oligonucleotides
GGCGCTCGGTACT
>LX294704.1 JP 2016515385-A/98: Modified TGF-beta oligonucleotides
GTCGCGGTTGCGT
>LX294703.1 JP 2016515385-A/97: Modified TGF-beta oligonucleotides
TTGCTCGCTTAGG
>LX294650.1 JP 2016515385-A/44: Modified TGF-beta oligonucleotides
TCTGTAGGAGGGC
>LX294642.1 JP 2016515385-A/36: Modified TGF-beta oligonucleotides
GGCGGGATGGCAT
>LX294630.1 JP 2016515385-A/24: Modified TGF-beta oligonucleotides
CGAAGGAGAGCCA
>LX294629.1 JP 2016515385-A/23: Modified TGF-beta oligonucleotides
TGTAGCGCTGGGT
>LX294628.1 JP 2016515385-A/22: Modified TGF-beta oligonucleotides
AAGTGGGCGGGAT
>LX294627.1 JP 2016515385-A/21: Modified TGF-beta oligonucleotides
GAAATCACCTCCG
>LX294625.1 JP 2016515385-A/19: Modified TGF-beta oligonucleotides
AAGTGGGCGGGAT
>LX294624.1 JP 2016515385-A/18: Modified TGF-beta oligonucleotides
CAGAAGTTGGCAT
>LX294618.1 JP 2016515385-A/12: Modified TGF-beta oligonucleotides
GGATCGCCTCGAT
>LX294614.1 JP 2016515385-A/8: Modified TGF-beta oligonucleotides
TCTGCCCGCGGAT
>LX294611.1 JP 2016515385-A/5: Modified TGF-beta oligonucleotides
AGCGCGACCGTGA
>LX294495.1 JP 2016513974-A/173: COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES
CAAGGAGGCCTTA
>LX269962.1 JP 2016052338-A/38: Vectors for Directional Cloning
GGCCNNNNNGGCC
>LX269959.1 JP 2016052338-A/35: Vectors for Directional Cloning
GGCCNNNNNGGCC
>LX269944.1 JP 2016052338-A/20: Vectors for Directional Cloning
GGCCNNNNNGGCC
>LX269929.1 JP 2016052338-A/5: Vectors for Directional Cloning
GCAGCNNNNNNNN
>LY478757.1 KR 1020170007414-A/641: OLIGOMERS AND OLIGOMER CONJUGATES
CGAAGTGCACACG
>LY478756.1 KR 1020170007414-A/640: OLIGOMERS AND OLIGOMER CONJUGATES
CGAAGTGCACACG
>LY478755.1 KR 1020170007414-A/639: OLIGOMERS AND OLIGOMER CONJUGATES
CGAAGTGCACACG
>LY478746.1 KR 1020170007414-A/630: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478745.1 KR 1020170007414-A/629: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478744.1 KR 1020170007414-A/628: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478743.1 KR 1020170007414-A/627: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478736.1 KR 1020170007414-A/620: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478735.1 KR 1020170007414-A/619: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478734.1 KR 1020170007414-A/618: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478733.1 KR 1020170007414-A/617: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478724.1 KR 1020170007414-A/608: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478723.1 KR 1020170007414-A/607: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478722.1 KR 1020170007414-A/606: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478721.1 KR 1020170007414-A/605: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478716.1 KR 1020170007414-A/600: OLIGOMERS AND OLIGOMER CONJUGATES
CGAACCACTGAAC
>LY478715.1 KR 1020170007414-A/599: OLIGOMERS AND OLIGOMER CONJUGATES
CGAACCACTGAAC
>LY478698.1 KR 1020170007414-A/582: OLIGOMERS AND OLIGOMER CONJUGATES
TGTTCCCAAGAAT
>LY478695.1 KR 1020170007414-A/579: OLIGOMERS AND OLIGOMER CONJUGATES
GTTCCCAAGAATA
>LY478648.1 KR 1020170007414-A/532: OLIGOMERS AND OLIGOMER CONJUGATES
TGCGAATCCACAC
>LY478687.1 KR 1020170007414-A/571: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAGGCGAGGGA
>LY478682.1 KR 1020170007414-A/566: OLIGOMERS AND OLIGOMER CONJUGATES
CGAGGCGAGGGAG
>LY478678.1 KR 1020170007414-A/562: OLIGOMERS AND OLIGOMER CONJUGATES
GAGGCGAGGGAGT
>LY478674.1 KR 1020170007414-A/558: OLIGOMERS AND OLIGOMER CONJUGATES
AGGCGAGGGAGTT
>LY478670.1 KR 1020170007414-A/554: OLIGOMERS AND OLIGOMER CONJUGATES
GGCGAGGGAGTTC
>LY478666.1 KR 1020170007414-A/550: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAGGGAGTTCT
>LY478628.1 KR 1020170007414-A/512: OLIGOMERS AND OLIGOMER CONJUGATES
GCTTGGAGGCTTG
>LY478622.1 KR 1020170007414-A/506: OLIGOMERS AND OLIGOMER CONJUGATES
CCAATTTATGCCT
>LY478621.1 KR 1020170007414-A/505: OLIGOMERS AND OLIGOMER CONJUGATES
AATTTATGCCTAC
>LY478619.1 KR 1020170007414-A/503: OLIGOMERS AND OLIGOMER CONJUGATES
TTTATGCCTACAG
>LY478616.1 KR 1020170007414-A/500: OLIGOMERS AND OLIGOMER CONJUGATES
CCTCAAGGTCGGT
>LY478615.1 KR 1020170007414-A/499: OLIGOMERS AND OLIGOMER CONJUGATES
CTCAAGGTCGGTC
>LY478614.1 KR 1020170007414-A/498: OLIGOMERS AND OLIGOMER CONJUGATES
CGTTCACGGTGGT
>LY478612.1 KR 1020170007414-A/496: OLIGOMERS AND OLIGOMER CONJUGATES
CGTGCAGAGGTGA
>LY478267.1 KR 1020170007414-A/151: OLIGOMERS AND OLIGOMER CONJUGATES
CGCGTAAAGAGAG
>LY478262.1 KR 1020170007414-A/146: OLIGOMERS AND OLIGOMER CONJUGATES
CGTAAAGAGAGGT
>LY478260.1 KR 1020170007414-A/144: OLIGOMERS AND OLIGOMER CONJUGATES
TCCGCAGTATGGA
>LY478258.1 KR 1020170007414-A/142: OLIGOMERS AND OLIGOMER CONJUGATES
CCGCAGTATGGAT
>LY478252.1 KR 1020170007414-A/136: OLIGOMERS AND OLIGOMER CONJUGATES
GCAGTATGGATCG
>LY478246.1 KR 1020170007414-A/130: OLIGOMERS AND OLIGOMER CONJUGATES
GCAACGGGGTAAA
>LY478242.1 KR 1020170007414-A/126: OLIGOMERS AND OLIGOMER CONJUGATES
GGGGGAAAGCCCT
>LY478212.1 KR 1020170007414-A/96: OLIGOMERS AND OLIGOMER CONJUGATES
TAGCAGCAGGATG
>LY478210.1 KR 1020170007414-A/94: OLIGOMERS AND OLIGOMER CONJUGATES
ATGATAAAACGCC
>LY478207.1 KR 1020170007414-A/91: OLIGOMERS AND OLIGOMER CONJUGATES
TGATAAAACGCCG
>LY478203.1 KR 1020170007414-A/87: OLIGOMERS AND OLIGOMER CONJUGATES
GATAAAACGCCGC
>LY478198.1 KR 1020170007414-A/82: OLIGOMERS AND OLIGOMER CONJUGATES
ATAAAACGCCGCA
>LY478191.1 KR 1020170007414-A/75: OLIGOMERS AND OLIGOMER CONJUGATES
AAAACGCCGCAGA
>LY478157.1 KR 1020170007414-A/41: OLIGOMERS AND OLIGOMER CONJUGATES
CACGAGTCTAGAC
>LY478152.1 KR 1020170007414-A/36: OLIGOMERS AND OLIGOMER CONJUGATES
ACGAGTCTAGACT
>LY478146.1 KR 1020170007414-A/30: OLIGOMERS AND OLIGOMER CONJUGATES
AAAACCCCGCCTG
>LY478135.1 KR 1020170007414-A/19: OLIGOMERS AND OLIGOMER CONJUGATES
CGAAGTGCACACG
>LY478132.1 KR 1020170007414-A/16: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478129.1 KR 1020170007414-A/13: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478126.1 KR 1020170007414-A/10: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478124.1 KR 1020170007414-A/8: OLIGOMERS AND OLIGOMER CONJUGATES
CGAACCACTGAAC
>LY400489.1 KR 1020160107326-A/8: CHIRAL DESIGN
GTGAGCAGCTGCA
>LY400484.1 KR 1020160107326-A/3: CHIRAL DESIGN
AATCGATCGATCG
>LY312242.1 KR 1020160079866-A/6301: OPTIMAL MAIZE LOCI
TTCACGTCATGCT
>LY312121.1 KR 1020160079866-A/6180: OPTIMAL MAIZE LOCI
AGCTTCAATAGTA
>LY312028.1 KR 1020160079866-A/5402: OPTIMAL MAIZE LOCI
TGCATGCGCAGTA
>LY330383.1 KR 1020160079117-A/30: METHODS FOR MULTIPLEX DETECTION OF ALLELES ASSOCIATED WITH OPHTHALMIC CONDITIONS
TACACGGACCACA
>LY330382.1 KR 1020160079117-A/29: METHODS FOR MULTIPLEX DETECTION OF ALLELES ASSOCIATED WITH OPHTHALMIC CONDITIONS
TACACGGACCGCA
>LY306550.1 KR 1020160079864-A/7413: OPTIMAL SOYBEAN LOCI
AAAGTGTCATGCC
>LY306549.1 KR 1020160079864-A/7412: OPTIMAL SOYBEAN LOCI
GGAGAAACAACTG
>LY268781.1 KR 1020170000262-A/24: Method for Discriminating Human Platelet Antigen Genotype Using PNA Probe
CTGGGGCTGGGGC
>LY268780.1 KR 1020170000262-A/23: Method for Discriminating Human Platelet Antigen Genotype Using PNA Probe
CTGGGGATGGGGC
>LY325304.1 KR 1020160078531-A/6301: OPTIMAL MAIZE LOCI
TTCACGTCATGCT
>LY410799.1 KR 1020160135754-A/73: COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION IN CONE CELLS
GCCGCCNCCATGG
>LY325183.1 KR 1020160078531-A/6180: OPTIMAL MAIZE LOCI
AGCTTCAATAGTA
>LY325090.1 KR 1020160078531-A/5402: OPTIMAL MAIZE LOCI
TGCATGCGCAGTA
>LY267597.1 KR 1020160134094-A/7: Method for Discriminating Antibody-dependent Cellular cytotoxicity(ADCC) Related Antibody Fc gamma receptor(FCGR) Genotype Using Peptide Nucleic Acids
CTCCCGTTTGGAT
>LY408992.1 KR 1020160127780-A/18: VIRAL RESISTANT CELLS AND USES THEREOF
GCCGCCACCAATG
>LY341051.1 KR 1020160110370-A/15: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
CCTTTCTAGTTGA
>LY341049.1 KR 1020160110370-A/13: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
CCTTTCTAGTTGA
>LY341047.1 KR 1020160110370-A/11: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
GTGACCAAAAGTA
>LY341045.1 KR 1020160110370-A/9: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
GTGACCAAAAGTA
>LY341039.1 KR 1020160110370-A/3: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
GCACCTTTCTAGA
>LY341037.1 KR 1020160110370-A/1: METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
GCACCTTTCTAGA
>LY340486.1 KR 1020160087903-A/19: SYNTHETIC PROMOTERS FOR CHO CELLS, METHODS OF PRODUCING SYNTHETIC PROMOTERS USING TRANSCRIPTION FACTOR BINDING SITE MODULES
GAAAAGTGAAACC
>LY340484.1 KR 1020160087903-A/17: SYNTHETIC PROMOTERS FOR CHO CELLS, METHODS OF PRODUCING SYNTHETIC PROMOTERS USING TRANSCRIPTION FACTOR BINDING SITE MODULES
GGGCCAAAGGTCT
>LG263759.1 KR 1020160077965-A/19: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
AGTACGCCGACGA
>LG263756.1 KR 1020160077965-A/16: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
AGTACGGCGACGA
>LG263754.1 KR 1020160077965-A/14: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
AGTACGGCGACCA
>LG263752.1 KR 1020160077965-A/12: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
ACTACGGCGACGA
>LG263750.1 KR 1020160077965-A/10: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
AGTACGCCGACGA
>LG263743.1 KR 1020160077965-A/3: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
AGTACGGCGACGA
>LG263742.1 KR 1020160077965-A/2: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
TCATGCCGCTGCT
>LG263741.1 KR 1020160077965-A/1: Method for Ensuring Quality of Synthetic Oligo Using Peptide Nucleic Acid Probe
TCATGCCGCTGCT
>LY319638.1 KR 1020160079156-A/7413: OPTIMAL SOYBEAN LOCI
AAAGTGTCATGCC
>LY319637.1 KR 1020160079156-A/7412: OPTIMAL SOYBEAN LOCI
GGAGAAACAACTG
>LY404720.1 KR 1020160117535-A/25: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES
GCATTGGTATTCA
>LY404704.1 KR 1020160117535-A/9: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES
GCATTGGTATTCA
>LY299378.1 KR 1020160079090-A/116: A UNIVERSAL DONOR SYSTEM FOR GENE TARGETING
TGCATGCGCAGTA
>LY336140.1 KR 1020160085353-A/30: DETECTION OF NUCLEIC ACIDS BY STRAND INVASION BASED AMPLIFICATION
ACCGCAGGAAACG
>LY478589.1 KR 1020170007414-A/473: OLIGOMERS AND OLIGOMER CONJUGATES
TGAAGCGAAGTGC
>LY478595.1 KR 1020170007414-A/479: OLIGOMERS AND OLIGOMER CONJUGATES
GGTGAAGCGAAGT
>LY478591.1 KR 1020170007414-A/475: OLIGOMERS AND OLIGOMER CONJUGATES
GTGAAGCGAAGTG
>LY478586.1 KR 1020170007414-A/470: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGCGAAGTGCA
>LY478581.1 KR 1020170007414-A/465: OLIGOMERS AND OLIGOMER CONJUGATES
AAGCGAAGTGCAC
>LY478578.1 KR 1020170007414-A/462: OLIGOMERS AND OLIGOMER CONJUGATES
AGCGAAGTGCACA
>LY478574.1 KR 1020170007414-A/458: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAAGTGCACAC
>LY478560.1 KR 1020170007414-A/444: OLIGOMERS AND OLIGOMER CONJUGATES
CCGCGTAAAGAGA
>LY478557.1 KR 1020170007414-A/441: OLIGOMERS AND OLIGOMER CONJUGATES
CGCGTAAAGAGAG
>LY478552.1 KR 1020170007414-A/436: OLIGOMERS AND OLIGOMER CONJUGATES
CGTAAAGAGAGGT
>LY478550.1 KR 1020170007414-A/434: OLIGOMERS AND OLIGOMER CONJUGATES
TCCGCAGTATGGA
>LY478548.1 KR 1020170007414-A/432: OLIGOMERS AND OLIGOMER CONJUGATES
CCGCAGTATGGAT
>LY478542.1 KR 1020170007414-A/426: OLIGOMERS AND OLIGOMER CONJUGATES
GCAGTATGGATCG
>LY478536.1 KR 1020170007414-A/420: OLIGOMERS AND OLIGOMER CONJUGATES
GCAACGGGGTAAA
>LY478532.1 KR 1020170007414-A/416: OLIGOMERS AND OLIGOMER CONJUGATES
GGGGGAAAGCCCT
>LY478502.1 KR 1020170007414-A/386: OLIGOMERS AND OLIGOMER CONJUGATES
TAGCAGCAGGATG
>LY478500.1 KR 1020170007414-A/384: OLIGOMERS AND OLIGOMER CONJUGATES
ATGATAAAACGCC
>LY478497.1 KR 1020170007414-A/381: OLIGOMERS AND OLIGOMER CONJUGATES
TGATAAAACGCCG
>LY478493.1 KR 1020170007414-A/377: OLIGOMERS AND OLIGOMER CONJUGATES
GATAAAACGCCGC
>LY478488.1 KR 1020170007414-A/372: OLIGOMERS AND OLIGOMER CONJUGATES
ATAAAACGCCGCA
>LY478481.1 KR 1020170007414-A/365: OLIGOMERS AND OLIGOMER CONJUGATES
AAAACGCCGCAGA
>LY478447.1 KR 1020170007414-A/331: OLIGOMERS AND OLIGOMER CONJUGATES
CACGAGTCTAGAC
>LY478442.1 KR 1020170007414-A/326: OLIGOMERS AND OLIGOMER CONJUGATES
ACGAGTCTAGACT
>LY478436.1 KR 1020170007414-A/320: OLIGOMERS AND OLIGOMER CONJUGATES
AAAACCCCGCCTG
>LY478425.1 KR 1020170007414-A/309: OLIGOMERS AND OLIGOMER CONJUGATES
CGAAGTGCACACG
>LY478422.1 KR 1020170007414-A/306: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGTGCACACGG
>LY478419.1 KR 1020170007414-A/303: OLIGOMERS AND OLIGOMER CONJUGATES
GCGTAAAGAGAGG
>LY478416.1 KR 1020170007414-A/300: OLIGOMERS AND OLIGOMER CONJUGATES
CGCAGTATGGATC
>LY478414.1 KR 1020170007414-A/298: OLIGOMERS AND OLIGOMER CONJUGATES
CGAACCACTGAAC
>LY478408.1 KR 1020170007414-A/292: OLIGOMERS AND OLIGOMER CONJUGATES
TGTTCCCAAGAAT
>LY478405.1 KR 1020170007414-A/289: OLIGOMERS AND OLIGOMER CONJUGATES
GTTCCCAAGAATA
>LY478397.1 KR 1020170007414-A/281: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAGGCGAGGGA
>LY478392.1 KR 1020170007414-A/276: OLIGOMERS AND OLIGOMER CONJUGATES
CGAGGCGAGGGAG
>LY478388.1 KR 1020170007414-A/272: OLIGOMERS AND OLIGOMER CONJUGATES
GAGGCGAGGGAGT
>LY478384.1 KR 1020170007414-A/268: OLIGOMERS AND OLIGOMER CONJUGATES
AGGCGAGGGAGTT
>LY478380.1 KR 1020170007414-A/264: OLIGOMERS AND OLIGOMER CONJUGATES
GGCGAGGGAGTTC
>LY297448.1 KR 1020160067184-A/77: ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENES
GCCGCCRCCATGG
>LY478376.1 KR 1020170007414-A/260: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAGGGAGTTCT
>LY297176.1 KR 1020160083876-A/30: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297171.1 KR 1020160083876-A/25: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297170.1 KR 1020160083876-A/24: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297168.1 KR 1020160083876-A/22: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297167.1 KR 1020160083876-A/21: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297166.1 KR 1020160083876-A/20: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297164.1 KR 1020160083876-A/18: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297163.1 KR 1020160083876-A/17: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297161.1 KR 1020160083876-A/15: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297160.1 KR 1020160083876-A/14: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297159.1 KR 1020160083876-A/13: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297151.1 KR 1020160083876-A/5: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297150.1 KR 1020160083876-A/4: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297149.1 KR 1020160083876-A/3: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY297147.1 KR 1020160083876-A/1: APOB ANTISENSE CONJUGATE COMPOUNDS
GCATTGGTATTCA
>LY296971.1 KR 1020160097193-A/48: Multiplex Probes
GGAGGTGGGGGAG
>LY296970.1 KR 1020160097193-A/47: Multiplex Probes
CTCCCCCACCTCC
>LY296969.1 KR 1020160097193-A/46: Multiplex Probes
GGAGGTGGGGGAG
>LY296965.1 KR 1020160097193-A/42: Multiplex Probes
TTTTTTCCCGTCC
>LY478358.1 KR 1020170007414-A/242: OLIGOMERS AND OLIGOMER CONJUGATES
TGCGAATCCACAC
>LY478338.1 KR 1020170007414-A/222: OLIGOMERS AND OLIGOMER CONJUGATES
GCTTGGAGGCTTG
>LY478332.1 KR 1020170007414-A/216: OLIGOMERS AND OLIGOMER CONJUGATES
CCAATTTATGCCT
>LY478331.1 KR 1020170007414-A/215: OLIGOMERS AND OLIGOMER CONJUGATES
AATTTATGCCTAC
>LY478329.1 KR 1020170007414-A/213: OLIGOMERS AND OLIGOMER CONJUGATES
TTTATGCCTACAG
>LY478326.1 KR 1020170007414-A/210: OLIGOMERS AND OLIGOMER CONJUGATES
CCTCAAGGTCGGT
>LY478325.1 KR 1020170007414-A/209: OLIGOMERS AND OLIGOMER CONJUGATES
CTCAAGGTCGGTC
>LY478324.1 KR 1020170007414-A/208: OLIGOMERS AND OLIGOMER CONJUGATES
CGTTCACGGTGGT
>LY478322.1 KR 1020170007414-A/206: OLIGOMERS AND OLIGOMER CONJUGATES
CGTGCAGAGGTGA
>LY478305.1 KR 1020170007414-A/189: OLIGOMERS AND OLIGOMER CONJUGATES
GGTGAAGCGAAGT
>LY478301.1 KR 1020170007414-A/185: OLIGOMERS AND OLIGOMER CONJUGATES
GTGAAGCGAAGTG
>LY478299.1 KR 1020170007414-A/183: OLIGOMERS AND OLIGOMER CONJUGATES
TGAAGCGAAGTGC
>LY478296.1 KR 1020170007414-A/180: OLIGOMERS AND OLIGOMER CONJUGATES
GAAGCGAAGTGCA
>LY478291.1 KR 1020170007414-A/175: OLIGOMERS AND OLIGOMER CONJUGATES
AAGCGAAGTGCAC
>LY478288.1 KR 1020170007414-A/172: OLIGOMERS AND OLIGOMER CONJUGATES
AGCGAAGTGCACA
>LY478284.1 KR 1020170007414-A/168: OLIGOMERS AND OLIGOMER CONJUGATES
GCGAAGTGCACAC
>LY478270.1 KR 1020170007414-A/154: OLIGOMERS AND OLIGOMER CONJUGATES
CCGCGTAAAGAGA
>KH706464.1 Sequence 2 from patent US 9605316
AGGTCANAGGTCA
>KH705453.1 Sequence 7 from patent US 9605271
AGCTTGGCCAAAT
>KH703943.1 Sequence 26 from patent US 9605039
CGTCGTAGGGGTA
>KH700961.1 Sequence 16 from patent US 9599628
GGGAGTCAAGAAC
>KH700960.1 Sequence 15 from patent US 9599628
GGGAGTCAAGAAC
>KH700951.1 Sequence 6 from patent US 9599628
GGGAGTCAAGAAC
>KH700950.1 Sequence 5 from patent US 9599628
GGGAGTCAAGAAC
>KH700651.1 Sequence 38 from patent US 9598739
TACAAGCTGGGCC
>KH700619.1 Sequence 6 from patent US 9598739
CTTGTAACTGAAA
>KH696410.1 Sequence 8 from patent US 9598471
ACTACTCGGGACA
>KH696409.1 Sequence 7 from patent US 9598471
ACCATTCGGGACA
>KH696408.1 Sequence 6 from patent US 9598471
ACTTTTTGGGACG
>KH696407.1 Sequence 5 from patent US 9598471
ACCGTTTGGGACG
>KH696143.1 Sequence 17 from patent US 9598355
AGGTCANAGGTCA
>KH689053.1 Sequence 76 from patent US 9593342
DTAAACATGTAGG
>KH688674.1 Sequence 89 from patent US 9593337
GGGTCGTCTGCGG
>KH688673.1 Sequence 88 from patent US 9593337
GGGTCGCAGCTGG
>KH688174.1 Sequence 95 from patent US 9593331
CCCTCCCCTCCCT
>KH688173.1 Sequence 94 from patent US 9593331
AGGGAGGGGAGGG
>KH688172.1 Sequence 93 from patent US 9593331
GGGAGGGGAGGGA
>KH687586.1 Sequence 82 from patent US 9593141
AGAGATTTTGGAG
>KH687582.1 Sequence 78 from patent US 9593141
TTAACAAGGAGTT
>KH657271.1 Sequence 36 from patent US 9587270
AATACATCATCAT
>KH657260.1 Sequence 25 from patent US 9587270
AATACATCATCAT
>KH657252.1 Sequence 17 from patent US 9587270
AATACATCATCAT
>KH650437.1 Sequence 157 from patent US 9580762
GAGCCGGGCTGTC
>KH600172.1 Sequence 90 from patent US 9580708
NGTCTATGTATAG
>KH600169.1 Sequence 87 from patent US 9580708
NAATCCATGGNAG
>KH600168.1 Sequence 86 from patent US 9580708
GGCAAGCATCNTG
>KH600154.1 Sequence 72 from patent US 9580708
GNATTGGTATTNA
>KH600151.1 Sequence 69 from patent US 9580708
TNNTCGGCCTNTG
>KH600113.1 Sequence 31 from patent US 9580708
NNTCTATGTANNN
>KH600110.1 Sequence 28 from patent US 9580708
NNATCCATGGNNN
>KH600109.1 Sequence 27 from patent US 9580708
NNCAAGCATCNNN
>KH600095.1 Sequence 13 from patent US 9580708
NNATTGGTATNNN
>KH600092.1 Sequence 10 from patent US 9580708
NNNTCGGCCTNNN
>KH599425.1 Sequence 130 from patent US 9580697
CCCTAGAAAGATA
>KH599422.1 Sequence 127 from patent US 9580697
CCCAGATTAGCCT
>KH599073.1 Sequence 12 from patent US 9580693
AAAACGAGGGGGG
>KH599072.1 Sequence 11 from patent US 9580693
TTTTGCTCCCCCC
>KH598755.1 Sequence 80 from patent US 9580503
CTATGATAGTAGT
>KH569756.1 Sequence 130 from patent US 9574209
CCCTAGAAAGATA
>KH569753.1 Sequence 127 from patent US 9574209
CCCAGATTAGCCT
>KH563327.1 Sequence 8 from patent US 9574194
TTGTCACACTCCA
>KH562595.1 Sequence 44 from patent US 9574191
ATGCATGCATGCA
>KH560153.1 Sequence 2 from patent US 9572891
TAGGGTTAGACAA
>KH560088.1 Sequence 122 from patent US 9572874
GCCGCCACCATGG
>KH560077.1 Sequence 111 from patent US 9572874
GCCGCCACCATGG
>KH560045.1 Sequence 71 from patent US 9572874
GGGTTTTTTTGGG
>KH560035.1 Sequence 60 from patent US 9572874
GGTTTTTTTTTGG
>KH549389.1 Sequence 543 from patent US 9567653
CGAAAAAAACGCG
>KH549101.1 Sequence 25 from patent US 9567650
TATTAAAAAAGTA
>KH547129.1 Sequence 46 from patent US 9567644
CGTACTATCCCAG
>KH547127.1 Sequence 44 from patent US 9567644
GCGCCTCGGCCAG
>KH546874.1 Sequence 7 from patent US 9567631
GAACNNNNNNTAC
>KH546872.1 Sequence 5 from patent US 9567631
GAAGNNNNNNTAC
>KH546871.1 Sequence 4 from patent US 9567631
GAACNNNNNNTCC
>KH546868.1 Sequence 1 from patent US 9567631
GGCCNNNNNGGCC
>KH546866.1 Sequence 61 from patent US 9567629
GGGGGAAAAAAAA
>KH546853.1 Sequence 10 from patent US 9567627
TCGCGTTACAAGA
>KH546852.1 Sequence 9 from patent US 9567627
TCGCGTTACAAGA
>KH546851.1 Sequence 8 from patent US 9567627
TCGCGCTACAAGA
>KH546636.1 Sequence 43 from patent US 9567609
TTTCTCTCCACAG
>KH539142.1 Sequence 5 from patent US 9567584
TTGCTACCAGTCT
>KH535949.1 Sequence 36 from patent US 9566293
GCATTGGTATTCA
>KH535948.1 Sequence 35 from patent US 9566293
GTCTGTGGAAGCG
>KH535934.1 Sequence 21 from patent US 9566293
CCATTGTCACACT
>KH535931.1 Sequence 18 from patent US 9566293
CATTGTCACACTC
>KH535919.1 Sequence 6 from patent US 9566293
ATTGTCACACTCC
>KH534335.1 Sequence 7 from patent US 9562897
TGACGACTGCATT
>KH527996.1 Sequence 16 from patent US 9562066
TCGTCGTTTTGTC
>KH526530.1 Sequence 11 from patent US 9556475
GTTGATGTTTCAA
>KH526522.1 Sequence 3 from patent US 9556475
CGCCCCTCAGATA
>KH526493.1 Sequence 109 from patent US 9556473
GGTCTAGCTACAG
>KH526488.1 Sequence 104 from patent US 9556473
AATCTCGATGGAG
>KH526412.1 Sequence 28 from patent US 9556473
GGTAGTTGGAGCT
>KH526407.1 Sequence 22 from patent US 9556473
GTTGGAGCTGGTG
>KH526402.1 Sequence 17 from patent US 9556473
GTAGTTGGAGCTG
>KH526394.1 Sequence 9 from patent US 9556473
TGGCGTAGGCAAG
>KH526388.1 Sequence 3 from patent US 9556473
GTGGCGTAGGCAA
>KH525423.1 Sequence 12 from patent US 9556435
CTGTGCCTGCTGT
>KH525342.1 Sequence 4 from patent US 9556433
GTCAGCAGTGCCT
>KH521838.1 Sequence 2 from patent US 9554564
GCCGCCRCCATGG
>KH521513.1 Sequence 109 from patent US 9551041
GCGTGGCCCGCGC
>KH510607.1 Sequence 13 from patent US 9550988
CTGGTCCAGAGCC
>KH509432.1 Sequence 17 from patent US 9549980
TCGTCGTTTTGTC
>KH505386.1 Sequence 16 from patent US 9540682
ATGAGCCTAATTT
>KH505385.1 Sequence 15 from patent US 9540682
ATGAGCCTGATTT
>KH505378.1 Sequence 4 from patent US 9540682
NAATTAGGCTCAT
>KH505377.1 Sequence 3 from patent US 9540682
NTGAGCCTAATTT
>KH505376.1 Sequence 2 from patent US 9540682
NAATCAGGCTCAT
>KH505375.1 Sequence 1 from patent US 9540682
NTGAGCCTGATTT
>KH500647.1 Sequence 66 from patent US 9540633
CGAGTCATGCATG
>KH500646.1 Sequence 65 from patent US 9540633
TGAGTCATGCATG
>KH497379.1 Sequence 3 from patent US 9534260
CCTTGCAAAATTC
>KH497335.1 Sequence 217 from patent US 9534255
TGAGGCGCTGCCC
>KH497328.1 Sequence 210 from patent US 9534255
CGCCACCAGCTCC
>KH497327.1 Sequence 209 from patent US 9534255
CGCCACCAGCTCC
>KH497324.1 Sequence 206 from patent US 9534255
CGCCACCAGCTCC
>KH497309.1 Sequence 191 from patent US 9534255
TGAGGCACTGCCC
>KH497302.1 Sequence 184 from patent US 9534255
CGCCAGCAGCTCC
>KH497301.1 Sequence 183 from patent US 9534255
CGCCATCAGCTCC
>KH496976.1 Sequence 130 from patent US 9534234
CCCTAGAAAGATA
>KH496973.1 Sequence 127 from patent US 9534234
CCCAGATTAGCCT
>KH496318.1 Sequence 52 from patent US 9534217
AAGGAAAAAAAAT
>KH496317.1 Sequence 51 from patent US 9534217
AAGGAAAAAAAAG
>KH496316.1 Sequence 50 from patent US 9534217
AAGGAAAAAAAAA
>KH495173.1 Sequence 5 from patent US 9533957
ATTCAACACTACC
>KH487872.1 Sequence 34 from patent US 9528156
CCCCAGGCCAATC
>KH483018.1 Sequence 788 from patent US 9528108
TGCTGCATCTCTG
>KH480554.1 Sequence 6 from patent US 9523698
CTAGAAAACCTTC
>KH480553.1 Sequence 5 from patent US 9523698
CTAGAAGACCTTC
>KH480552.1 Sequence 4 from patent US 9523698
AGAGTTGGTATCC
>KH480551.1 Sequence 3 from patent US 9523698
AGAGTTCGTATCC
>KH480550.1 Sequence 2 from patent US 9523698
CTGAAGGTTTTGC
>KH480549.1 Sequence 1 from patent US 9523698
CTGAAGTTTTTGC
>KH480504.1 Sequence 60 from patent US 9523674
TTTCAGNCCTGGC
>KH480502.1 Sequence 58 from patent US 9523674
TTTCAGGCCTGGC
>KH479963.1 Sequence 14 from patent US 9523118
TTGGCCAGCCCAA
>KH479959.1 Sequence 9 from patent US 9523118
TTGGGCTGGCCAA
>KH479433.1 Sequence 15 from patent US 9523092
GCCGCCACCATGG
>KH479431.1 Sequence 13 from patent US 9523092
GGCCNNNNNGGCC
>KH479424.1 Sequence 6 from patent US 9523092
GGCCTCAGGGGCC
>KH479423.1 Sequence 5 from patent US 9523092
GGCCCAGGCGGCC
>KH428973.1 Sequence 631 from patent US 9512473
TGTGGCAGTGGCA
>KH428957.1 Sequence 615 from patent US 9512473
ATCACGCAGCTCA
>KH428939.1 Sequence 597 from patent US 9512473
TGGTGGCGTAGGC
>KH428931.1 Sequence 589 from patent US 9512473
TGTGGCAGTGGCA
>KH428927.1 Sequence 585 from patent US 9512473
TGGTGACGTAGGC
>KH428925.1 Sequence 583 from patent US 9512473
GCCACTAGCTCCA
>KH428921.1 Sequence 579 from patent US 9512473
ATCACGCAGCTCA
>KH428795.1 Sequence 453 from patent US 9512473
TGGTGGCGTAGGC
>KH428787.1 Sequence 445 from patent US 9512473
TGTGGCAGTGGCA
>KH428783.1 Sequence 441 from patent US 9512473
TGGTGACGTAGGC
>KH428781.1 Sequence 439 from patent US 9512473
GCCACTAGCTCCA
>KH428777.1 Sequence 435 from patent US 9512473
ATCACGCAGCTCA
>KH428653.1 Sequence 311 from patent US 9512473
TGAGGCGCTGCCC
>KH428646.1 Sequence 304 from patent US 9512473
CGCCACCAGCTCC
>KH428645.1 Sequence 303 from patent US 9512473
CGCCACCAGCTCC
>KH428642.1 Sequence 300 from patent US 9512473
CGCCACCAGCTCC
>KH428627.1 Sequence 285 from patent US 9512473
TGAGGCACTGCCC
>KH428620.1 Sequence 278 from patent US 9512473
CGCCAGCAGCTCC
>KH428619.1 Sequence 277 from patent US 9512473
CGCCATCAGCTCC
>KH383867.1 Sequence 6 from patent US 9506119
TTCAGGGGGGGCT
>KH377682.1 Sequence 6 from patent US 9506030
TTGTCACACTCCA
>KH377137.1 Sequence 10 from patent US 9505815
TAGGGTTAGGGTT
>KH377134.1 Sequence 7 from patent US 9505815
GGGTTAGGGTTAG
>KH376817.1 Sequence 3 from patent US 9504742
TCGNNTCGNNTCG
>KH375922.1 Sequence 13 from patent US 9499860
GGGNGGGTGGGTG
>KH375921.1 Sequence 12 from patent US 9499860
GGGNGGGTGGGTG
>KH375856.1 Sequence 12 from patent US 9499848
GGTTGGATCCGAT
>KH375845.1 Sequence 1 from patent US 9499848
ATCGGATCCATTT
>KH374901.1 Sequence 28 from patent US 9499831
GCTAGCCGCCAGC
>KH372687.1 Sequence 23 from patent US 9499808
GTAGYCCAGGGTG
>KH372686.1 Sequence 22 from patent US 9499808
GTCGYCCAGGAGG
>KH372685.1 Sequence 21 from patent US 9499808
TCGTCCCAGTAAA
>KH371288.1 Sequence 3 from patent US 9499576
TACCAGNCACCAT
>KH371287.1 Sequence 2 from patent US 9499576
AAAAAAAAAAAAA
>KH371286.1 Sequence 1 from patent US 9499576
TTTTTTNTTTTTT
>KH366712.1 Sequence 35 from patent US 9493831
CCAGGTGGCTTCC
>KH366645.1 Sequence 14 from patent US 9493830
TCACTCTGTTCGT
>KH366464.1 Sequence 265 from patent US 9493828
AGCACTGCAGGTA
>KH365882.1 Sequence 29 from patent US 9493818
AGTCTGATAAGCT
>KH365881.1 Sequence 28 from patent US 9493818
CACTATAAGCACT
>KH365436.1 Sequence 19 from patent US 9493803
GTGGAGATCAAAC
>KH365434.1 Sequence 16 from patent US 9493803
ACCGTCTCTTCAG
>KH365432.1 Sequence 13 from patent US 9493803
CTGCTACTTCTAG
>KH365430.1 Sequence 10 from patent US 9493803
TCAGGAACTGCAG
>KH359564.1 Sequence 96 from patent US 9493774
CAAGTGTGACAGT
>KH359562.1 Sequence 94 from patent US 9493774
AGTTTATTCGGAA
>KH359554.1 Sequence 86 from patent US 9493774
CAAGTGTGACAGT
>KH359552.1 Sequence 84 from patent US 9493774
AGTTTATTCGGAA
>KH358169.1 Sequence 449 from patent US 9493750
TGATACTGACTGT
>KH358124.1 Sequence 377 from patent US 9493750
GCTCTTCAGCCTT
>KH358004.1 Sequence 186 from patent US 9493750
GACCCTGCCTGCT
>KH357944.1 Sequence 121 from patent US 9493750
TGATACTGACTGT
>KH357937.1 Sequence 114 from patent US 9493750
CTTCATTACACCT
>KH357036.1 Sequence 133 from patent US 9493545
GTGGGATCCAAAT
>KH357035.1 Sequence 132 from patent US 9493545
GTGGGCAGCAAAT
>KH356193.1 Sequence 11 from patent US 9492568
AGAAACNNAACAN
>KH355931.1 Sequence 22 from patent US 9492533
CTGTGGCAATGGC
>KH355545.1 Sequence 26 from patent US 9492482
AGGTCANAGGTCA
>LX251235.1 WO 2017111166-A/14: Therapeutic agent for disease associated with the amount of TDP-43 present in the cell
AAGTGTTTGTGGG
>LX156808.1 WO 2017078099-A/3: PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER
TGTAGGGTGGAGC
>LX246854.1 JP 2017099389-A/393: Diagnostic Methods and Compositions for Treatment of Cancer
CCTTCGCAAAGCT
>LX244280.1 JP 2017099387-A/85175: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCTGGCCGTCCA
>LX243836.1 JP 2017099387-A/84731: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCGGCTCCACCA
>LX155651.1 JP 2017510296-A/46: COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION IN CONE CELLS
GCCGCCNCCATGG
>LX155766.1 JP 2017510301-A/9: Melting Curve Analysis using PNA Probe, Method and Kit for Analyzing Nucleotide Polymorphism using Melting Curve Analysis
GAGCTTGGTGGCG
>LX155280.1 JP 2017510277-A/105: Ureohydrolases as dominant selectable markers in yeast
TTTTAGTAGTTGG
>LX155276.1 JP 2017510277-A/101: Ureohydrolases as dominant selectable markers in yeast
TCTTAGTAATGCC
>LX155271.1 JP 2017510277-A/96: Ureohydrolases as dominant selectable markers in yeast
GCCCTAATCTACG
>LX155263.1 JP 2017510277-A/88: Ureohydrolases as dominant selectable markers in yeast
ACCCTGAAGTATA
>LX155253.1 JP 2017510277-A/78: Ureohydrolases as dominant selectable markers in yeast
AGTTACGCTAGGG
>LX155252.1 JP 2017510277-A/77: Ureohydrolases as dominant selectable markers in yeast
CAGGGTAATATAG
>LX155249.1 JP 2017510277-A/74: Ureohydrolases as dominant selectable markers in yeast
CACTAGTTATTAC
>LX155244.1 JP 2017510277-A/69: Ureohydrolases as dominant selectable markers in yeast
TGGCAAACAGCTA
>LX155243.1 JP 2017510277-A/68: Ureohydrolases as dominant selectable markers in yeast
GGGTATTATGGGT
>LX155235.1 JP 2017510277-A/60: Ureohydrolases as dominant selectable markers in yeast
GGGTGTGTACGGG
>LX155218.1 JP 2017510277-A/43: Ureohydrolases as dominant selectable markers in yeast
CCATATCATTTTT
>LX155209.1 JP 2017510277-A/34: Ureohydrolases as dominant selectable markers in yeast
CAAAACGTCGTAA
>LX155190.1 JP 2017510277-A/15: Ureohydrolases as dominant selectable markers in yeast
GAAGGTTTGGCAC
>LX155189.1 JP 2017510277-A/14: Ureohydrolases as dominant selectable markers in yeast
ATGTCGGCTCATC
>LX155179.1 JP 2017510277-A/4: Ureohydrolases as dominant selectable markers in yeast
TTGAGGAGGTTTC
>LX155299.1 JP 2017510277-A/124: Ureohydrolases as dominant selectable markers in yeast
TAYGCNGAYACNG
>LX153052.1 JP 2017511694-A/44: COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
NTCTGATAAGCTA
>LX153053.1 JP 2017511694-A/45: COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
NGTAAGCACTTTG
>LX153054.1 JP 2017511694-A/46: COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
NTCAGATATGCTA
>LX147925.1 JP 2017079635-A/8: Carrier for capturing tumor cells
GCACGGTGTGGGG
>LX147900.1 JP 2017079634-A/13: Method for detecting target cells in a biological sample
GCACGGTGTGGGG
>LX147095.1 JP 2017506903-A/10: VIRAL RESISTANT CELLS AND USES THEREOF
GCCGCCACCAATG
>LX095870.1 WO 2017068790-A/37: Nucleic acid complex
TGAATATCAATGC
>LX095869.1 WO 2017068790-A/36: Nucleic acid complex
TGAATACCAATGC
>LX095868.1 WO 2017068790-A/35: Nucleic acid complex
GCATTGGTATTCA
>LX095634.1 WO 2017057540-A/10: Nucleic derivatives having immunostimulatory activity
AACGTCAGGAACG
>LX095382.1 JP 2017074064-A/2: Cardiomyocytes from Induced Pluripotent Stem Cells from Patient and Methods of Use Thereof
GAGGCCTGGAAGA
>LX095381.1 JP 2017074064-A/1: Cardiomyocytes from Induced Pluripotent Stem Cells from Patient and Methods of Use Thereof
GAGGCCCGGAAGA
>LX095202.1 JP 2017070299-A/23: MODIFICATIONS FOR ANTISENSE COMPOUNDS
ATCNGTNTGNCTA
>LX087738.1 JP 2017070241-A/45: Primer, method, and kit for detecting influenza A virus
GCGTGAACACAAA
>LX087735.1 JP 2017070241-A/42: Primer, method, and kit for detecting influenza A virus
GCGTGAACACAAA
>LX087728.1 JP 2017070241-A/35: Primer, method, and kit for detecting influenza A virus
CTTAGTCAGAGGT
>LX087725.1 JP 2017070241-A/32: Primer, method, and kit for detecting influenza A virus
TAGTCAGAGGTGA
>LX087720.1 JP 2017070241-A/27: Primer, method, and kit for detecting influenza A virus
TTAGTCAGAGGTG
>LX087714.1 JP 2017070241-A/21: Primer, method, and kit for detecting influenza A virus
CCCTTAGTCAGAG
>LX087703.1 JP 2017070241-A/10: Primer, method, and kit for detecting influenza A virus
GTCAGAGGTGACA
>MS657889.1 Sequence 136 from Patent EP3129477
CTGGCTCCCTCCC
>MS657888.1 Sequence 135 from Patent EP3129477
CTGTCTCTCCCCA
>MS794168.1 Sequence 10 from Patent WO2017009588
GGCCGCGCCATGG
>MS656491.1 Sequence 130 from Patent EP3129487
CCCTAGAAAGATA
>MS656488.1 Sequence 127 from Patent EP3129487
CCCAGATTAGCCT
>MS656079.1 Sequence 90 from Patent EP3129391
TAGGGTTAGACAA
>MS656068.1 Sequence 79 from Patent EP3129391
TAGGGTTAGACAA
>MS656067.1 Sequence 78 from Patent EP3129391
TAGGGTTAGACAA
>MS656066.1 Sequence 77 from Patent EP3129391
TAGGGTTAGACAA
>MS656065.1 Sequence 76 from Patent EP3129391
TAGGGTTAGACAA
>MS656064.1 Sequence 75 from Patent EP3129391
TAGGGTTAGACAA
>MS656063.1 Sequence 74 from Patent EP3129391
TAGGGTTAGACAA
>MS656062.1 Sequence 73 from Patent EP3129391
TAGGGTTAGACAA
>MS656061.1 Sequence 72 from Patent EP3129391
TAGGGTTAGACAA
>MS656060.1 Sequence 71 from Patent EP3129391
TAGGGTTAGACAA
>MS656059.1 Sequence 70 from Patent EP3129391
TAGGGTTAGACAA
>MS656037.1 Sequence 48 from Patent EP3129391
TGCTGGATGGGAA
>MS656021.1 Sequence 32 from Patent EP3129391
TGCTGGATGGGAA
>MS656018.1 Sequence 29 from Patent EP3129391
TGCTGGATGGGAA
>MS792950.1 Sequence 7 from Patent EP3174985
CCATCTCCCGTCC
>MS790906.1 Sequence 20 from Patent WO2017025471
TCGCCATGCTGCT
>MS653930.1 Sequence 1023 from Patent EP3137119
GCACCTTTCTAGA
>MS653928.1 Sequence 1021 from Patent EP3137119
GCACCTTTCTAGA
>MS653924.1 Sequence 1017 from Patent EP3137119
CCTCATGTTTATA
>MS653922.1 Sequence 1015 from Patent EP3137119
AAATACCTCATGA
>MS653920.1 Sequence 1013 from Patent EP3137119
GAAATACCTCATA
>MS653918.1 Sequence 1011 from Patent EP3137119
ACTTTGAAATACA
>MS653916.1 Sequence 1009 from Patent EP3137119
TGCTGCATCTTAA
>MS653914.1 Sequence 1007 from Patent EP3137119
AGTGCTGCATCTA
>MS653912.1 Sequence 1005 from Patent EP3137119
TAGTGCTGCATCA
>MS653910.1 Sequence 1003 from Patent EP3137119
TTAGTGCTGCATA
>MS653908.1 Sequence 1001 from Patent EP3137119
TTCTGTGTTTAAA
>MS653906.1 Sequence 999 from Patent EP3137119
GTTCTGTGTTTAA
>MS653904.1 Sequence 997 from Patent EP3137119
AGTTCTGTGTTTA
>MS653902.1 Sequence 995 from Patent EP3137119
GGTGCATAGAACA
>MS653900.1 Sequence 993 from Patent EP3137119
TTTGGTGCATAGA
>MS653898.1 Sequence 991 from Patent EP3137119
GTTTGGTGCATAA
>MS653896.1 Sequence 989 from Patent EP3137119
TTCATGTTTGGTA
>MS653894.1 Sequence 987 from Patent EP3137119
GTTCATGTTTGGA
>MS653892.1 Sequence 985 from Patent EP3137119
TGTTCATGTTTGA
>MS653890.1 Sequence 983 from Patent EP3137119
AGCCTGTTTCTTA
>MS653888.1 Sequence 981 from Patent EP3137119
CCTAGCCTGTTTA
>MS653886.1 Sequence 979 from Patent EP3137119
TCCTAGCCTGTTA
>MS653884.1 Sequence 977 from Patent EP3137119
GTTTTGAGTAGAA
>MS653882.1 Sequence 975 from Patent EP3137119
AGTTTTGAGTAGA
>MS653880.1 Sequence 973 from Patent EP3137119
AAGTTTTGAGTAA
>MS653878.1 Sequence 971 from Patent EP3137119
TGAAAGTTTTGAA
>MS653876.1 Sequence 969 from Patent EP3137119
GAGTTGTGAAAGA
>MS653874.1 Sequence 967 from Patent EP3137119
AAAATGAGTTGTA
>MS653872.1 Sequence 965 from Patent EP3137119
GAAAATGAGTTGA
>MS653870.1 Sequence 963 from Patent EP3137119
TGAAAATGAGTTA
>MS653868.1 Sequence 961 from Patent EP3137119
TACATAACTAAAA
>MS653866.1 Sequence 959 from Patent EP3137119
GATACATAACTAA
>MS653864.1 Sequence 957 from Patent EP3137119
CTGATACATAACA
>MS653862.1 Sequence 955 from Patent EP3137119
GCTGATACATAAA
>MS653860.1 Sequence 953 from Patent EP3137119
ACGCTGATACATA
>MS653858.1 Sequence 951 from Patent EP3137119
GACGCTGATACAA
>MS653856.1 Sequence 949 from Patent EP3137119
TGACGCTGATACA
>MS653854.1 Sequence 947 from Patent EP3137119
AGTATGACGCTGA
>MS653852.1 Sequence 945 from Patent EP3137119
TTTAGTATGACGA
>MS653850.1 Sequence 943 from Patent EP3137119
CTTTAGTATGACA
>MS653848.1 Sequence 941 from Patent EP3137119
TACTTTAGTATGA
>MS653846.1 Sequence 939 from Patent EP3137119
TATACTTTAGTAA
>MS653844.1 Sequence 937 from Patent EP3137119
GTATACTTTAGTA
>MS653842.1 Sequence 935 from Patent EP3137119
TAATTCTTACACA
>MS653840.1 Sequence 933 from Patent EP3137119
CTAATTCTTACAA
>MS653838.1 Sequence 931 from Patent EP3137119
TGTACTGTACTAA
>MS653836.1 Sequence 929 from Patent EP3137119
TATGTACTGTACA
>MS653834.1 Sequence 927 from Patent EP3137119
TGTTTTGTATACA
>MS653832.1 Sequence 925 from Patent EP3137119
AGCATGTTTTGTA
>MS653830.1 Sequence 923 from Patent EP3137119
GGAGCATGTTTTA
>MS653828.1 Sequence 921 from Patent EP3137119
AGGAGCATGTTTA
>MS653826.1 Sequence 919 from Patent EP3137119
GAGGAGCATGTTA
>MS653824.1 Sequence 917 from Patent EP3137119
TGAGGAGCATGTA
>MS653822.1 Sequence 915 from Patent EP3137119
TTGAGGAGCATGA
>MS653820.1 Sequence 913 from Patent EP3137119
TTTGAGGAGCATA
>MS653818.1 Sequence 911 from Patent EP3137119
GTTTGAGGAGCAA
>MS653816.1 Sequence 909 from Patent EP3137119
ATGTTTGAGGAGA
>MS653814.1 Sequence 907 from Patent EP3137119
AATGTTTGAGGAA
>MS653812.1 Sequence 905 from Patent EP3137119
CAATGTTTGAGGA
>MS653810.1 Sequence 903 from Patent EP3137119
ACCTAAGTACTGA
>MS653808.1 Sequence 901 from Patent EP3137119
ATACCTAAGTACA
>MS653806.1 Sequence 899 from Patent EP3137119
CATACCTAAGTAA
>MS653804.1 Sequence 897 from Patent EP3137119
TTCATACCTAAGA
>MS653802.1 Sequence 895 from Patent EP3137119
GAAGTTCATACCA
>MS653800.1 Sequence 893 from Patent EP3137119
GGAAGTTCATACA
>MS653798.1 Sequence 891 from Patent EP3137119
TGGAAGTTCATAA
>MS653796.1 Sequence 889 from Patent EP3137119
CTGGAAGTTCATA
>MS653794.1 Sequence 887 from Patent EP3137119
GACTGGAAGTTCA
>MS653792.1 Sequence 885 from Patent EP3137119
TAGACTGGAAGTA
>MS653790.1 Sequence 883 from Patent EP3137119
CCAGTATTAGACA
>MS653788.1 Sequence 881 from Patent EP3137119
GCCAGTATTAGAA
>MS653786.1 Sequence 879 from Patent EP3137119
GGCCAGTATTAGA
>MS653784.1 Sequence 877 from Patent EP3137119
AGGTGGCTTTTGA
>MS653782.1 Sequence 875 from Patent EP3137119
GAGGTGGCTTTTA
>MS653780.1 Sequence 873 from Patent EP3137119
AGAGGTGGCTTTA
>MS653778.1 Sequence 871 from Patent EP3137119
GAGAGGTGGCTTA
>MS653776.1 Sequence 869 from Patent EP3137119
GTATACATCCTGA
>MS653774.1 Sequence 867 from Patent EP3137119
TTTTGTATACATA
>MS653772.1 Sequence 865 from Patent EP3137119
TCCGCCTTTTGTA
>MS653770.1 Sequence 863 from Patent EP3137119
ATACCATTGACAA
>MS653768.1 Sequence 861 from Patent EP3137119
AATACCATTGACA
>MS653766.1 Sequence 859 from Patent EP3137119
AAATACCATTGAA
>MS653764.1 Sequence 857 from Patent EP3137119
TGCTTAAGTTCCA
>MS653762.1 Sequence 855 from Patent EP3137119
GTGCTTAAGTTCA
>MS653760.1 Sequence 853 from Patent EP3137119
CTTTCAAATCGGA
>MS653758.1 Sequence 851 from Patent EP3137119
ACTTTCAAATCGA
>MS653756.1 Sequence 849 from Patent EP3137119
TACTTTCAAATCA
>MS653754.1 Sequence 847 from Patent EP3137119
TTACTTTCAAATA
>MS653752.1 Sequence 845 from Patent EP3137119
AAGAATGTTGGTA
>MS653750.1 Sequence 843 from Patent EP3137119
TAAGAATGTTGGA
>MS653748.1 Sequence 841 from Patent EP3137119
TTAAGAATGTTGA
>MS653746.1 Sequence 839 from Patent EP3137119
ACATTAAGAATGA
>MS653744.1 Sequence 837 from Patent EP3137119
GTTGACATTAAGA
>MS653742.1 Sequence 835 from Patent EP3137119
TTGTGTTGACATA
>MS653740.1 Sequence 833 from Patent EP3137119
ATTGTGTTGACAA
>MS653738.1 Sequence 831 from Patent EP3137119
GCACATTTTGATA
>MS653736.1 Sequence 829 from Patent EP3137119
TGCACATTTTGAA
>MS653734.1 Sequence 827 from Patent EP3137119
ACTTTGCACATTA
>MS653732.1 Sequence 825 from Patent EP3137119
CCACTTTGCACAA
>MS653730.1 Sequence 823 from Patent EP3137119
ACACGCTCGGACA
>MS653728.1 Sequence 821 from Patent EP3137119
TGAACACGCTCGA
>MS653726.1 Sequence 819 from Patent EP3137119
TTGAACACGCTCA
>MS653724.1 Sequence 817 from Patent EP3137119
ATTGAACACGCTA
>MS653722.1 Sequence 815 from Patent EP3137119
AATTGAACACGCA
>MS653720.1 Sequence 813 from Patent EP3137119
GAAAATTGAACAA
>MS653718.1 Sequence 811 from Patent EP3137119
GCTAAAGAAAATA
>MS653716.1 Sequence 809 from Patent EP3137119
TGCTAAAGAAAAA
>MS653714.1 Sequence 807 from Patent EP3137119
GTTGCTAAAGAAA
>MS653712.1 Sequence 805 from Patent EP3137119
GCAGCAGTTGCTA
>MS653710.1 Sequence 803 from Patent EP3137119
TTGCAGGCAAGAA
>MS653708.1 Sequence 801 from Patent EP3137119
ATTGCAGGCAAGA
>MS653706.1 Sequence 799 from Patent EP3137119
CACTGAGTATGTA
>MS653704.1 Sequence 797 from Patent EP3137119
GCCACTGAGTATG
>MS653702.1 Sequence 795 from Patent EP3137119
TTTGAAAAAGGCA
>MS653700.1 Sequence 793 from Patent EP3137119
ATTTTGAAAAAGA
>MS653698.1 Sequence 791 from Patent EP3137119
CATTTTGAAAAAA
>MS653696.1 Sequence 789 from Patent EP3137119
TGGTCATTTTGAA
>MS653694.1 Sequence 787 from Patent EP3137119
AAAGAATGAGAAA
>MS653692.1 Sequence 785 from Patent EP3137119
GTAAAGAATGAGA
>MS653690.1 Sequence 783 from Patent EP3137119
TGGTAAAGAATGA
>MS653688.1 Sequence 781 from Patent EP3137119
TTGGTAAAGAATA
>MS653686.1 Sequence 779 from Patent EP3137119
TAAGAGCTTGAGA
>MS653684.1 Sequence 777 from Patent EP3137119
CTAAGAGCTTGAA
>MS653682.1 Sequence 775 from Patent EP3137119
GCTAAGAGCTTGA
>MS653680.1 Sequence 773 from Patent EP3137119
CACATTCACCATA
>MS653678.1 Sequence 771 from Patent EP3137119
ATCGACGTGGTCA
>MS653676.1 Sequence 769 from Patent EP3137119
TTCAGATGATGAA
>MS653674.1 Sequence 767 from Patent EP3137119
ATTCAGATGATGA
>MS653672.1 Sequence 765 from Patent EP3137119
AAGTTTGAGCTGA
>MS653670.1 Sequence 763 from Patent EP3137119
AGAAGTTTGAGCA
>MS653668.1 Sequence 761 from Patent EP3137119
TGGAAGAAGTTTA
>MS653666.1 Sequence 759 from Patent EP3137119
ACTTCTACTTCGA
>MS653664.1 Sequence 757 from Patent EP3137119
AGATGACTTCTAA
>MS653662.1 Sequence 755 from Patent EP3137119
AAGATGACTTCTA
>MS653636.1 Sequence 729 from Patent EP3137119
CAAATGATTGTGA
>MS653635.1 Sequence 728 from Patent EP3137119
ATTCAAATGATTA
>MS653634.1 Sequence 727 from Patent EP3137119
CAAAGAAGCTAAA
>MS653633.1 Sequence 726 from Patent EP3137119
AAAATGGTTGCAA
>MS653632.1 Sequence 725 from Patent EP3137119
ATAGCAGCCAAGA
>MS653631.1 Sequence 724 from Patent EP3137119
TTATTTATAGCAA
>MS653630.1 Sequence 723 from Patent EP3137119
AACTGGAAAACTA
>MS653629.1 Sequence 722 from Patent EP3137119
ATGAAATGAATCA
>MS653628.1 Sequence 721 from Patent EP3137119
TGCAATGAAATGA
>MS653627.1 Sequence 720 from Patent EP3137119
TGACTATTGGAAA
>MS653626.1 Sequence 719 from Patent EP3137119
AGCTGACTATTGA
>MS653625.1 Sequence 718 from Patent EP3137119
TAGCTGACTATTA
>MS653624.1 Sequence 717 from Patent EP3137119
TCCTTAGCTGACA
>MS653623.1 Sequence 716 from Patent EP3137119
TGAAATTTCCTTA
>MS653622.1 Sequence 715 from Patent EP3137119
AGTTGAATCTCTA
>MS653621.1 Sequence 714 from Patent EP3137119
CAGTTTAGTGTAA
>MS653620.1 Sequence 713 from Patent EP3137119
CAGGATTCAGTTA
>MS653619.1 Sequence 712 from Patent EP3137119
ATCTAGAAGGAGA
>MS653618.1 Sequence 711 from Patent EP3137119
GAAACCTTCATCA
>MS653617.1 Sequence 710 from Patent EP3137119
ACAGGAAAATATA
>MS653616.1 Sequence 709 from Patent EP3137119
ATATTATGACTAA
>MS653615.1 Sequence 708 from Patent EP3137119
CAGTATATTATGA
>MS653614.1 Sequence 707 from Patent EP3137119
CAACATGTCTGTA
>MS653613.1 Sequence 706 from Patent EP3137119
ACCAACATGTCTA
>MS653612.1 Sequence 705 from Patent EP3137119
GTGCAATACCAAA
>MS653610.1 Sequence 703 from Patent EP3137119
TGCGGATCAAACA
>MS653596.1 Sequence 689 from Patent EP3137119
AGAACAGTCCTTA
>MS653595.1 Sequence 688 from Patent EP3137119
AGAACAGTCCTTA
>MS653594.1 Sequence 687 from Patent EP3137119
AGAACAGTCCTTA
>MS653592.1 Sequence 685 from Patent EP3137119
AGAACAGTCCTTA
>MS653588.1 Sequence 681 from Patent EP3137119
CACTAGCTTATCA
>MS653586.1 Sequence 679 from Patent EP3137119
TCACTAGCTTATA
>MS653584.1 Sequence 677 from Patent EP3137119
ATCTTTTGCTCTA
>MS653582.1 Sequence 675 from Patent EP3137119
TATCTTTTGCTCA
>MS653580.1 Sequence 673 from Patent EP3137119
AACCACTAGTTCA
>MS653578.1 Sequence 671 from Patent EP3137119
GAAACCACTAGTA
>MS653576.1 Sequence 669 from Patent EP3137119
CAGAAAGACAGAA
>MS653574.1 Sequence 667 from Patent EP3137119
TTGACTGCTGTGA
>MS653572.1 Sequence 665 from Patent EP3137119
GGATTCGCCATTA
>MS653570.1 Sequence 663 from Patent EP3137119
TGCGGATCAAACA
>MS653568.1 Sequence 661 from Patent EP3137119
GATTATGCGGATA
>MS653566.1 Sequence 659 from Patent EP3137119
TGCAGATTATGCA
>MS653564.1 Sequence 657 from Patent EP3137119
CAGAACAGTCCTA
>MS653562.1 Sequence 655 from Patent EP3137119
TGCTACTGTTTAA
>MS653560.1 Sequence 653 from Patent EP3137119
ATTGGTGCTACTA
>MS653558.1 Sequence 651 from Patent EP3137119
CTCTCTCCTTTTA
>MS653556.1 Sequence 649 from Patent EP3137119
TCTCTCTCCTTTA
>MS653554.1 Sequence 647 from Patent EP3137119
AATCTCTCTCCTA
>MS653552.1 Sequence 645 from Patent EP3137119
AAATAAGGTTTCA
>MS653550.1 Sequence 643 from Patent EP3137119
ACACTCAGCTCTA
>MS653548.1 Sequence 641 from Patent EP3137119
GAAAAGAGAAAGA
>MS653546.1 Sequence 639 from Patent EP3137119
AGAAAAGAGAAAA
>MS653544.1 Sequence 637 from Patent EP3137119
GAGAAAAGAGAAA
>MS653542.1 Sequence 635 from Patent EP3137119
TTGAAACCACTAA
>MS653540.1 Sequence 633 from Patent EP3137119
TGTTATTGGTGTA
>MS653538.1 Sequence 631 from Patent EP3137119
TTAATCCAGAAAA
>MS653536.1 Sequence 629 from Patent EP3137119
GTCCTTAATCCAA
>MS653534.1 Sequence 627 from Patent EP3137119
CAGTCCTTAATCA
>MS653532.1 Sequence 625 from Patent EP3137119
GAACAGTCCTTAA
>MS653530.1 Sequence 623 from Patent EP3137119
AGAACAGTCCTTA
>MS653528.1 Sequence 621 from Patent EP3137119
GATGAGCTTCCTA
>MS653526.1 Sequence 619 from Patent EP3137119
GTGACCAAAAGTA
>MS653524.1 Sequence 617 from Patent EP3137119
GTGACCAAAAGTA
>MS653522.1 Sequence 615 from Patent EP3137119
GCACCTTTCTAGA
>MS653520.1 Sequence 613 from Patent EP3137119
GTGACCAAAAGTA
>MS653518.1 Sequence 611 from Patent EP3137119
GTGACCAAAAGTA
>MS653516.1 Sequence 609 from Patent EP3137119
GTGACCAAAAGTA
>MS653514.1 Sequence 607 from Patent EP3137119
GTGACCAAAAGTA
>MS653512.1 Sequence 605 from Patent EP3137119
GTGACCAAAAGTA
>MS653510.1 Sequence 603 from Patent EP3137119
GTGACCAAAAGTA
>MS653508.1 Sequence 601 from Patent EP3137119
GTGACCAAAAGTA
>MS653506.1 Sequence 599 from Patent EP3137119
GTGACCAAAAGTA
>MS653504.1 Sequence 597 from Patent EP3137119
GTGACCAAAAGTA
>MS653502.1 Sequence 595 from Patent EP3137119
GCACCTTTCTAGA
>MS653500.1 Sequence 593 from Patent EP3137119
GCACCTTTCTAGA
>MS653498.1 Sequence 591 from Patent EP3137119
GCACCTTTCTAGA
>MS653496.1 Sequence 589 from Patent EP3137119
GCACCTTTCTAGA
>MS653494.1 Sequence 587 from Patent EP3137119
GCACCTTTCTAGA
>MS653492.1 Sequence 585 from Patent EP3137119
CCTTTCTAGTTGA
>MS653490.1 Sequence 583 from Patent EP3137119
CCTTTCTAGTTGA
>MS653488.1 Sequence 581 from Patent EP3137119
CCTTTCTAGTTGA
>MS653462.1 Sequence 555 from Patent EP3137119
GCACCTTTCTAGA
>MS653460.1 Sequence 553 from Patent EP3137119
GCACCTTTCTAGA
>MS653458.1 Sequence 551 from Patent EP3137119
GCACCTTTCTAGA
>MS653456.1 Sequence 549 from Patent EP3137119
GCACCTTTCTAGA
>MS653454.1 Sequence 547 from Patent EP3137119
GCACCTTTCTAGA
>MS653452.1 Sequence 545 from Patent EP3137119
GCACCTTTCTAGA
>MS653450.1 Sequence 543 from Patent EP3137119
GCACCTTTCTAGA
>MS653448.1 Sequence 541 from Patent EP3137119
GCACCTTTCTAGA
>MS653446.1 Sequence 539 from Patent EP3137119
GCACCTTTCTAGA
>MS653444.1 Sequence 537 from Patent EP3137119
CCTTTCTAGTTGA
>MS653442.1 Sequence 535 from Patent EP3137119
CCTTTCTAGTTGA
>MS653440.1 Sequence 533 from Patent EP3137119
CCTTTCTAGTTGA
>MS653438.1 Sequence 531 from Patent EP3137119
CCTTTCTAGTTGA
>MS653436.1 Sequence 529 from Patent EP3137119
CCTTTCTAGTTGA
>MS653434.1 Sequence 527 from Patent EP3137119
CCTTTCTAGTTGA
>MS653432.1 Sequence 525 from Patent EP3137119
CCTTTCTAGTTGA
>MS653430.1 Sequence 523 from Patent EP3137119
CCTTTCTAGTTGA
>MS653428.1 Sequence 521 from Patent EP3137119
CCTTTCTAGTTGA
>MS653426.1 Sequence 519 from Patent EP3137119
CCTTTCTAGTTGA
>MS653424.1 Sequence 517 from Patent EP3137119
CCTTTCTAGTTGA
>MS653422.1 Sequence 515 from Patent EP3137119
CCTTTCTAGTTGA
>MS653420.1 Sequence 513 from Patent EP3137119
CCTTTCTAGTTGA
>MS653342.1 Sequence 435 from Patent EP3137119
TGAGAGTGTGACA
>MS653386.1 Sequence 479 from Patent EP3137119
GTGACCAAAAGTA
>MS653382.1 Sequence 475 from Patent EP3137119
GCACCTTTCTAGA
>MS653378.1 Sequence 471 from Patent EP3137119
GCACCTTTCTAGA
>MS653374.1 Sequence 467 from Patent EP3137119
GCACCTTTCTAGA
>MS653370.1 Sequence 463 from Patent EP3137119
GCACCTTTCTAGA
>MS653366.1 Sequence 459 from Patent EP3137119
GCACCTTTCTAGA
>MS653362.1 Sequence 455 from Patent EP3137119
GCACCTTTCTAGA
>MS653358.1 Sequence 451 from Patent EP3137119
GCACCTTTCTAGA
>MS653354.1 Sequence 447 from Patent EP3137119
GTGACCAAAAGTA
>MS653350.1 Sequence 443 from Patent EP3137119
TGTGACCAAAAGA
>MS653330.1 Sequence 423 from Patent EP3137119
CAGTTTATTTGTA
>MS653326.1 Sequence 419 from Patent EP3137119
ACAAGCCAGATTA
>MS653322.1 Sequence 415 from Patent EP3137119
TTTGCCTGTAACA
>MS653318.1 Sequence 411 from Patent EP3137119
TTCTGATTCGAAA
>MS653314.1 Sequence 407 from Patent EP3137119
TTGAGAAGGAAAA
>MS653310.1 Sequence 403 from Patent EP3137119
TGAAGTGTAATTA
>MS653306.1 Sequence 399 from Patent EP3137119
GATAGCATCTTAA
>MS653302.1 Sequence 395 from Patent EP3137119
TGAAGAATGTTAA
>MS653388.1 Sequence 481 from Patent EP3137119
GTGACCAAAAGTA
>MS653384.1 Sequence 477 from Patent EP3137119
GTGACCAAAAGTA
>MS653380.1 Sequence 473 from Patent EP3137119
GCACCTTTCTAGA
>MS653376.1 Sequence 469 from Patent EP3137119
GCACCTTTCTAGA
>MS653372.1 Sequence 465 from Patent EP3137119
GCACCTTTCTAGA
>MS653368.1 Sequence 461 from Patent EP3137119
GCACCTTTCTAGA
>MS653364.1 Sequence 457 from Patent EP3137119
GCACCTTTCTAGA
>MS653360.1 Sequence 453 from Patent EP3137119
CCTTTCTAGTTGA
>MS653356.1 Sequence 449 from Patent EP3137119
GACCAAAAGTTAA
>MS653348.1 Sequence 441 from Patent EP3137119
GTGTGACCAAAAA
>MS653344.1 Sequence 437 from Patent EP3137119
AGTGTGACCAAAA
>MS653340.1 Sequence 433 from Patent EP3137119
TTGAGCTTTCTGA
>MS653336.1 Sequence 429 from Patent EP3137119
TGCACCTTTCTAA
>MS653332.1 Sequence 425 from Patent EP3137119
TGTTGAGAGTGTA
>MS653320.1 Sequence 413 from Patent EP3137119
CTGTCGATTAGAA
>MS653316.1 Sequence 409 from Patent EP3137119
CATTCTGATTCGA
>MS653312.1 Sequence 405 from Patent EP3137119
AATTGAGAAGGAA
>MS653198.1 Sequence 291 from Patent EP3137119
AGGCCTTGCGAAG
>MS653194.1 Sequence 287 from Patent EP3137119
ATGGTCAGGCCTT
>MS653190.1 Sequence 283 from Patent EP3137119
AAGCTGACCTGGA
>MS653098.1 Sequence 191 from Patent EP3137119
GCCATTACAACTG
>MS653094.1 Sequence 187 from Patent EP3137119
CGACTGGAAGACA
>MS653090.1 Sequence 183 from Patent EP3137119
ACAGGAAGATGTA
>MS653186.1 Sequence 279 from Patent EP3137119
AGTTGTTCCTTAA
>MS653182.1 Sequence 275 from Patent EP3137119
ACATACCGAGCTA
>MS653178.1 Sequence 271 from Patent EP3137119
ATACCGAGCTAAA
>MS653174.1 Sequence 267 from Patent EP3137119
GACTGGACAGCTT
>MS653170.1 Sequence 263 from Patent EP3137119
TTATCTAAGTTAA
>MS653278.1 Sequence 371 from Patent EP3137119
TACGGAGACATGG
>MS653274.1 Sequence 367 from Patent EP3137119
GTACCAGTGCACG
>MS653270.1 Sequence 363 from Patent EP3137119
TTGCGAAGCTGAC
>MS653266.1 Sequence 359 from Patent EP3137119
TGTTCCAAGACCT
>MS653262.1 Sequence 355 from Patent EP3137119
CCGACTGGAAGAC
>MS653258.1 Sequence 351 from Patent EP3137119
GGCCTTGCGAAGC
>MS653202.1 Sequence 295 from Patent EP3137119
ACCGCAAGATCGG
>MS653166.1 Sequence 259 from Patent EP3137119
AGCTGATCAGTTT
>MS653102.1 Sequence 195 from Patent EP3137119
AGTGGAGCGCCTG
>MS653106.1 Sequence 199 from Patent EP3137119
GTTTGAGCTTTCT
>MS653110.1 Sequence 203 from Patent EP3137119
ACTGGAAGACACG
>MS653114.1 Sequence 207 from Patent EP3137119
AGACCTGTGCCTG
>MS653162.1 Sequence 255 from Patent EP3137119
AGCTAAATTCTGT
>MS653158.1 Sequence 251 from Patent EP3137119
GGAAGACACGTTT
>MS653118.1 Sequence 211 from Patent EP3137119
CCTGGTCCAGACC
>MS653122.1 Sequence 215 from Patent EP3137119
CTGCCATTACAAC
>MS653298.1 Sequence 391 from Patent EP3137119
ACATTAACTCATA
>MS653294.1 Sequence 387 from Patent EP3137119
TATCAAGTTTGAG
>MS653290.1 Sequence 383 from Patent EP3137119
AGACACGTTTGGC
>MS653286.1 Sequence 379 from Patent EP3137119
GCTAAATTCTGTG
>MS653282.1 Sequence 375 from Patent EP3137119
CCTTGCGAAGCTG
>MS653126.1 Sequence 219 from Patent EP3137119
CATTACAACTGTC
>MS653130.1 Sequence 223 from Patent EP3137119
ACCGACTGGAAGA
>MS653134.1 Sequence 227 from Patent EP3137119
GCCTTGCGAAGCT
>MS653138.1 Sequence 231 from Patent EP3137119
GCCTATCAAGTTT
>MS653142.1 Sequence 235 from Patent EP3137119
TGTACGGAGACAT
>MS653146.1 Sequence 239 from Patent EP3137119
CAAGTTTGAGCTT
>MS653254.1 Sequence 347 from Patent EP3137119
AAGACACGTTTGG
>MS653250.1 Sequence 343 from Patent EP3137119
GGTCAGGCCTTGC
>MS653246.1 Sequence 339 from Patent EP3137119
TGGAGTATGTACC
>MS653242.1 Sequence 335 from Patent EP3137119
TCAAGTTTGAGCT
>MS653238.1 Sequence 331 from Patent EP3137119
TGACTTCGGCTCC
>MS653234.1 Sequence 327 from Patent EP3137119
GGAAGATGTACGG
>MS653230.1 Sequence 323 from Patent EP3137119
TCAGGCCTTGCGA
>MS653226.1 Sequence 319 from Patent EP3137119
GACACGTTTGGCC
>MS653222.1 Sequence 315 from Patent EP3137119
AATGACAACGCCT
>MS653218.1 Sequence 311 from Patent EP3137119
TGGAAGACACGTT
>MS653214.1 Sequence 307 from Patent EP3137119
GAGGTCATGAAGA
>MS653210.1 Sequence 303 from Patent EP3137119
CGGAGACATGGCA
>MS653206.1 Sequence 299 from Patent EP3137119
CGAGCTAAATTCT
>MS653150.1 Sequence 243 from Patent EP3137119
AAATTCTGTGGAG
>MS653154.1 Sequence 247 from Patent EP3137119
CAATGACATCTTT
>MS653100.1 Sequence 193 from Patent EP3137119
GAGCTTTCTGGCT
>MS653096.1 Sequence 189 from Patent EP3137119
GGAGCGCCTGTTC
>MS653092.1 Sequence 185 from Patent EP3137119
GAGTGGAGCGCCT
>MS653296.1 Sequence 389 from Patent EP3137119
GAAGCTGACCTGG
>MS653292.1 Sequence 385 from Patent EP3137119
CCGCAAGATCGGC
>MS653288.1 Sequence 381 from Patent EP3137119
CTAAATTCTGTGG
>MS653284.1 Sequence 377 from Patent EP3137119
CTGTGACTTCGGC
>MS653280.1 Sequence 373 from Patent EP3137119
TGCGAAGCTGACC
>MS653276.1 Sequence 369 from Patent EP3137119
CCTGTTCCAAGAC
>MS653272.1 Sequence 365 from Patent EP3137119
CAATGACAACGCC
>MS653268.1 Sequence 361 from Patent EP3137119
CGAAGCTGACCTG
>MS653264.1 Sequence 357 from Patent EP3137119
CCTATCAAGTTTG
>MS653260.1 Sequence 353 from Patent EP3137119
CTTGCGAAGCTGA
>MS653256.1 Sequence 349 from Patent EP3137119
CGAGGTCATGAAG
>MS653252.1 Sequence 345 from Patent EP3137119
GAGCTAAATTCTG
>MS653248.1 Sequence 341 from Patent EP3137119
GCTAGAGAAGCAG
>MS653244.1 Sequence 337 from Patent EP3137119
GCCAGAACTGCAG
>MS653240.1 Sequence 333 from Patent EP3137119
TGGTCAGGCCTTG
>MS653236.1 Sequence 329 from Patent EP3137119
GTGACTTCGGCTC
>MS653200.1 Sequence 293 from Patent EP3137119
TACCGACTGGAAG
>MS653196.1 Sequence 289 from Patent EP3137119
GAAGACACGTTTG
>MS653192.1 Sequence 285 from Patent EP3137119
GGTCATGAAGAAG
>MS653188.1 Sequence 281 from Patent EP3137119
ATTTGAAGTGTAA
>MS653184.1 Sequence 277 from Patent EP3137119
AGCAGAAAGGTTA
>MS653180.1 Sequence 273 from Patent EP3137119
TTGTTGAGAGTGT
>MS653104.1 Sequence 197 from Patent EP3137119
TGGAGCGCCTGTT
>MS653108.1 Sequence 201 from Patent EP3137119
TGCCATTACAACT
>MS653112.1 Sequence 205 from Patent EP3137119
AACTGCCTGGTCC
>MS653116.1 Sequence 209 from Patent EP3137119
CAGAGTGGAGCGC
>MS653120.1 Sequence 213 from Patent EP3137119
CCATTACAACTGT
>MS653124.1 Sequence 217 from Patent EP3137119
ATTACAACTGTCC
>MS653128.1 Sequence 221 from Patent EP3137119
AGAGTGGAGCGCC
>MS653132.1 Sequence 225 from Patent EP3137119
ATGTACGGAGACA
>MS653136.1 Sequence 229 from Patent EP3137119
GCTGCGAGGAGTG
>MS653140.1 Sequence 233 from Patent EP3137119
AATTCTGTGGAGT
>MS653144.1 Sequence 237 from Patent EP3137119
AGCCTATCAAGTT
>MS653148.1 Sequence 241 from Patent EP3137119
CTGTGGAGTATGT
>MS653152.1 Sequence 245 from Patent EP3137119
TTTCAGTAGCACA
>MS653156.1 Sequence 249 from Patent EP3137119
AGTACCAGTGCAC
>MS653160.1 Sequence 253 from Patent EP3137119
CTATCAAGTTTGA
>MS653164.1 Sequence 257 from Patent EP3137119
AGGTAGAATGTAA
>MS653168.1 Sequence 261 from Patent EP3137119
TTCTGCTCAGATA
>MS653172.1 Sequence 265 from Patent EP3137119
TATACGAGTAATA
>MS653232.1 Sequence 325 from Patent EP3137119
GCGAAGCTGACCT
>MS653228.1 Sequence 321 from Patent EP3137119
ACGGAGACATGGC
>MS653224.1 Sequence 317 from Patent EP3137119
GGCGAGGTCATGA
>MS653220.1 Sequence 313 from Patent EP3137119
AAGATGTACGGAG
>MS653216.1 Sequence 309 from Patent EP3137119
TAAATTCTGTGGA
>MS653212.1 Sequence 305 from Patent EP3137119
ATGACAACGCCTC
>MS653208.1 Sequence 301 from Patent EP3137119
TCTGTGGAGTATG
>MS653204.1 Sequence 297 from Patent EP3137119
CAGGCCTTGCGAA
>MS653176.1 Sequence 269 from Patent EP3137119
ATGGCCTTTATTA
>MS651920.1 Sequence 1431 from Patent EP3137118
GCACCTTTCTAGA
>MS651918.1 Sequence 1429 from Patent EP3137118
CTGTGGAAGTCTA
>MS651916.1 Sequence 1427 from Patent EP3137118
CTGTGGAAGTCTA
>MS651912.1 Sequence 1423 from Patent EP3137118
CTGTGGAAGTCTA
>MS651910.1 Sequence 1421 from Patent EP3137118
CTGTGGAAGTCTA
>MS651908.1 Sequence 1419 from Patent EP3137118
CTGTGGAAGTCTA
>MS651906.1 Sequence 1417 from Patent EP3137118
CTGTGGAAGTCTA
>MS651904.1 Sequence 1415 from Patent EP3137118
CTGTGGAAGTCTA
>MS651894.1 Sequence 1405 from Patent EP3137118
CTGTGGAAGTCTA
>MS651892.1 Sequence 1403 from Patent EP3137118
CTGTGGAAGTCTA
>MS651890.1 Sequence 1401 from Patent EP3137118
CTGTGGAAGTCTA
>MS651886.1 Sequence 1397 from Patent EP3137118
TGCGGATCAAACA
>MS651872.1 Sequence 1383 from Patent EP3137118
AGAACAGTCCTTA
>MS651871.1 Sequence 1382 from Patent EP3137118
AGAACAGTCCTTA
>MS651870.1 Sequence 1381 from Patent EP3137118
AGAACAGTCCTTA
>MS651868.1 Sequence 1379 from Patent EP3137118
AGAACAGTCCTTA
>MS651864.1 Sequence 1375 from Patent EP3137118
CACTAGCTTATCA
>MS651862.1 Sequence 1373 from Patent EP3137118
TCACTAGCTTATA
>MS651860.1 Sequence 1371 from Patent EP3137118
ATCTTTTGCTCTA
>MS651858.1 Sequence 1369 from Patent EP3137118
TATCTTTTGCTCA
>MS651856.1 Sequence 1367 from Patent EP3137118
AACCACTAGTTCA
>MS651854.1 Sequence 1365 from Patent EP3137118
GAAACCACTAGTA
>MS651852.1 Sequence 1363 from Patent EP3137118
CAGAAAGACAGAA
>MS651850.1 Sequence 1361 from Patent EP3137118
TTGACTGCTGTGA
>MS651848.1 Sequence 1359 from Patent EP3137118
GGATTCGCCATTA
>MS651846.1 Sequence 1357 from Patent EP3137118
TGCGGATCAAACA
>MS651844.1 Sequence 1355 from Patent EP3137118
GATTATGCGGATA
>MS651842.1 Sequence 1353 from Patent EP3137118
TGCAGATTATGCA
>MS651840.1 Sequence 1351 from Patent EP3137118
CAGAACAGTCCTA
>MS651640.1 Sequence 1149 from Patent EP3137118
TCATCAGTGTTAA
>MS651638.1 Sequence 1147 from Patent EP3137118
TCATCAGTGTTAA
>MS651636.1 Sequence 1145 from Patent EP3137118
TCATCAGTGTTAA
>MS651634.1 Sequence 1143 from Patent EP3137118
TCATCAGTGTTAA
>MS651632.1 Sequence 1141 from Patent EP3137118
TCATCAGTGTTAA
>MS651630.1 Sequence 1139 from Patent EP3137118
TCATCAGTGTTAA
>MS651628.1 Sequence 1137 from Patent EP3137118
TCATCAGTGTTAA
>MS651626.1 Sequence 1135 from Patent EP3137118
TCATCAGTGTTAA
>MS651624.1 Sequence 1133 from Patent EP3137118
TCATCAGTGTTAA
>MS651622.1 Sequence 1131 from Patent EP3137118
TCATCAGTGTTAA
>MS651612.1 Sequence 1121 from Patent EP3137118
ATTCTACATTTCA
>MS651610.1 Sequence 1119 from Patent EP3137118
GCTGCCTAAGGAA
>MS651608.1 Sequence 1117 from Patent EP3137118
ACGACAACGATGA
>MS651606.1 Sequence 1115 from Patent EP3137118
CGACAACAACAAA
>MS651604.1 Sequence 1113 from Patent EP3137118
AACTCAAACGAGA
>MS651602.1 Sequence 1111 from Patent EP3137118
TCATCAGTGTTAA
>MS651600.1 Sequence 1109 from Patent EP3137118
TTGTCAGTTTAGA
>MS651598.1 Sequence 1107 from Patent EP3137118
GTAAACCAGTGAA
>MS651596.1 Sequence 1105 from Patent EP3137118
CGACGACAACGAA
>MS651594.1 Sequence 1103 from Patent EP3137118
ATATGACCGAGAA
>MS651592.1 Sequence 1101 from Patent EP3137118
ACTCAAACGAGCA
>MS651590.1 Sequence 1099 from Patent EP3137118
CCAGAAACTCATA
>MS651588.1 Sequence 1097 from Patent EP3137118
GTATTGCTATGCA
>MS651586.1 Sequence 1095 from Patent EP3137118
CAGAAACTCATGA
>MS651584.1 Sequence 1093 from Patent EP3137118
ATGCTTGTAACAA
>MS651582.1 Sequence 1091 from Patent EP3137118
GACAACAACAACA
>MS651578.1 Sequence 1087 from Patent EP3137118
ATAAAACAGGTGA
>MS651574.1 Sequence 1083 from Patent EP3137118
TTGCACTACAAAA
>MS651570.1 Sequence 1079 from Patent EP3137118
GAATTTATTAGTA
>MS651566.1 Sequence 1075 from Patent EP3137118
CTTGCACTACAAA
>MS651562.1 Sequence 1071 from Patent EP3137118
AAATACTTTGCCA
>MS651558.1 Sequence 1067 from Patent EP3137118
TTGTGTTCTGTTA
>MS651554.1 Sequence 1063 from Patent EP3137118
ATGGCTTAAGGAA
>MS651550.1 Sequence 1059 from Patent EP3137118
ATCAGTGTTAAAA
>MS651546.1 Sequence 1055 from Patent EP3137118
TATTTATTGTGTA
>MS651544.1 Sequence 1053 from Patent EP3137118
ACGCCAAGGAGGT
>MS651542.1 Sequence 1051 from Patent EP3137118
AGTCCACTAGGAA
>MS651540.1 Sequence 1049 from Patent EP3137118
TGGTGATCAGAAA
>MS651538.1 Sequence 1047 from Patent EP3137118
AAGTCCACTAGGA
>MS651536.1 Sequence 1045 from Patent EP3137118
ACCTCCACATATA
>MS651534.1 Sequence 1043 from Patent EP3137118
CTCCTGCTAATGT
>MS651532.1 Sequence 1041 from Patent EP3137118
GTGGTGATCAGAA
>MS651530.1 Sequence 1039 from Patent EP3137118
CGCCAAGGAGGTT
>MS651528.1 Sequence 1037 from Patent EP3137118
TTTCCATCTACAA
>MS651526.1 Sequence 1035 from Patent EP3137118
TCCATCTACAACA
>MS651524.1 Sequence 1033 from Patent EP3137118
ATTTCCATCTACA
>MS651522.1 Sequence 1031 from Patent EP3137118
CCAAGGAGGTTTA
>MS651520.1 Sequence 1029 from Patent EP3137118
GACAGGAACCTGG
>MS651518.1 Sequence 1027 from Patent EP3137118
GGCTCTCCTTCGA
>MS651516.1 Sequence 1025 from Patent EP3137118
GTGACCAAAAGTA
>MS651514.1 Sequence 1023 from Patent EP3137118
GTGACCAAAAGTA
>MS651512.1 Sequence 1021 from Patent EP3137118
GCACCTTTCTAGA
>MS651510.1 Sequence 1019 from Patent EP3137118
GTGACCAAAAGTA
>MS651508.1 Sequence 1017 from Patent EP3137118
GTGACCAAAAGTA
>MS651506.1 Sequence 1015 from Patent EP3137118
GTGACCAAAAGTA
>MS651504.1 Sequence 1013 from Patent EP3137118
GTGACCAAAAGTA
>MS651502.1 Sequence 1011 from Patent EP3137118
GTGACCAAAAGTA
>MS651500.1 Sequence 1009 from Patent EP3137118
GTGACCAAAAGTA
>MS651498.1 Sequence 1007 from Patent EP3137118
GTGACCAAAAGTA
>MS651496.1 Sequence 1005 from Patent EP3137118
GTGACCAAAAGTA
>MS651494.1 Sequence 1003 from Patent EP3137118
GTGACCAAAAGTA
>MS651492.1 Sequence 1001 from Patent EP3137118
GCACCTTTCTAGA
>MS651490.1 Sequence 999 from Patent EP3137118
GCACCTTTCTAGA
>MS651488.1 Sequence 997 from Patent EP3137118
GCACCTTTCTAGA
>MS651486.1 Sequence 995 from Patent EP3137118
GCACCTTTCTAGA
>MS651484.1 Sequence 993 from Patent EP3137118
GCACCTTTCTAGA
>MS651482.1 Sequence 991 from Patent EP3137118
CCTTTCTAGTTGA
>MS651480.1 Sequence 989 from Patent EP3137118
CCTTTCTAGTTGA
>MS651478.1 Sequence 987 from Patent EP3137118
CCTTTCTAGTTGA
>MS651452.1 Sequence 961 from Patent EP3137118
GCACCTTTCTAGA
>MS651450.1 Sequence 959 from Patent EP3137118
GCACCTTTCTAGA
>MS651448.1 Sequence 957 from Patent EP3137118
GCACCTTTCTAGA
>MS651446.1 Sequence 955 from Patent EP3137118
GCACCTTTCTAGA
>MS651444.1 Sequence 953 from Patent EP3137118
GCACCTTTCTAGA
>MS651838.1 Sequence 1349 from Patent EP3137118
TGCTACTGTTTAA
>MS651836.1 Sequence 1347 from Patent EP3137118
ATTGGTGCTACTA
>MS651834.1 Sequence 1345 from Patent EP3137118
CTCTCTCCTTTTA
>MS651832.1 Sequence 1343 from Patent EP3137118
TCTCTCTCCTTTA
>MS651830.1 Sequence 1341 from Patent EP3137118
AATCTCTCTCCTA
>MS651828.1 Sequence 1339 from Patent EP3137118
AAATAAGGTTTCA
>MS651826.1 Sequence 1337 from Patent EP3137118
ACACTCAGCTCTA
>MS651824.1 Sequence 1335 from Patent EP3137118
GAAAAGAGAAAGA
>MS651822.1 Sequence 1333 from Patent EP3137118
AGAAAAGAGAAAA
>MS651820.1 Sequence 1331 from Patent EP3137118
GAGAAAAGAGAAA
>MS651818.1 Sequence 1329 from Patent EP3137118
TTGAAACCACTAA
>MS651816.1 Sequence 1327 from Patent EP3137118
TGTTATTGGTGTA
>MS651814.1 Sequence 1325 from Patent EP3137118
TTAATCCAGAAAA
>MS651812.1 Sequence 1323 from Patent EP3137118
GTCCTTAATCCAA
>MS651810.1 Sequence 1321 from Patent EP3137118
CAGTCCTTAATCA
>MS651808.1 Sequence 1319 from Patent EP3137118
GAACAGTCCTTAA
>MS651806.1 Sequence 1317 from Patent EP3137118
AGAACAGTCCTTA
>MS651804.1 Sequence 1315 from Patent EP3137118
GATGAGCTTCCTA
>MS651802.1 Sequence 1313 from Patent EP3137118
CACACAGCATATA
>MS651800.1 Sequence 1311 from Patent EP3137118
CACACAGCATATA
>MS651798.1 Sequence 1309 from Patent EP3137118
CACACAGCATATA
>MS651796.1 Sequence 1307 from Patent EP3137118
CACACAGCATATA
>MS651794.1 Sequence 1305 from Patent EP3137118
CACACAGCATATA
>MS651792.1 Sequence 1301 from Patent EP3137118
AGATTCAAGTCAA
>MS651790.1 Sequence 1299 from Patent EP3137118
CACACAGCATATA
>MS651788.1 Sequence 1297 from Patent EP3137118
CACACAGCATATA
>MS651786.1 Sequence 1295 from Patent EP3137118
CACACAGCATATA
>MS651784.1 Sequence 1293 from Patent EP3137118
CACACAGCATATA
>MS651782.1 Sequence 1291 from Patent EP3137118
CACACAGCATATA
>MS651780.1 Sequence 1289 from Patent EP3137118
CACACAGCATATA
>MS651778.1 Sequence 1287 from Patent EP3137118
CACACAGCATATA
>MS651776.1 Sequence 1285 from Patent EP3137118
CACACAGCATATA
>MS651774.1 Sequence 1283 from Patent EP3137118
GAGATTCAAGTCA
>MS651772.1 Sequence 1281 from Patent EP3137118
ATGACAAAACCAA
>MS651770.1 Sequence 1279 from Patent EP3137118
TGACAGCAAAGAA
>MS651768.1 Sequence 1277 from Patent EP3137118
CTGTGGAGCAACA
>MS651766.1 Sequence 1275 from Patent EP3137118
AGATTCAAGTCAA
>MS651764.1 Sequence 1273 from Patent EP3137118
CAATCTATGACAA
>MS651762.1 Sequence 1271 from Patent EP3137118
ACAGCAAAGATAA
>MS651760.1 Sequence 1269 from Patent EP3137118
ACTCTACCAGAAA
>MS651758.1 Sequence 1267 from Patent EP3137118
AACTCTACCAGAA
>MS651756.1 Sequence 1265 from Patent EP3137118
GCAAAGATAATGA
>MS651754.1 Sequence 1263 from Patent EP3137118
GAACTCTACCAGA
>MS651752.1 Sequence 1261 from Patent EP3137118
GAAATATAGCAAA
>MS651750.1 Sequence 1259 from Patent EP3137118
CACACAGCATATA
>MS651748.1 Sequence 1257 from Patent EP3137118
AATCTATGACAAA
>MS651746.1 Sequence 1255 from Patent EP3137118
CAAGCAGAGTACA
>MS651744.1 Sequence 1253 from Patent EP3137118
AAGTTCAAGCAGA
>MS651742.1 Sequence 1251 from Patent EP3137118
TATGACAAGTTCA
>MS651740.1 Sequence 1249 from Patent EP3137118
CAACGAAATCTAA
>MS651738.1 Sequence 1247 from Patent EP3137118
CTATGACAAGTTA
>MS651736.1 Sequence 1245 from Patent EP3137118
TTAAAGATGGAGA
>MS651734.1 Sequence 1243 from Patent EP3137118
GACAAGTTCAAGA
>MS651732.1 Sequence 1241 from Patent EP3137118
ATATATGTTCTTA
>MS651730.1 Sequence 1239 from Patent EP3137118
AGCAGAGTACACA
>MS651728.1 Sequence 1237 from Patent EP3137118
TTCAACACATCAA
>MS651726.1 Sequence 1235 from Patent EP3137118
AAGCAGAGTACAA
>MS651724.1 Sequence 1233 from Patent EP3137118
AGAGTACACACAA
>MS651722.1 Sequence 1231 from Patent EP3137118
AGCATATATATGA
>MS651720.1 Sequence 1229 from Patent EP3137118
TCAAGCAGAGTAA
>MS651718.1 Sequence 1227 from Patent EP3137118
CAGCATATATATA
>MS651716.1 Sequence 1225 from Patent EP3137118
ACACACAGCATAA
>MS651714.1 Sequence 1223 from Patent EP3137118
CAGAGTACACACA
>MS651712.1 Sequence 1221 from Patent EP3137118
CAAGTTCAAGCAA
>MS651708.1 Sequence 1217 from Patent EP3137118
ATTGCTTCAGCTA
>MS651706.1 Sequence 1215 from Patent EP3137118
ACAGCATATATAA
>MS651702.1 Sequence 1211 from Patent EP3137118
TTGCTTCAGCTCA
>MS651700.1 Sequence 1209 from Patent EP3137118
CATATATATGTTA
>MS651698.1 Sequence 1207 from Patent EP3137118
CAGCAACAATTCA
>MS651696.1 Sequence 1205 from Patent EP3137118
AGCATATATATGA
>MS651692.1 Sequence 1201 from Patent EP3137118
TGTACATTGACTA
>MS651690.1 Sequence 1199 from Patent EP3137118
GCATATATATGTA
>MS651686.1 Sequence 1195 from Patent EP3137118
AACTATTGCTTCA
>MS651682.1 Sequence 1191 from Patent EP3137118
GTACATTGACTTA
>MS651680.1 Sequence 1189 from Patent EP3137118
CAGCATATATATA
>MS651678.1 Sequence 1187 from Patent EP3137118
CACAGCATATATA
>MS651676.1 Sequence 1185 from Patent EP3137118
GCTCCACGGAGAA
>MS651674.1 Sequence 1183 from Patent EP3137118
ACCTGCAAGACTA
>MS651672.1 Sequence 1181 from Patent EP3137118
GACTATCGACATG
>MS651670.1 Sequence 1179 from Patent EP3137118
GCATCGAGGCCAT
>MS651668.1 Sequence 1177 from Patent EP3137118
AGCGGAAGCGCAT
>MS651666.1 Sequence 1175 from Patent EP3137118
CCAACATGATCGT
>MS651664.1 Sequence 1173 from Patent EP3137118
CAGCAAGGTCCTG
>MS651662.1 Sequence 1171 from Patent EP3137118
ACATGATCGTGCG
>MS651660.1 Sequence 1169 from Patent EP3137118
AACATGATCGTGC
>MS651658.1 Sequence 1167 from Patent EP3137118
TACAGCAAGGTCC
>MS651656.1 Sequence 1165 from Patent EP3137118
AGTGGATCCACGA
>MS651654.1 Sequence 1163 from Patent EP3137118
CAATTCCTGGCGA
>MS651652.1 Sequence 1161 from Patent EP3137118
TGATCGTGCGCTC
>MS651648.1 Sequence 1157 from Patent EP3137118
TCATCAGTGTTAA
>MS651646.1 Sequence 1155 from Patent EP3137118
TCATCAGTGTTAA
>MS651644.1 Sequence 1153 from Patent EP3137118
TCATCAGTGTTAA
>MS651642.1 Sequence 1151 from Patent EP3137118
TCATCAGTGTTAA
>MS651442.1 Sequence 951 from Patent EP3137118
GCACCTTTCTAGA
>MS651440.1 Sequence 949 from Patent EP3137118
GCACCTTTCTAGA
>MS651438.1 Sequence 947 from Patent EP3137118
GCACCTTTCTAGA
>MS651436.1 Sequence 945 from Patent EP3137118
GCACCTTTCTAGA
>MS651434.1 Sequence 943 from Patent EP3137118
CCTTTCTAGTTGA
>MS651432.1 Sequence 941 from Patent EP3137118
CCTTTCTAGTTGA
>MS651430.1 Sequence 939 from Patent EP3137118
CCTTTCTAGTTGA
>MS651428.1 Sequence 937 from Patent EP3137118
CCTTTCTAGTTGA
>MS651426.1 Sequence 935 from Patent EP3137118
CCTTTCTAGTTGA
>MS651424.1 Sequence 933 from Patent EP3137118
CCTTTCTAGTTGA
>MS651422.1 Sequence 931 from Patent EP3137118
CCTTTCTAGTTGA
>MS651420.1 Sequence 929 from Patent EP3137118
CCTTTCTAGTTGA
>MS651418.1 Sequence 927 from Patent EP3137118
CCTTTCTAGTTGA
>MS651416.1 Sequence 925 from Patent EP3137118
CCTTTCTAGTTGA
>MS651414.1 Sequence 923 from Patent EP3137118
CCTTTCTAGTTGA
>MS651412.1 Sequence 921 from Patent EP3137118
CCTTTCTAGTTGA
>MS651410.1 Sequence 919 from Patent EP3137118
CCTTTCTAGTTGA
>MS651378.1 Sequence 887 from Patent EP3137118
GTGACCAAAAGTA
>MS651376.1 Sequence 885 from Patent EP3137118
GTGACCAAAAGTA
>MS651374.1 Sequence 883 from Patent EP3137118
GTGACCAAAAGTA
>MS651372.1 Sequence 881 from Patent EP3137118
GCACCTTTCTAGA
>MS651370.1 Sequence 879 from Patent EP3137118
GCACCTTTCTAGA
>MS651368.1 Sequence 877 from Patent EP3137118
GCACCTTTCTAGA
>MS651366.1 Sequence 875 from Patent EP3137118
GCACCTTTCTAGA
>MS651364.1 Sequence 873 from Patent EP3137118
GCACCTTTCTAGA
>MS651362.1 Sequence 871 from Patent EP3137118
GCACCTTTCTAGA
>MS651360.1 Sequence 869 from Patent EP3137118
GCACCTTTCTAGA
>MS651358.1 Sequence 867 from Patent EP3137118
GCACCTTTCTAGA
>MS651356.1 Sequence 865 from Patent EP3137118
GCACCTTTCTAGA
>MS651354.1 Sequence 863 from Patent EP3137118
GCACCTTTCTAGA
>MS651352.1 Sequence 861 from Patent EP3137118
GCACCTTTCTAGA
>MS651350.1 Sequence 859 from Patent EP3137118
CCTTTCTAGTTGA
>MS651348.1 Sequence 857 from Patent EP3137118
GCACCTTTCTAGA
>MS651346.1 Sequence 855 from Patent EP3137118
GACCAAAAGTTAA
>MS651344.1 Sequence 853 from Patent EP3137118
GTGACCAAAAGTA
>MS651340.1 Sequence 849 from Patent EP3137118
TGTGACCAAAAGA
>MS651338.1 Sequence 847 from Patent EP3137118
GTGTGACCAAAAA
>MS651334.1 Sequence 843 from Patent EP3137118
AGTGTGACCAAAA
>MS651332.1 Sequence 841 from Patent EP3137118
TGAGAGTGTGACA
>MS651330.1 Sequence 839 from Patent EP3137118
TTGAGCTTTCTGA
>MS651326.1 Sequence 835 from Patent EP3137118
TGCACCTTTCTAA
>MS651322.1 Sequence 831 from Patent EP3137118
TGTTGAGAGTGTA
>MS651320.1 Sequence 829 from Patent EP3137118
CAGTTTATTTGTA
>MS651316.1 Sequence 825 from Patent EP3137118
ACAAGCCAGATTA
>MS651312.1 Sequence 821 from Patent EP3137118
TTTGCCTGTAACA
>MS651310.1 Sequence 819 from Patent EP3137118
CTGTCGATTAGAA
>MS651308.1 Sequence 817 from Patent EP3137118
TTCTGATTCGAAA
>MS651306.1 Sequence 815 from Patent EP3137118
CATTCTGATTCGA
>MS651304.1 Sequence 813 from Patent EP3137118
TTGAGAAGGAAAA
>MS651302.1 Sequence 811 from Patent EP3137118
AATTGAGAAGGAA
>MS651300.1 Sequence 809 from Patent EP3137118
TGAAGTGTAATTA
>MS651296.1 Sequence 805 from Patent EP3137118
GATAGCATCTTAA
>MS651292.1 Sequence 801 from Patent EP3137118
TGAAGAATGTTAA
>MS651288.1 Sequence 797 from Patent EP3137118
ACATTAACTCATA
>MS651286.1 Sequence 795 from Patent EP3137118
GAAGCTGACCTGG
>MS651284.1 Sequence 793 from Patent EP3137118
TATCAAGTTTGAG
>MS651282.1 Sequence 791 from Patent EP3137118
CCGCAAGATCGGC
>MS651280.1 Sequence 789 from Patent EP3137118
AGACACGTTTGGC
>MS651278.1 Sequence 787 from Patent EP3137118
CTAAATTCTGTGG
>MS651276.1 Sequence 785 from Patent EP3137118
GCTAAATTCTGTG
>MS651274.1 Sequence 783 from Patent EP3137118
CTGTGACTTCGGC
>MS651272.1 Sequence 781 from Patent EP3137118
CCTTGCGAAGCTG
>MS651270.1 Sequence 779 from Patent EP3137118
TGCGAAGCTGACC
>MS651268.1 Sequence 777 from Patent EP3137118
TACGGAGACATGG
>MS651266.1 Sequence 775 from Patent EP3137118
CCTGTTCCAAGAC
>MS651264.1 Sequence 773 from Patent EP3137118
GTACCAGTGCACG
>MS651262.1 Sequence 771 from Patent EP3137118
CAATGACAACGCC
>MS651260.1 Sequence 769 from Patent EP3137118
TTGCGAAGCTGAC
>MS651258.1 Sequence 767 from Patent EP3137118
CGAAGCTGACCTG
>MS651256.1 Sequence 765 from Patent EP3137118
TGTTCCAAGACCT
>MS651254.1 Sequence 763 from Patent EP3137118
CCTATCAAGTTTG
>MS651252.1 Sequence 761 from Patent EP3137118
CCGACTGGAAGAC
>MS651250.1 Sequence 759 from Patent EP3137118
CTTGCGAAGCTGA
>MS651248.1 Sequence 757 from Patent EP3137118
GGCCTTGCGAAGC
>MS651246.1 Sequence 755 from Patent EP3137118
CGAGGTCATGAAG
>MS651244.1 Sequence 753 from Patent EP3137118
AAGACACGTTTGG
>MS651242.1 Sequence 751 from Patent EP3137118
GAGCTAAATTCTG
>MS651240.1 Sequence 749 from Patent EP3137118
GGTCAGGCCTTGC
>MS651238.1 Sequence 747 from Patent EP3137118
GCTAGAGAAGCAG
>MS651236.1 Sequence 745 from Patent EP3137118
TGGAGTATGTACC
>MS651234.1 Sequence 743 from Patent EP3137118
GCCAGAACTGCAG
>MS651232.1 Sequence 741 from Patent EP3137118
TCAAGTTTGAGCT
>MS651230.1 Sequence 739 from Patent EP3137118
TGGTCAGGCCTTG
>MS651228.1 Sequence 737 from Patent EP3137118
TGACTTCGGCTCC
>MS651226.1 Sequence 735 from Patent EP3137118
GTGACTTCGGCTC
>MS651224.1 Sequence 733 from Patent EP3137118
GGAAGATGTACGG
>MS651222.1 Sequence 731 from Patent EP3137118
GCGAAGCTGACCT
>MS651220.1 Sequence 729 from Patent EP3137118
TCAGGCCTTGCGA
>MS651218.1 Sequence 727 from Patent EP3137118
ACGGAGACATGGC
>MS651216.1 Sequence 725 from Patent EP3137118
GACACGTTTGGCC
>MS651214.1 Sequence 723 from Patent EP3137118
GGCGAGGTCATGA
>MS651212.1 Sequence 721 from Patent EP3137118
AATGACAACGCCT
>MS651210.1 Sequence 719 from Patent EP3137118
AAGATGTACGGAG
>MS651208.1 Sequence 717 from Patent EP3137118
TGGAAGACACGTT
>MS651206.1 Sequence 715 from Patent EP3137118
TAAATTCTGTGGA
>MS651204.1 Sequence 713 from Patent EP3137118
GAGGTCATGAAGA
>MS651202.1 Sequence 711 from Patent EP3137118
ATGACAACGCCTC
>MS651200.1 Sequence 709 from Patent EP3137118
CGGAGACATGGCA
>MS651198.1 Sequence 707 from Patent EP3137118
TCTGTGGAGTATG
>MS651196.1 Sequence 705 from Patent EP3137118
CGAGCTAAATTCT
>MS651194.1 Sequence 703 from Patent EP3137118
CAGGCCTTGCGAA
>MS651192.1 Sequence 701 from Patent EP3137118
ACCGCAAGATCGG
>MS651190.1 Sequence 699 from Patent EP3137118
TACCGACTGGAAG
>MS651188.1 Sequence 697 from Patent EP3137118
AGGCCTTGCGAAG
>MS651186.1 Sequence 695 from Patent EP3137118
GAAGACACGTTTG
>MS651184.1 Sequence 693 from Patent EP3137118
ATGGTCAGGCCTT
>MS651182.1 Sequence 691 from Patent EP3137118
GGTCATGAAGAAG
>MS651180.1 Sequence 689 from Patent EP3137118
AAGCTGACCTGGA
>MS651178.1 Sequence 687 from Patent EP3137118
ATTTGAAGTGTAA
>MS651176.1 Sequence 685 from Patent EP3137118
AGTTGTTCCTTAA
>MS651174.1 Sequence 683 from Patent EP3137118
AGCAGAAAGGTTA
>MS651172.1 Sequence 681 from Patent EP3137118
ACATACCGAGCTA
>MS651170.1 Sequence 679 from Patent EP3137118
TTGTTGAGAGTGT
>MS651168.1 Sequence 677 from Patent EP3137118
ATACCGAGCTAAA
>MS651166.1 Sequence 675 from Patent EP3137118
ATGGCCTTTATTA
>MS651164.1 Sequence 673 from Patent EP3137118
GACTGGACAGCTT
>MS651162.1 Sequence 671 from Patent EP3137118
TATACGAGTAATA
>MS651160.1 Sequence 669 from Patent EP3137118
TTATCTAAGTTAA
>MS651158.1 Sequence 667 from Patent EP3137118
TTCTGCTCAGATA
>MS651156.1 Sequence 665 from Patent EP3137118
AGCTGATCAGTTT
>MS651154.1 Sequence 663 from Patent EP3137118
AGGTAGAATGTAA
>MS651152.1 Sequence 661 from Patent EP3137118
AGCTAAATTCTGT
>MS651150.1 Sequence 659 from Patent EP3137118
CTATCAAGTTTGA
>MS651148.1 Sequence 657 from Patent EP3137118
GGAAGACACGTTT
>MS651146.1 Sequence 655 from Patent EP3137118
AGTACCAGTGCAC
>MS651144.1 Sequence 653 from Patent EP3137118
CAATGACATCTTT
>MS651142.1 Sequence 651 from Patent EP3137118
TTTCAGTAGCACA
>MS651140.1 Sequence 649 from Patent EP3137118
AAATTCTGTGGAG
>MS651138.1 Sequence 647 from Patent EP3137118
CTGTGGAGTATGT
>MS651136.1 Sequence 645 from Patent EP3137118
CAAGTTTGAGCTT
>MS651134.1 Sequence 643 from Patent EP3137118
AGCCTATCAAGTT
>MS651132.1 Sequence 641 from Patent EP3137118
TGTACGGAGACAT
>MS651130.1 Sequence 639 from Patent EP3137118
AATTCTGTGGAGT
>MS651128.1 Sequence 637 from Patent EP3137118
GCCTATCAAGTTT
>MS651126.1 Sequence 635 from Patent EP3137118
GCTGCGAGGAGTG
>MS651124.1 Sequence 633 from Patent EP3137118
GCCTTGCGAAGCT
>MS651122.1 Sequence 631 from Patent EP3137118
ATGTACGGAGACA
>MS651120.1 Sequence 629 from Patent EP3137118
ACCGACTGGAAGA
>MS651118.1 Sequence 627 from Patent EP3137118
AGAGTGGAGCGCC
>MS651116.1 Sequence 625 from Patent EP3137118
CATTACAACTGTC
>MS651114.1 Sequence 623 from Patent EP3137118
ATTACAACTGTCC
>MS651112.1 Sequence 621 from Patent EP3137118
CTGCCATTACAAC
>MS651110.1 Sequence 619 from Patent EP3137118
CCATTACAACTGT
>MS651108.1 Sequence 617 from Patent EP3137118
CCTGGTCCAGACC
>MS651106.1 Sequence 615 from Patent EP3137118
CAGAGTGGAGCGC
>MS651104.1 Sequence 613 from Patent EP3137118
AGACCTGTGCCTG
>MS651102.1 Sequence 611 from Patent EP3137118
AACTGCCTGGTCC
>MS651100.1 Sequence 609 from Patent EP3137118
ACTGGAAGACACG
>MS651098.1 Sequence 607 from Patent EP3137118
TGCCATTACAACT
>MS651096.1 Sequence 605 from Patent EP3137118
GTTTGAGCTTTCT
>MS651094.1 Sequence 603 from Patent EP3137118
TGGAGCGCCTGTT
>MS651092.1 Sequence 601 from Patent EP3137118
AGTGGAGCGCCTG
>MS651090.1 Sequence 599 from Patent EP3137118
GAGCTTTCTGGCT
>MS651088.1 Sequence 597 from Patent EP3137118
GCCATTACAACTG
>MS651086.1 Sequence 595 from Patent EP3137118
GGAGCGCCTGTTC
>MS651084.1 Sequence 593 from Patent EP3137118
CGACTGGAAGACA
>MS651082.1 Sequence 591 from Patent EP3137118
GAGTGGAGCGCCT
>MS651080.1 Sequence 589 from Patent EP3137118
ACAGGAAGATGTA
>MS651078.1 Sequence 587 from Patent EP3137118
GATCACATTTGAA
>MS651076.1 Sequence 585 from Patent EP3137118
GATCACATTTGAA
>MS651074.1 Sequence 583 from Patent EP3137118
GATCACATTTGAA
>MS651072.1 Sequence 581 from Patent EP3137118
GATCACATTTGAA
>MS651040.1 Sequence 549 from Patent EP3137118
GATCACATTTGAA
>MS651038.1 Sequence 547 from Patent EP3137118
GATCACATTTGAA
>MS651036.1 Sequence 545 from Patent EP3137118
GATCACATTTGAA
>MS651034.1 Sequence 543 from Patent EP3137118
GATCACATTTGAA
>MS651032.1 Sequence 541 from Patent EP3137118
GATCACATTTGAA
>MS651028.1 Sequence 537 from Patent EP3137118
CATCTGCAATAAA
>MS651024.1 Sequence 533 from Patent EP3137118
ATTTGATTGACAA
>MS651020.1 Sequence 529 from Patent EP3137118
ACATTTGATTGAA
>MS651016.1 Sequence 525 from Patent EP3137118
TCACATTTGATTA
>MS651014.1 Sequence 523 from Patent EP3137118
AAGAAGAAAGTTA
>MS651012.1 Sequence 521 from Patent EP3137118
GAAGTCTAATGAA
>MS651010.1 Sequence 519 from Patent EP3137118
ACCAGTATAAGTA
>MS651008.1 Sequence 517 from Patent EP3137118
GTGCAACACTTGA
>MS651006.1 Sequence 515 from Patent EP3137118
TACTGATAGGAGA
>MS651004.1 Sequence 513 from Patent EP3137118
TCCAGATCACATA
>MS651000.1 Sequence 509 from Patent EP3137118
ATCACATTTGATA
>MS650998.1 Sequence 507 from Patent EP3137118
AATTTCATGTCTA
>MS650996.1 Sequence 505 from Patent EP3137118
GTCTTTTAATGAA
>MS650994.1 Sequence 503 from Patent EP3137118
GACCAGTATAAGA
>MS650992.1 Sequence 501 from Patent EP3137118
AATACCAGTCTTA
>MS650988.1 Sequence 497 from Patent EP3137118
CCACCAACTTACA
>MS650986.1 Sequence 495 from Patent EP3137118
CACTCCAAACACA
>MS650982.1 Sequence 491 from Patent EP3137118
ACTCCAAACACAA
>MS650980.1 Sequence 489 from Patent EP3137118
CCTTCCTTCGAAA
>MS650978.1 Sequence 487 from Patent EP3137118
GTTGACATCCAGA
>MS650976.1 Sequence 485 from Patent EP3137118
AACCTCTCCTATA
>MS650972.1 Sequence 481 from Patent EP3137118
GATCACATTTGAA
>MS650970.1 Sequence 479 from Patent EP3137118
CTCCTATTATACA
>MS650966.1 Sequence 475 from Patent EP3137118
TCCACCAACTTAA
>MS650964.1 Sequence 473 from Patent EP3137118
ACCTCTCCTATTA
>MS650962.1 Sequence 471 from Patent EP3137118
GAAAACTGCTCAA
>MS650960.1 Sequence 469 from Patent EP3137118
CATTTGATTGACA
>MS650958.1 Sequence 467 from Patent EP3137118
AAATACCAGTCTT
>MS650956.1 Sequence 465 from Patent EP3137118
CACTGCCTCAATT
>MS650954.1 Sequence 463 from Patent EP3137118
CACATTTGATTGA
>MS650944.1 Sequence 453 from Patent EP3137118
GGCTGATTCTGGA
>MS650942.1 Sequence 451 from Patent EP3137118
GAATTGCAGTGAA
>MS650940.1 Sequence 449 from Patent EP3137118
ACCTGAAATTTCA
>MS650938.1 Sequence 447 from Patent EP3137118
TGAAAGAGAACAA
>MS650936.1 Sequence 445 from Patent EP3137118
TGCAGTGATTTGA
>MS650934.1 Sequence 443 from Patent EP3137118
AATGAAAGAGAAA
>MS650876.1 Sequence 385 from Patent EP3137118
CCAGCAATTAATA
>MS650878.1 Sequence 387 from Patent EP3137118
GACTCGAACGACT
>MS650880.1 Sequence 389 from Patent EP3137118
ACCTGCCAGCAAC
>MS650882.1 Sequence 391 from Patent EP3137118
GATGAATCTGATA
>MS650886.1 Sequence 395 from Patent EP3137118
ATTTGCTTTTGCA
>MS650890.1 Sequence 399 from Patent EP3137118
GTGATTTGCTTTA
>MS650894.1 Sequence 403 from Patent EP3137118
AATTTCGTATTTA
>MS650898.1 Sequence 407 from Patent EP3137118
CACAGCCATGAAA
>MS650932.1 Sequence 441 from Patent EP3137118
CACTCCAGTTGTA
>MS650930.1 Sequence 439 from Patent EP3137118
TTCTCACTTTGCA
>MS650928.1 Sequence 437 from Patent EP3137118
CTCACTTTGCATA
>MS650926.1 Sequence 435 from Patent EP3137118
TTTGCATTTAGTA
>MS650924.1 Sequence 433 from Patent EP3137118
CTTTGCATTTAGA
>MS650922.1 Sequence 431 from Patent EP3137118
GAAAGAGAACATA
>MS650920.1 Sequence 429 from Patent EP3137118
TCTTTCTCAGTTA
>MS650918.1 Sequence 427 from Patent EP3137118
TTCTTTCTCAGTA
>MS650916.1 Sequence 425 from Patent EP3137118
ATTTAGTCAAAAA
>MS650914.1 Sequence 423 from Patent EP3137118
ACTTTGCATTTAA
>MS650912.1 Sequence 421 from Patent EP3137118
TTGCATTTAGTCA
>MS650910.1 Sequence 419 from Patent EP3137118
TTTCTCAGTTTAA
>MS650906.1 Sequence 415 from Patent EP3137118
TTGCTTTTGCCTA
>MS650902.1 Sequence 411 from Patent EP3137118
GATTTGCTTTTGA
>MS650874.1 Sequence 383 from Patent EP3137118
GTCCAGCAATTAA
>MS650872.1 Sequence 381 from Patent EP3137118
TTGAGTCTGGAAA
>MS650870.1 Sequence 379 from Patent EP3137118
AATGTGTATCTAT
>MS650868.1 Sequence 377 from Patent EP3137118
GTCAGCCGTGAAT
>MS650866.1 Sequence 375 from Patent EP3137118
GATGTGATTGATA
>MS650864.1 Sequence 373 from Patent EP3137118
GACCAGAGTGCTG
>MS650862.1 Sequence 371 from Patent EP3137118
TGGTTTATGGACT
>MS650860.1 Sequence 369 from Patent EP3137118
CTGGTCACTGATT
>MS650858.1 Sequence 367 from Patent EP3137118
CCAACGAAAGCCA
>MS650856.1 Sequence 365 from Patent EP3137118
ACCATGAGAATTG
>MS650854.1 Sequence 363 from Patent EP3137118
TGTCAATTGCTTA
>MS650852.1 Sequence 361 from Patent EP3137118
AATTCCACAGCCA
>MS650850.1 Sequence 359 from Patent EP3137118
TGAGCATTCCGAT
>MS650848.1 Sequence 357 from Patent EP3137118
GAGTGCTGAAACC
>MS650846.1 Sequence 355 from Patent EP3137118
AAACAGGCTGATT
>MS650844.1 Sequence 353 from Patent EP3137118
ACTACCATGAGAA
>MS650842.1 Sequence 351 from Patent EP3137118
AGTCAGCCGTGAA
>MS650840.1 Sequence 349 from Patent EP3137118
ATAGTCAGGAACT
>MS650838.1 Sequence 347 from Patent EP3137118
AAGCCAATGATGA
>MS650836.1 Sequence 345 from Patent EP3137118
TAGTGTGGTTTAT
>MS650834.1 Sequence 343 from Patent EP3137118
ACGACTCTGATGA
>MS650832.1 Sequence 341 from Patent EP3137118
AGCAATTAATAAA
>MS650830.1 Sequence 339 from Patent EP3137118
GTCAATTGCTTAT
>MS650828.1 Sequence 337 from Patent EP3137118
AACTATCACTGTA
>MS650826.1 Sequence 335 from Patent EP3137118
TCATTCTATAGAA
>MS650824.1 Sequence 333 from Patent EP3137118
ATAACTAATGTGT
>MS650822.1 Sequence 331 from Patent EP3137118
TTCCGATGTGATT
>MS650820.1 Sequence 329 from Patent EP3137118
TATAAGCGGAAAG
>MS650818.1 Sequence 327 from Patent EP3137118
AGTCAGCTGGATG
>MS650816.1 Sequence 325 from Patent EP3137118
AGTTGAATGGTGC
>MS650814.1 Sequence 323 from Patent EP3137118
CACCTCACACATG
>MS650812.1 Sequence 321 from Patent EP3137118
GCCAGCAACCGAA
>MS650810.1 Sequence 319 from Patent EP3137118
TCATGAATAGAAA
>MS650808.1 Sequence 317 from Patent EP3137118
GGAAATAACTAAT
>MS650806.1 Sequence 315 from Patent EP3137118
GGTTGAATGTGTA
>MS650804.1 Sequence 313 from Patent EP3137118
ATTGGTTGAATGT
>MS650802.1 Sequence 311 from Patent EP3137118
CAGCCATGAATTT
>MS650800.1 Sequence 309 from Patent EP3137118
CCAGAGTGCTGAA
>MS650798.1 Sequence 307 from Patent EP3137118
ATGAAACGAGTCA
>MS650796.1 Sequence 305 from Patent EP3137118
TGGTGCATACAAG
>MS650794.1 Sequence 303 from Patent EP3137118
TTAGATAGTGCAT
>MS650792.1 Sequence 301 from Patent EP3137118
AGCAATGAGCATT
>MS650790.1 Sequence 299 from Patent EP3137118
AAGTTTCGCAGAC
>MS650788.1 Sequence 297 from Patent EP3137118
AGTCCAACGAAAG
>MS650786.1 Sequence 295 from Patent EP3137118
AGTTTGTGGCTTC
>MS650784.1 Sequence 293 from Patent EP3137118
AGTCTGGAAATAA
>MS650782.1 Sequence 291 from Patent EP3137118
CAGCCGTGAATTC
>MS650780.1 Sequence 289 from Patent EP3137118
CAGACGAGGACAT
>MS650778.1 Sequence 287 from Patent EP3137118
TAGACACATATGA
>MS650776.1 Sequence 285 from Patent EP3137118
GTCTGATGAGTCT
>MS650774.1 Sequence 283 from Patent EP3137118
TGCATTTAGTCAA
>MS650772.1 Sequence 281 from Patent EP3137118
TAGTCAGGAACTT
>MS650770.1 Sequence 279 from Patent EP3137118
AGCATTCCGATGT
>MS650768.1 Sequence 277 from Patent EP3137118
GCATTTAGTCAAA
>MS650766.1 Sequence 275 from Patent EP3137118
AGCAGTCCAGATT
>MS650764.1 Sequence 273 from Patent EP3137118
ATATGATGGCCGA
>MS650762.1 Sequence 271 from Patent EP3137118
GAATGGTGCATAC
>MS650760.1 Sequence 269 from Patent EP3137118
CCGACCAAGGAAA
>MS650758.1 Sequence 267 from Patent EP3137118
TGTTCATTCTATA
>MS650756.1 Sequence 265 from Patent EP3137118
TACCAGTTAAACA
>MS650754.1 Sequence 263 from Patent EP3137118
ATATAAGCGGAAA
>MS650752.1 Sequence 261 from Patent EP3137118
CAGTCCAGATTAT
>MS650750.1 Sequence 259 from Patent EP3137118
TTATGAAACGAGT
>MS650748.1 Sequence 257 from Patent EP3137118
TGGTTGAATGTGT
>MS650746.1 Sequence 255 from Patent EP3137118
GCAGTCCAGATTA
>MS650744.1 Sequence 253 from Patent EP3137118
ACATGGAAAGCGA
>MS650742.1 Sequence 251 from Patent EP3137118
TTGTCCAGCAATT
>MS650740.1 Sequence 249 from Patent EP3137118
TTCTATAGAAGAA
>MS650738.1 Sequence 247 from Patent EP3137118
ATGTGTATCTATT
>MS650736.1 Sequence 245 from Patent EP3137118
AGATAGTGCATCT
>MS650734.1 Sequence 243 from Patent EP3137118
TGATTGATAGTCA
>MS650732.1 Sequence 241 from Patent EP3137118
GCGAGGAGTTGAA
>MS650730.1 Sequence 239 from Patent EP3137118
ATGATGAGAGCAA
>MS650728.1 Sequence 237 from Patent EP3137118
AAGTCCAACGAAA
>MS650726.1 Sequence 235 from Patent EP3137118
CTCTCATGAATAG
>MS650724.1 Sequence 233 from Patent EP3137118
ATTTCTCATGAAT
>MS650722.1 Sequence 231 from Patent EP3137118
GCGCCTTCTGATT
>MS650720.1 Sequence 229 from Patent EP3137118
GAAATTTCGTATT
>MS650718.1 Sequence 227 from Patent EP3137118
ACATGGATGATAT
>MS650716.1 Sequence 225 from Patent EP3137118
AAAGCCATGACCA
>MS650714.1 Sequence 223 from Patent EP3137118
ATTTCGTATTTCT
>MS650712.1 Sequence 221 from Patent EP3137118
AAATTTCGTATTT
>MS650710.1 Sequence 219 from Patent EP3137118
GCGGAAAGCCAAT
>MS650708.1 Sequence 217 from Patent EP3137118
AAGCCATGACCAC
>MS650706.1 Sequence 215 from Patent EP3137118
GCCATGACCACAT
>MS650704.1 Sequence 213 from Patent EP3137118
ACCACATGGATGA
>MS650702.1 Sequence 211 from Patent EP3137118
AGCGGAAAGCCAA
>MS650700.1 Sequence 209 from Patent EP3137118
AAGCGGAAAGCCA
>MS650698.1 Sequence 207 from Patent EP3137118
AGTCTCACCATTC
>MS650696.1 Sequence 205 from Patent EP3137118
TCACAGCCATGAA
>MS650694.1 Sequence 203 from Patent EP3137118
GACTGAGGTCAAA
>MS650692.1 Sequence 201 from Patent EP3137118
GAGTCTCACCATT
>MS650690.1 Sequence 199 from Patent EP3137118
TGGACTGAGGTCA
>MS650688.1 Sequence 197 from Patent EP3137118
TTCTGATGAATCT
>MS650686.1 Sequence 195 from Patent EP3137118
GTCAGCTGGATGA
>MS650684.1 Sequence 193 from Patent EP3137118
TTCTGAGGTCAAT
>MS650682.1 Sequence 191 from Patent EP3137118
TGAGGTCAATTAA
>MS650680.1 Sequence 189 from Patent EP3137118
TCTGAGGTCAATT
>MS650678.1 Sequence 187 from Patent EP3137118
GAGGTCAATTAAA
>MS650676.1 Sequence 185 from Patent EP3137118
CTGAGGTCAATTA
>MS650674.1 Sequence 183 from Patent EP3137118
CTCATGAATTAGA
>MS995693.1 Sequence 33 from Patent EP3158085
TTCCCGAGACATG
>MS995505.1 Sequence 127 from Patent EP3158089
GCATCTTGCAGAA
>MS647353.1 Sequence 16 from Patent EP3137479
GTTAGGGTTAGAC
>MS647349.1 Sequence 12 from Patent EP3137479
ACGGTGGAAGGCG
>MS647348.1 Sequence 11 from Patent EP3137479
CGGTGGAAGGCGG
>MS647346.1 Sequence 9 from Patent EP3137479
GTGGAAGGCGGCA
>MS647345.1 Sequence 8 from Patent EP3137479
GGAAGGCGGCAGG
>MS647342.1 Sequence 5 from Patent EP3137479
CAGTTAGGGTTAG
>MS647340.1 Sequence 3 from Patent EP3137479
TAGGGTTAGACAA
>MS995382.1 Sequence 4 from Patent EP3158089
ATTGTTATTGTTA
>MS995380.1 Sequence 2 from Patent EP3158089
ATTTATTTATTTA
>MS995071.1 Sequence 9 from Patent EP3126511
GAGCTTGGTGGCG
>MS993323.1 Sequence 606 from Patent EP3107373
AGGCGAAACATCT
>MS991380.1 Sequence 41 from Patent EP3158065
TGGAGGAGACACA
>MS637257.1 Sequence 359 from Patent EP3115059
GGGTTTTTTTGGG
>MS637247.1 Sequence 348 from Patent EP3115059
GGTTTTTTTTTGG
>MS952323.1 Sequence 1 from Patent EP3177310
GAANNTTCNNGAA
>MS633388.1 Sequence 4 from Patent WO2017042381
GGACACRTGATGG
>MS633387.1 Sequence 3 from Patent WO2017042381
ATAATGRTGAAGG
>MS633386.1 Sequence 2 from Patent WO2017042381
GGACACGTGATGG
>MS633385.1 Sequence 1 from Patent WO2017042381
ATAATGATGAAGG
>MS633306.1 Sequence 16 from Patent EP3115064
GCCGCCACCATGG
>MS946425.1 Sequence 9 from Patent WO2017035319
TGTAAGCACTTTG
>MS631680.1 Sequence 12 from Patent WO2017044651
TAGTCGCTCTTGG
>MS631676.1 Sequence 8 from Patent WO2017044651
GGTCGTACCTCAG
>MS631671.1 Sequence 3 from Patent WO2017044651
GCACACACTACTT
>MS847581.1 Sequence 16 from Patent EP3130681
GTTACAGATCTAC
>MS936676.1 Sequence 73 from Patent EP3119798
GCCGCCNCCATGG
>MS931368.1 Sequence 2 from Patent EP3178928
GCCGCCRCCATGG
>MS671371.1 Sequence 16 from Patent EP3101142
CGCGGCGTAACGA
>MS671370.1 Sequence 15 from Patent EP3101142
CGCGGCATAACGA
>MS925040.1 Sequence 24 from Patent WO2017017424
ATTTTGATGGTAT
>MS837470.1 Sequence 2 from Patent WO2017013170
ACCGATTAGGGAA
>MS835902.1 Sequence 32 from Patent EP3112474
GTGGGGGCAAGGA
>MS835678.1 Sequence 40 from Patent EP3112465
GTGATWTTNCWNS
>MS912632.1 Sequence 324 from Patent WO2017021541
TTGTCACGAAAAC
>MS912612.1 Sequence 304 from Patent WO2017021541
CATATGCGCTTTT
>MS912592.1 Sequence 284 from Patent WO2017021541
CTGTATTGTTAGA
>MS912580.1 Sequence 272 from Patent WO2017021541
TGTAGGGTCCCCA
>MS912645.1 Sequence 337 from Patent WO2017021541
TAATCAAACAAAA
>MS912617.1 Sequence 309 from Patent WO2017021541
CTCTTTTGTCAAG
>MS912613.1 Sequence 305 from Patent WO2017021541
CTTTTACCCCCTC
>MS912609.1 Sequence 301 from Patent WO2017021541
GAAACGCGCTATT
>MS912605.1 Sequence 297 from Patent WO2017021541
GCAGTGCATGCAA
>MS912601.1 Sequence 293 from Patent WO2017021541
TTGATTGTTAACC
>MS912626.1 Sequence 318 from Patent WO2017021541
GATATGCATCAAA
>MS912610.1 Sequence 302 from Patent WO2017021541
ATAGCGCGTTTCA
>MS912602.1 Sequence 294 from Patent WO2017021541
CTTGATTGTTAAC
>MS912598.1 Sequence 290 from Patent WO2017021541
TATACACGAACCA
